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INTRODUCTION A N D OUTLINE OF THE THESIS 
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Chapter ι 
H E A D A N D N E C K S Q U A M O U S C E L L C A R C I N O M A 
Cancer of the head and neck refers t o a collection of cancers, arising from the fo l lowing sites: 
( i) the lip and oral cavity, ( n ) the pharynx (oropharynx, nasopharynx, and hypopharynx), 
( i n ) the larynx, ( iv) the maxillary sinus, and (v) the salivary glands (figure i ) . T h e predominant 
malignancy w i t h i n these anatomically defined regions is squamous cell carcinoma {>95%). When 
using the term "head and neck squamous cell carcinoma" (HNSCC), squamous cell carcinomas of 
the oral cavity, the oropharynx, the hypopharynx, and the larynx are meant, in general1. The 
annual incidence of HNSCC in the Netherlands is 2280 cases, w i t h a male t o female ratio of 3 : 1 2 . 
HNSCC is associated w i t h the use of tobacco and alcohol. Other risk factors that may play a role 
include viral infect ion, occupational exposure, radiation and genetic susceptibility. 
The staging of the HNSCC is according to the AJCC (American Joint Committee on Cancer), 
and consists of three staging systems, which characterize the primary tumor (T), the number and 
size of enlarged lymph nodes (N), and the presence or absence of distant metastasis ( M ) 3 . There is 
a site-specific Τ classification, whereas the staging of the Ν is independent of the primary site of 
the tumor. The Τ and Ν classification is added in Appendix. Approximately 30 to 40% of patients 
w i t h HNSCC present w i t h early disease. The 5-year overall survival for this patient group ranges 
from 60 t o 98%, depending on the site and size of the primary tumor and the presence of lymph 
node metastasis. Dependent of the site of the tumor, these small tumors are treated w i t h surgery 
and/or radiotherapy. Locoregional advanced disease is present in more than 50% of patients. 
Dependent of the site and the resectability of the tumor and the neck, these patients are treated 
w i t h combined therapy, i.e., surgery and postoperative radiotherapy, or concomitant chemo-
radiotherapy. Especially patients w i t h unresectable disease, have a poor prognosis w i t h five-year 
survival rates of only 10 to 30%. Radiotherapy alone, unt i l recently, was the standard of 
t reatment for these patients. However, several randomized phase I I I studies showed t h a t 




concomitant chemo-radiotherapy produced a clear absolute survival advantage of 15-20% over 
radiotherapy alone. A meta-analysis showed an overall survival benefit of 10%. However, 
concomitant chemo-radiotherapy induces more morbidity. At this moment chemo-radiotherapy is 
the standard of treatment for this group, providing the patient has a good condition4. If distant 
metastases are present at presentation, after primary treatment, or when an unresectable local 
recurrence develops, the patient cannot be cured anymore. The median survival is only 6 months. 
Palliative chemotherapy is an option, but no survival gain is shown in studies using either single 
agent chemotherapy or combination chemotherapy. Because of the poor prognosis when 
metastasis or a local recurrence occurs, but also because of the high mortality after development 
of a second primary tumor (in 15-20% of the HNSCC patients), new treatments and approaches 
are necessary4. 
HNSCC, IMMUNE DYSFUNCTION AND LOCORECIONAL INTERLEUKIN-2 
In HNSCC several kinds of immune dysfunction, starting at the site of the tumor and eventually 
generalized, have been reported5. It is an immunogenic tumor, as demonstrated by a variable 
amount of infiltrating lymphocytes and other immune cells. These infiltrating leukocytes are 
susceptible to activation by immunomodulatory cytokines'. In the past, the therapeutic effects 
of locoregional interleukin-2 (IL-2) administration in HNSCC have been studied extensively. 
Locoregional immunotherapy may be preferred over the systemic administration for several 
reasons. In animal models it has been shown that with locoregionally administered IL-2 higher 
concentrations of IL-2 are achieved at the site of the tumor with less toxicity in comparison to 
systemic treatment7·'. Furthermore, after local administration IL-2 has preferential access to the 
draining lymph nodes. Mattijssen et al. showed in a syngeneic guinea-pig line-io tumor model, 
that intratumoral (i.t.) (and not peri-lymphatic) administration of polyethylene-glycol-modified 
IL-2 could cure animals with palpable experimental tumors and regional lymph node 
micrometastasis. Moreover, protective systemic antitumor activity was induced». In a phase I I 
study in HNSCC patients the effect of i.t. injection of polyethylene-glycol-modified IL-2 was 
evaluated. It was feasible, but the objective response rate was only 6%1 0. 
HNSCC AS MODEL TO STUDY THE EFFECTS OF IMMUNE MODULATION 
HNSCC provides an excellent model to study the effects of locoregional immunotherapy such as 
cytokines. Tumors in the oral cavity or oropharynx permit local injection of cytokines. A resection 
of the primary tumor, along with a regional lymph node neck dissection, is part of the standard 
treatment in limited disease. Locoregional immunotherapy given preoperatively allows for study 
of the effects of the treatment on the primary tumor, the lymph nodes, and peripheral blood. 
Therefore, we discuss some important topics concerning the immune response to tumors, the 
architecture and organisation of the lymph node and the lymphocyte recirculation. 
I M M U N E RESPONSES TO TUMORS 
The principle mechanism of tumor immunity is killing of tumor cells. Generally, killing of tumor 
cells by CD8+ cytotoxic Τ lymphocytes (CTLs) is thought to be most effective11. Once properly 
activated CTLs can directly kill tumor cells via recognition of antigen presented within MHC class I 
molecules on tumor cells. However, class I MHC expression may be down-regulated on tumor cells 
so that tumor cells cannot be recognized by CTLs. For the generation of effective CTLs they need 
to be activated by professional antigen presenting cells (APCs). Tumor cells or their antigens are 
ingested by dendritic cells (DCs); after processing inside the DCs, these antigens are presented 
within class I MHC molecules (cross-presentation) for recognition by CD8+ Τ cells. The DCs 
express costimulators that provide the signals needed for full differentiation of CD8+ Τ cells into 
anti-tumor CTLs. Once effector CTLs are generated, they are able to recognize and kill the tumor 
12 
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The lymph node architecture showing the Τ cell rich and Β cell rich zones and the routes of entry of lymphocytes 
and antigen. 
Efferent lymphatic vessel 
cells w i t h o u t a requirement for further costimulat ion.The DC can also express class I I 
MHC molecules that may present internalized tumor antigens and activate CD4+ Th cells3. 
The CD4+ Th cell can contr ibute t o ki l l ing of tumor cells by producing IFN-γ, which can activate 
the CTL response, increase tumor cell class I MHC expression and activate macrophages to kill 
tumor cells1 1. Antibodies produced by Β cells may kill tumor cells mediated by NK cells or through 
complement activation or Fc receptor mediated kil l ing by macrophages. NK cells kill many types 
of tumor cells, especially cells that have reduced class I MHC expression and can escape by CTLs. 
The mechanisms by which activated macrophages1 1 and neutrophi ls 1 2 can kill tumor cells are less 
studied, but might involve increase synthesis of reactive oxygen intermediates and nitr ic oxide, 
lysosomal enzymes, and cytokines, mainly TNF. Both cell types have a role in tumor immunity. 
L Y M P H N O D E S A N D L Y M P H O C Y T E C I R C U L A T I O N 
The lymph nodes are the organs in which adaptive immune responses to antigens are in i t ia ted. 
Lymph nodes consist of an outer cortex and an inner medulla. A fibrous capsule t h a t is penetrated 
by numerous afferent lymphatics, which empty the lymph into a subcapsular or marginal sinus, 
surrounds each lymph node. The lymph percolates through the cortex into the medullary sinus 
and leaves the node through the efferent lymphatic vessel in the h i l u m 1 3 . 
The different classes of lymphocytes are sequestered in dist inct regions of the lymph node, 
(figure 2) In the outer cortex follicles, primarily containing Β cells, are situated. Primary follicles 
contain mostly mature, naieve Β lymphocytes. After antigenic st imulat ion germinal centers (CC), 
central areas in follicles, develop; these follicles are called secondary follicles. In the CC Β cell 
prol iferation, selection of Β cells producing h igh-aff in i ty antibodies, and generation of memory 
M 
Β cells occurs. Other cells in the CC are follicular dendritic cells (FDCs), CD57+ Th cells and 
tingible body macrophages. The paracortex, between the outer cortex and medulla, contains 
Τ cells and interdigitating DCs. The medulla contains cords consisting of macrophages and plasma 
cells. The anatomic segregation of the Τ and Β cells is dependent on cytokines. Naive Τ cells and 
DCs express a chemokine receptor CCR7 and are attracted to the Τ cell zones, where CCL19 and 
CCL21 are produced, which attract the CCR7+ cells. Naïve Β cells and CD57+ Thelper cells express 
another chemokine receptor, CXCR5, that recognizes CXCL13 produced only in the follicles13. 
In the lymph node DCs, which have picked up antigens, for example tumor antigens, enter 
through the afferent lymphatic vessels, and migrate to paracortex, the T-cell rich areas of the 
node. Naive Τ and Β lymphocytes enter through the artery and finally through specialised vessels, 
called high endothelial venules in the cortex. If the naive Τ cell in the paracortex recognize 
antigen after contact with the interdigitating DC, they are activated, and they return to the 
circulation through the efferent lymphatics and the thoracic duct, which empties into the 
superior vena cava, then into the heart, and ultimately into the arterial circulation. Effector and 
memory Τ cells preferentially leave the blood and enter peripheral tissues through venules at sites 
of inflammation. In principle the recirculation of the Β cell is similar to that of Τ cells. After 
activation of the Β cell following encounter antigen presented by FDCs in the CC, the Β cells 
lose expression of CXCR5 and exit the follicles into the Τ cell zones of the lymph node. Activated 
antibody-producing Β cells or plasma cells can migrate to peripheral tissue, to the bone marrow, 
or remain in the lymph node13. 
I N T E R L E U K I N - 1 2 
Cytokines are proteins secreted by the cells of innate and adaptive immune system and mediate 
many of the functions of these cells. Cytokines are produced in response to microbes and other 
antigens, for example tumor antigens. They stimulate the growth and differentiation of 
lymphocytes, and activate different effector cells to eliminate microbes and other antigens". 
Both interleukin-12 (IL-12) and IL-2 are cytokines. 
IL-2 mediates and regulates the adaptive immune response. IL-2 is a growth factor for antigen-
stimulated Τ lymphocytes and is crucial for Τ cell clonal expansion after antigen recognition. IL-12 
is a cytokine that plays an essential role in the interaction between the innate and adaptive arms 
of immunity and the type of immune response that is induced. 
The APCs, such as dendritic cells (DCs), neutrophils, macrophages, and natural killer (NK) cells 
are the principal immune cells of the innate immune system, which provides the initial defence 
against infections. The adaptive immune responses develop later and consist of activation of 
Τ and Β lymphocytes by professional APCs like DCs". DCs therefore provide an important link 
between the innate and adaptive immune system. IL-2 production by these DCs is one of the 
mechanisms by which the DC orchestrates the type of immunity that is induced. 
IL-12 is a heterodimeric cytokine, which consists of two disulfide-linked subunits, i.e., IL-12p40 
and IL-12p3515.The p40 chain is also part of two other cytokines, i.e., IL-23 and IL-27. IL-12 is 
mainly produced by phagocytic cells (macrophages and neutrophils), Β cells, and dendritic cells 
(DCs) after encounter with infectious agents16. The IL-12 receptor (IL-12R) is composed of two 
chains, IL-12Rßi and IL-12Rß2. Both chains are required for high-affinity binding of the cytokine, 
and the ß2 chain is involved in signaling. The IL-12R is expressed mainly by activated Τ cells and 
NK cells. Expression of IL-12R has been shown also on other cell types, such as DCs and Β cells. 
IL-12R is undetectable on most resting Τ cells, but is expressed at a low level by NK cells, which 
probably explains the ability of these cells to respond rapidly to IL-1216. It stimulates NK cells and 
Τ cells to produce interferon-γ (lFN-γ), and also other cytokines, for example granulocyte-
14 
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figure 3 The Thl and Th2 response. IL-12, made by activated macrophages and dendritic cells, induces Thl development through 
a STAT4-dependent pathway. IL-4, which may be produced by Τ cells themselves, favors induction of Th2 cells through 
a STAT6-dependent pathway. The transcriptionfactor T-bet amplifies the Thl response, and CATA-3 is critical forTh2 
differentiation. 
Naive CD4+ Τ cell 
Ο '^  
IL-12 
IFN-γ 
T h l cells 
|GATA-3| 
IL-4 I IL-4 
STAT 6 . 
Th2 cells 
Abbreviations; IP-10-interferon-gamma inducible protein-10; Mig- monokine induced by interferon-γ 
macrophage colony-stimulatory factor (CM-CSF) and tumor necrosis factor-α (TNF-a) 1 5 . IL-12 
stimulates the di f ferent iat ion of CD4+ helper Τ lymphocytes into IFN-y-producing T h l cells1 7 
(figure 2). IL-10 is a potent inhibi tor of IL-12 product ion 1 6 . Next to its role in the modulation of 
the T h l response IL-12 induces the proliferation and activation of cytotoxic Τ lymphocytes and 
NK cells. IL-12 strongly inhibits angiogenesis1 8. This effect is mediated by IFN-γ, which 
upregulates t w o chemokines, i.e., interferon-gamma inducible protein-10 (IP-10) and monokine 
induced by interferon-γ ( M i g ) 1 9 . However, the mechanism by which these chemokines affect 
angiogenesis is largely unknown. 
T H E C O N C E P T OF Τ HELPER 1 A N D Τ H E L P E R 2 RESPONSE 
Naive CD4+ Th cells may differentiate into subsets of effector cells that produce different sets of 
cytokines and therefore perform dist inct effector functions dependent on the type of antigen and 
local environment they encounter. CD4+ cells can be divided in T h l and Τ helper 2 (Th2) cells, 
which are distinguished by the cytokines they produce. The T h l subset produces IFN-γ and 
expresses the IL-12Rß2, which correlates w i th responsiveness to IL-12. The Th2 cells produce IL-4, 
IL-5, and IL-13 and do not express the IL-12Rß220. Recently, Th3 cells, i.e., regulatory Τ cells, are 
indicated. Regulatory Τ cells can produce immunosuppressive cytokines like transforming g r o w t h 
factor-ß (TCF-ß) and IL-10 or can suppress other immune cells via direct cell-cell contact21 '23. 
IL-12 is the major cytokine responsible for the induction of the development of T h l cells. IL-12 
binds to the IL-12R on antigen-stimulated Τ helper cells and activates the transcriptionfactor 
STAT4, which promotes the di f ferent iat ion of the Th cells into T h l cells, which start production 
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of IFN-γ. Another important transcriptionfactor in the development of Thl cells is T-bet T-bet is 
induced by IFN-γ (figure 3) T-bet induces IFN-γ production, thereby sustaining the Thl response 
IFN-γ also stimulates the production of IL-12 by macrophages and the expression of IL-12Rß2 on 
Τ lymphocytes. Thus, by these actions an amplification of the Thl response occurs. The produced 
IFN-γ acts on macrophages to increase phagocytosis and killing of microbes and on Β cells to 
stimulate production of IgC antibodies that opsonize microbes. Neutrophils are activated by the 
production of lymphotoxm and tumor necrosis factor (TNF). IL-2 is made by the Thl cells and is 
an autocrine growth factor Furthermore, Thl cells stimulate differentiation of naive CD8+ Τ cells 
into cytotoxic Τ lymphocytes (CTLs), which are effector Τ cells that recognize and kill target cells 
expressing foreign peptide antigens in association with class I MHC molecules20. 
IL-4 which may be produced mainly by the Τ cell themselves, favours induction of Th2 cells 
through a STAT6-dependent pathway. Other important transcription factors for theTh2 response 
are CATA-3 and c-Maf The principal effector function of Th2 cells is in IgE- and eosmophils/mast 
cell-mediated immune reactions20 (figure 3). 
IL-18 is a cytokine, that stimulates the production of IFN-γ by NK cells and Τ cells and synergizes 
with IL-12 to induce a Thl response24 
I L - 1 2 AND ANTI-TUMOR I M M U N I T Y IN EXPERIMENTAL T U M O R MODELS 
Treatment with IL-12 has been shown to have a marked anti-tumor effect on mouse tumors, 
by inducing regression of established tumors and by preventing tumor development25 (figure 4) 
In most experimental models, the IL-12 anti-tumor effect was shown to require the induction 
of IFN-γ and a Thl response Cytotoxic lymphocytes, 1 e , CD8+ Τ cells, NK cells and NKT cells, are 
often involved m the mechanism of action of IL-12, but their cytotoxic activity is not required in 
every case. IFN-γ and a cascade of induced cytokines have a direct toxic effect on the tumor cells 
and might activate potent anti-angiogemc mechanisms. In addition IL-12 also augments the 
production of lgC2a antibodies that have been shown to have anti-tumor activity in vivo. 
However, during the induction of the Thl response, a temporary immunosuppression has also 
been reported and shown to be due to production of nitric oxide by activated macrophages25 
INTERLEUKIN-12 I N CLINICAL TRIALS 
Because of the aforementioned immunomodulatory characteristics, IL-12 is an interesting 
candidate cytokine for the induction of anti-tumor immunity Recombinant human IL-12 
(rhl-12) is used m clinical trials in oncology, hepatitis C and B, and HIV Here we will only 
discuss the studies m patients with cancer 
Phase I studies with systemic odministrotion 
In cancer patients with various tumor types, but especially in renal cell cancer and melanoma, 
several phase I studies have been performed with either intravenous (ι ν ) or subcutaneous (s c ) 
administration of rhlL-122 4 3 1 Different schedules were used Toxicity was highly dependent on 
the schedule of administration32 The maximal tolerated dose of s.c or ι ν administration of 
rhlL-12 varies between 500 and 1000 ng/kg, with varying frequencies of administration between 
the different studies Toxicity mainly consisted of a flu-like syndrome. Dose limiting toxicities 
consisted of elevated hepatic transaminases, cytopemas, hyperbilirubinemia, tnglyceridemia, 
pulmonary toxicity, deterioration of performance status, fever, vomiting, and mental depression 
IFN-γ production was seen, which exhibited attenuation with subsequent administrations 
Lymphopenia was observed, with recovery occurring within several days and without rebound 
lymphocytosis, as seen after IL-2 therapy IL-12 could reverse defects m NK cell and Τ cell function33 
Although determination of a clinical response is and cannot be the primary goal of a phase I 
study, the number of responses in patients with advanced cancers was limited, 1 e , five 
responses in 156 treated patients. In the phase I study in which nine patients with cutaneous 
16 
Chapter ι 
figure 4 The anti-tumor effects of IL-12. IL-12 stimulates the production of IFN-γ by NK cells and Τ cells, induces a Thl response, 
activates the cytolytic functions of NK cells and CTLs and inhibits angiogenesis. 
INTERLEUKIN-12 
w 
Naive CD4+Τ cell NK cell CD8+CTL NK cell CD8+CTL 
Thl cell 
Stimulation of IFN-γ secretion Increased proliferation and cytotoxicity 
Cytotoxicity 
IP-10 
M S Anti-angiogenesis 
T-cell lymphoma were treated an overall response rate of 56% was seen3 0. 
It was shown that patients w i t h tumor regression or prolonged disease stabil ization were able to 
maintain IFN-γ induction after repeated injections, while in patients w i t h disease progression the 
IFN-γ induction was at tenuated 3 1 . 
Phase I studies with locoregional administration 
Two phase I studies w i t h locoregional administrat ion of rhlL-12 were performed, i.e., 
intraperitoneal administrat ion in patients w i t h peritonit is carcinomatosis caused by diverse 
cancers3 4 and intravesical administrat ion in patients w i t h recurrent superficial transit ional cell 
carcinoma of the bladder3 5. Both administrations were feasible. After the peritoneal 
administrat ion biological act iv i ty was seen and a phase I I study wi l l be performed. However, 
the intravesical administrat ion did not show ant i tumor or immunological effects. 
Phase I I studies 
In the f irst phase I I study in patients w i t h renal cell carcinoma, the tox ic i ty was extremely h igh. 
The administered dose of i.v. rhlL-12 was based on a previous phase I escalation study of a single 
test dose of rhlL-12 followed 14 days later by cycles of five consecutive daily i.v. injections every 
3 weeks. In the phase I study 500 ng/kg could be administered w i t h acceptable levels of safety. 
Of the 17 patients treated in the phase I I study 12 patients were hospitalized and t w o patients 
died due to toxicity. It appeared that the single injection of rhlL-12 t w o weeks before consecutive 
dosing had a profound abrogating effect on IL-12-induced IFN-γ production and t o x i c i t y 3 6 . 
Therefore careful a t tent ion t o the schedule of administrat ion is required. 
In three phase I I studies w i t h systemic administrat ion of rhlL-12 in patients w i t h advanced renal 
cell carcinoma 3 7 , ovarian cancer3 8 and cervical cancer3 ' the response to rhlL-12 was only 7%, 4%, 
and 3%, respectively. In the study in patients w i t h cervical cancer cell-mediated immune 
responses to specific antigens after t reatment were detected. 
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The phase I I study performed in patients with cutaneous T-cell lymphoma showed a response 
rate of 43%<0 Biopsy of regressing lesions revealed an increase in numbers of CD8+ Τ 
lymphocytes, suggesting a role for these cells in the observed anti-tumor immunity. 
Phase I studies with systemic administration in combination with another drug 
To maintain IFN-γ induction by rhlL-12 and to enhance its activity against melanoma and renal 
cell cancer ι ν rhlL-12 was combined with s c. rhlL-241.This was well tolerated, restored and 
maintained immune activation by rhlL-12, and showed clinical activity, especially in melanoma 
patients This combination will be further investigated in a phase I I study 
Preclinical studies showed synergistic antitumor effects of the combination of IL-12 with IFN-a 
In a phase I study this combination was tested. Both rhlL-12 and IFN-a were s c administered to 
patients with renal cell carcinoma or melanoma. This combination was feasible and immunological 
effects, ι e , induction of IP-10, Mig and IFN-γ mRNA expression was seen42. A phase I study in 
patients with B-cell non-Hodgkm lymphoma was performed with the combination of s c IL-12 
and rituximab, a monoclonal antibody that binds to CD20 on Β lymphocytes43. This well-tolerated 
combination showed a response rate of 69% and will be further investigated. 
Other studies 
A phase I study was performed m which IL-12 gene therapy of cancer by peritumoral injection of 
transduced autologous fibroblasts was administered44 It was feasible and m four of nine patients 
remissions were seen. Recently, a phase I study with mtratumoral injection of an adenovirus 
encoding IL-12 for advanced digestive tumors was performed. It was feasible and well-tolerated45 
Several phase I studies were performed in which a relatively low dose (30 to 100 ng/kg) rhlL-12 
was added to a peptide vaccine m melanoma patients4 6 4· IL-12 seemed to elevate the immune 
response, i.e., an antigen-specific immune response against the peptide vaccine This approach 
is promising and further studies are planned. 
O U T L I N E OF T H E THESIS 
In the recent past IL-2 was i.t. administered to HNSCC patients. Unfortunately, the response rate 
was very low. One of the explanations could be that IL-2 induces a predominant Th2 response, as 
reflected m the presence of eosinophils at the site of the tumor m some cases. Cytokines 
produced byTh2 cells have a negative influence on theThl response, the latter being regarded 
as crucial for a strong cell-mediated immunity. IL-12, a relative new cytokine, is a strong inducer 
of the Thl response and is of great interest to explore in this context. 
By performing two clinical studies with mtratumoral administration of IL-12 in patients with 
HNSCC we wanted to answer the following questions: 
ι What is the toxicity of rhlL-12 after mtratumoral administration and how does this relate 
to the toxicity observed after systemic administration7 
2 How is the pharmacokinetics (PK) of IL-12 after mtratumoral administration compared 
to systemic administration7 
3 What are the pharmacodynamic effects (PD) of IL-12 m the peripheral blood, the 
locoregional lymph nodes and the primary tumors7 
3.1 Can we detect more IFN-γ7 
3.2 Can we detect other signs of a Thl response7 
3 3 Which cells are most important in humans m mediating the anti-tumor effect of 
IL-12, 1.e , the NK cell, or the cytotoxic Τ cell? Do we detect effects on other cells 
of the innate or adaptive immune system, eg , DCs, Β cells, eosinophils and 
neutrophils7 
4 Can we detect any clinical activity7 
18 
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In chapter 2 we have summarised the clinical studies using loco-regional immunotherapy in 
patients w i t h cancer. The results of mainly phase I and I I studies in patients w i t h HNSCC and 
other cancers are reviewed. 
In chapter 3 the results of a phase I study w i t h weekly administrat ion of s.c. rhlL-12 are 
described. Based on this study and the pharmacodynamic analysis of these patients4», the 
treatment schedule for the performed phase l b and phase I I study in HNSCC was determined. 
Chapter 4 describes a phase l b study t o assess the toxic i ty and safety of i.t. injected rhlL-12 at 
t w o dose levels in patients w i t h recurrent HNSCC. The secondary objectives were the assessment 
of clinical act iv i ty, the PK of rhlL-12 after i.t. administrat ion, and the PD effects on leukocyte 
subsets, cytokine profiles and T h l (T-bet) and Th2 (c-Maf) transcription factors in peripheral blood. 
Because of the observed tumor colour change in the phase l b study, suggesting a vascular effect, 
a study in an implanted human tumor model, HNSCC xenograft in nude mice, was performed. 
We investigated the micro-environmental effects of i.t. recombinant mouse IL-12 (rmlL-12) on 
the vasculature, blood perfusion, hypoxia and proliferation of the tumor cells. This study is 
described in chapter 5. 
To evaluate the pharmacodynamic (PD) and immune effects of i.t. injected rhlL-12 on the 
regional lymph nodes, the primary tumor, and the peripheral blood, a phase I I study was 
performed. Previously untreated HNSCC patients received rhlL-12 i.t. before surgery. We 
compared the results w i t h the collected material of control HNSCC patients, who did not receive 
rhlL-12. In chapter 6 the distr ibut ion of the different lymphocyte subsets locoregional and the 
mRNA expression levels of IFN-γ, IL-10, and the T-bet/c-Maf ratio locoregional are described. 
Also, the toxicity, clinical activity, and the PK of rhlL-12 after i.t. administrat ion are studied. In 
chapter 7 the cascade of effects of IL-12 on the cells of the immune system in the primary tumor 
and the locoregional lymph nodes is unravelled. We report on the histologic and 
immunohistochemical f indings in the primary tumor and lymph nodes of the IL-12-treated 
patients. 
Based on the observed changes in the architecture of the lymph nodes after i.t. rhlL-12 
administrat ion, we investigated the Β cell in more detai l. In chapter 8 the Β cell activation 
in patients treated in the phase l b and the phase I I study is described. 
In chapter 9 the results and future perspectives are discussed. Finally, the summary, 
in English and Dutch, of the performed studies is presented. 
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S U M M A R Y 
Many patients w i th invasive cancer have a compromised immune system This immune 
dysfunction does appear to start at the site of the tumor Locoregional immunotherapy is given 
to stimulate the immune system in order to kill tumor cells either indirectly via a specific or a 
non-specific way or directly via cell transfer therapy Advantages to give this immunotherapy 
locoregionally instead of systemically are a higher concentration of the immunomodulator at the 
site of the tumor, to attract or activate effector cells, and diminished toxic i ty In this review we 
have summarised the clinical studies using loco-regional immunotherapy in patients w i t h cancer 
Mainly phase I and I I studies were performed Clinical responses were seen No single 
locoregional t reatment has become a standard therapy Relatively few investigations were 
performed to estimate the influence on the locally effector mechanisms or immune dysfunction 
In future clinical trials it is essential to get a better insight in these mechanisms 
I N T R O D U C T I O N 
OBJECTIVES OF T H I S R E V I E W 
In this review clinical studies m which patients were exclusively treated w i th locoregional 
immunotherapy are summarised 
Although locoregional immunotherapy originates from the 19th century only the most recent 
studies are discussed For example the early studies w i t h mtralesional BCC or BCC cell wall 
products in melanoma or head and neck carcinoma are not considered Only trials in patients w i t h 
invasive tumors are described Patients w i t h basaliomas, papilloma of the trachea and superficial 
bladder cancer are therefore not mentioned Studies in which the effector mechanisms were 
immune-related are reviewed Therefore, trials w i th radio-immunotherapy and gene-therapy w i t h 
a vector that not primarily affects the immune system are excluded For the same reason, the 
trials w i t h loco-regional perfusion in which cytokines faci l i tate the retention of cytostatic agents 
by an increased vascular permeability at the tumor site are excluded12 The combination of local 
and systemic therapy only is discussed when the approach is rationally designed and executed 
1 e , combination after the availability of sufficient data on the efficacy of each modality 
L O C O R E G I O N A L I M M U N O T H E R A P Y 
Immunotherapy can be broadly grouped into three major categories 1 specific, 2 non-specific 
and 3 adoptive cell transfer Therapy is considered specific if i t enhances a certain aspect of the 
specific immune response to the tumor in question, 1 e , and immunosuppression, T-cell or B-cell 
(w i th monoclonal antibodies (Mab) or antibody-dependent cell-mediated cytotoxic i ty (ADCC)) 
A more general, non-specific activation of the immune system is when NK-cells, T-LAK cells, 
macrophages or granulocytes are activated Adoptive cell transfer therapy is an immunotherapy 
w i t h mostly autologous immune cells that have been activated and expanded m v i t ro , for example 
lymphokme activated killer (LAK) cells, tumor in f i l t ra t ing lymphocytes (TILs), or dendrit ic cells 
IL-2 gives st imulat ion both in a specific and non-specific way The interferons stimulate mostly 
in a non-specific way, but have also a direct anti-prol i ferative effect on tumor cells 
In many patients w i t h cancer the immune system is compromised, even early m the course of the 
disease This impaired immune funct ion is dif ferent from the generalised immunosuppression seen 
m patients receiving high doses corticosteroids or chemotherapy This immune dysfunct ion, w i t h 
both specific and non-specific changes, does appear to start at the site of the tumor and 
eventually becomes more generalised3 The f irst sign of immune dysfunction is the diminished or 
absence of tumor recognition This can be caused by immunological ignorance4, down-regulation 
of tumor-associated antigens (TAAs) or major histocompatibi l i ty complex (MHC) molecules5 or 
reduction in the proteins of the endoplasmic reticulum (ER), that process and transport antigens 
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over the ER membrane (TAP, i.e., transporter-associated w i t h antigen processing)6 Furthermore 
TILs' dysfunction is caused by the loss of theT-cell receptor (TCR) ζ chain 7 , inhibi t ion of 
activation of NF-Kb pós8 or apoptosis by Fas hgand (FasL) expression by tumor cells79 The lack 
of co-stimulatory signals (ι e , CD80 or CD86) might be another important event preventing the 
adequate response of the immune system 1 0 . 
Factors known t o interfere w i t h the immune response areTGF-ß11, prostaglandins12, msulm-like 
growth factor13, shedding of intercellular adhesion molecule (ICAM)14 and ganghosides15 In many 
tumors, the cytokine profile is altered w i t h a decrease in the amount of interleukin-2 (IL-2) and 
interferon-γ (IFN-γ) and an increase of interleukin-10 (IL-10), which gives rise to less 
presentation of TAAs and a lower expression of the MHC molecules1 6. 
There are several reasons for giving immunotherapy locoregional instead of systemic IL-2 is one 
of the most frequently used and investigated immunomodulators in oncology. In a lot of animal 
models it is shown that locoregional immune therapy is far more effective than systemic 
t r e a t m e n t 1 7 2 1 The concentration of IL-2 at the site of the tumor is very high after local 
application compared to intravenous (ι v ) infusion or subcutaneous (s.c.) administrat ion. The 
target cells, specific primed Τ cells in combination w i t h macrophages, NK cells and granulocytes, 
are mainly present at the site of the tumor IL-2 levels at the site of the tumor wil l therefore 
be crucial 2 2 . Another advantage of locoregional administrat ion compared w i t h systemic 
administrat ion is a lower toxicity. In another animal study measuring the biodistr ibution of 
lymphokme-activated killer Τ cells (T-LAK cells) it was shown that T-LAK cells administrated 
by different routes were able to localise into tumor metastases in various organs, but the 
concentration of the cells were highest after locoregional admin ist rat ion 2 3 . 
The therapeutically effects of locoregional immunotherapy in human cancer have been studied 
on a modest scale Most clinical studies deal w i t h local recurrent or residual disease, or primarily 
far-advanced disease for which no conventional treatment was available Access to the tumor was 
obtained by direct, endoscopic or ultrasound-guided mtra-or peri-tumoral inject ion, perilymphatic 
in ject ion, ι e., ,around the tumor-drammg lymph nodes, selected mtra-artenal infusion, or 
compartmental administrat ion into localised body cavities such as peritoneum, pleura, lung 
(by inhalation), or leptomenmges 
Published studies on locoregional immunotherapy wil l be discussed by tumor site Mostly 
phase I and I I studies were performed 
CLINICAL STUDIES 
H E A D A N D N E C K S Q U A M O U S C E L L C A R C I N O M A (HNSCC) 
HNSCC is characterised by locoregional tumor spread near extensive submucosal and nodular 
lymphatic tissue. The f irst therapeutically study w i t h locoregional cytokine based immunotherapy 
was founded on Form's compelling data m a mouse system w i t h IL-22 4. Cortesma et a l . 2 5 treated 
patients w i t h locoregional recurrent HNSCC w i t h penlymphatically injected low doses IL-2 in 
order to activate regional lymphocytes They obtained three complete responses (CR) and three 
partial responses (PR) in 10 patients. Subsequent studies using the similar treatment did not 
equal this high response r a t e 2 6 2 * (table i ) . Responses were also described w i t h pentumoral and 
mtra-artenal IL-2 a d m i n i s t r a t i o n 2 9 3 1 . Generally, fewer responses were seen in patients w i t h large 
tumor masses In patients w i t h a bilateral lymph node dissection no responses were seen, 
suggesting the necessity of regional lymph nodes to elicit an immune response The available 
data do not permit conclusions regarding the optimal dose or route of administrat ion, i.e., 
perilymphatic or mtratumoral In the 3 dose-escalation studies objective responses occurred 
at the lowest IL-2 dose used, at the highest, or both Systemic tox ic i ty varied from none or mild 
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fever only, to significant at high dose-levels in the dose-escalation studies. Side effects included 
temporary moderate local swelling and redness, or pain that appeared not to be dose related. 
Histological examination of treated tumors showed increased infiltration of lymphocytes, 
macrophages, and giant cells, and fibrous changes at the tumor site, and degeneration of cancer 
cells2 9 3 2·3 3 Also systemic activation of antitumor effector cells (ι e., increase in NK and LAK cell 
activity and activated T-lymphocytes) was observed33. Because polyethylene glycol (PEG)-modified 
IL-2 showed in several experimental tumors an enhanced efficacy as compared to IL-2, PEC-IL-2 
was used m a clinical study3< The response rate was low. Even though, the results of locoregional 
IL-2 in phase I I studies were disappointing, a phase I I I study was performed with or without 
adding of IL-2 perilymphatic to standard therapy m patients with resectable HNSCC Some 
prolonged survival was observed in patients that received IL-235. 
OK-432 is a pulverised preparation of the low-virulence SU stram of Streptococcus pyogenes 
of human origin It is a multi-cytokme inducer with limited efficacy after systemic 
administration and has great similarity with the initial studies of Coley m 189836 Surprisingly, 
Kitahara et al described eight responses in 12 patients after pentumoral injections37 The mam 
toxicity was fever (table i) The anti-tumor mechanism of OK-432 was not well understood 
Recently, it was shown that OK-432 induces a Thl response by toll-like receptor 4 (TLR4) 
signalling3*. 
A new approach is gene therapy Gleich et al 3'reported a phase I study using a HLA-B7 (MHC 
class I) gene by direct mtratumoral injection in patients with advanced HNSCC (see "direct gene 
transfer to other sites" for the mechanism of action) In nine patients four PR were seen There were 
no toxic effects of the gene therapy. An update of this study and the results of two phase I I 
studies showed in six of 60 treated patients a PR40. Further testing in patients with less advanced 
disease is planned 
Overall, m HNSCC the response rate of the locoregional immunotherapy (mostly IL-2) was low 
HNSCC is a good model for investigating the locally induced effects of (new) immunotherapy 
The gene transfer therapy is very interesting and phase I I studies are ongoing 
CENTRAL NERVOUS SYSTEM 
Malignant gliomas 
The brain has been considered an immunological privileged site, functionally protected from 
normal cancer immunosurveillance mechanisms. Pathological studies of malignant gliomas often 
show only a minimal host inflammatory response41. In addition, several systemic deficiencies 
of immune function have been identified in brain tumor patients and several inhibiting factors 
(i.e., transforming growth factor-beta (TGF-ßa) and an inhibitory mterleukm-i like substance) 
produced by malignant gliomas have been found42·43 In malignant gliomas immunotherapy is 
given in case of recurrent disease, mostly after total or subtotal resection. In most studies the 
locoregional immunotherapy was administered in the cavity which was artificially created after 
resection of the tumor, often through an Ommaya reservoir. In most studies adoptive cell transfer 
therapy was given 
In recurrent malignant glioma autologous leucocytes or autologous stimulated lymphocytes (ASL) 
were administered locoregionally4445 The cells were given either intrathecal or directly injected 
mtratumorally The response rate was not exactly determined in these patients, although 
improvement of neurological signs was described44 (table 1). The efficacy of this treatment 
was not obvious. There was no toxicity 
Several clinical trials were conducted with adoptive transfer of LAK cells and IL-2 in patients with 
recurrence of malignant glioma, mainly glioblastoma multiforme46-4' (table 1) The response rate 
was difficult to determine. In one study in which 23 patients were treated with IL-2 and LAK 
V 
table ι Clinical studies w i t h locoregional immunotherapy. In th is table only studies in w h i c h more than 10 patients are treated 
are included. 
T u m o r ( y e a r ) ref 
HNSCC 
Cortesma et al . ( 1 9 8 8 ) 2 5 
Squadrelli et al . ( 1 9 9 0 ) " 
Cortesina et al. (1991) 2 6 
Mattijssen é tal . (1991)" 
Saito et al. (1991)" 
Coreeta l . (1992) 3 0 
Vlocketal . (1994) 2 · 
Mattijssen et al. (1994)" 
Kitahara et al. (1996)" 
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IL-2 








Route o f 










































5 CR, 3 PR 
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- /Malignant gliomo 
Young ( 1 9 7 7 ) « 
Vaquero ( 1 9 8 7 ) 4 5 
Merchant ( 1 9 8 8 ) « 
Yoshida ( 1 9 8 8 ) " 
Fetell ( 1 9 9 0 ) " 
N i t t a ( 1 9 9 0 ) 5 4 
Ingram ( 1 9 9 0 ) 5 1 
Tsuboi ( 2 0 0 3 ) " 
Lillehei (1991) 5 2 
Hayes (1995)4» 
- Leptomeningeal metostases 
List ( 1 9 9 2 ) " 
autologous leucocytes 
autologous leucocytes 
IL-2 and LAK cells 
IL-2 and LAK cells 
IFN-ß 
LAK cells coated 
ASL stimulated with IL-2 
Autologous Τ cells stimulated 
with cytokines 
IL-2AAK cells/ASL 
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1 CR, 4 PR 
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4 PR 
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umor (year ) ref 
Malignom pleural effusion 
Yasumoto (1987) « 
Rosso (1988) " 
Lissoni ( 1 9 9 2 ) " 
Stathopoulos ( 1 9 9 6 ) " 






a t ion 
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Phase η ( e v a l ) ' Response 
o f s t u d y 
Ovarian c a r c i n o m a 
B e r e k ( 1 9 8 5 ) 7 1 
B e r e M i g e S ) 6 » 
Freedman ( 1 9 8 8 ) 7 0 
Stewart ( 1 9 9 0 ) " 
Steis ( 1 9 9 0 ) " 
Willemse (1990) " 
Nardi ( 1 9 9 0 ) " 
Bezwoda ( 1 9 9 1 ) 7 4 
Markman ( 1 9 9 2 ) " 
Freedman ( 1 9 9 4 ) « 
Canevan ( 1 9 9 5 ) « 
Pujade-Lauraine ( 1 9 9 6 ) 8 ( 
Edwards ( 1 9 9 7 ) β 5 
Freedman ( 2 0 0 0 ) M 
Direct gene t r a n s f e r 
Nabel (1996) ( M M ) » 2 
Rubin (1997) (colorectal c a ) " 
Stopeck (1997) ( M M ) » 3 
Gleich (1998) ( H N S C C ) " 
Heo (1998) (all kinds o f ca)»* 




( M M , breast ca)»» 
Nemunait is (1999) ( M M ) 1 0 0 
d e i c h (2001) (HNSCC) 4 0 
Stopeck (2001) ( M M ) » 4 
Sangro (2004) 




IL-2 and LAK cells 




IFN-a +/- Cisplatin 
IFN-a+/- Cisplatin 




IL-2 (2 schedules) 
IL-2 and IFN-γ+/-TIL 
gene transfer of HLA-B7 
gene transfer OF HLA-B7 
gene transfer of HLA-B7 
gene transfer of HLA-B7 
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gene transfer of IL2 
gene transfer of IL2 
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IL-2 and LAK cells 
TNF-a 
IL-2 and OK-432 
TNF-a and IFN-γ 









Phase η (eval)' Response 
of study 







22 CR, 6 PR 
8 CR, 10 PR 
3 CR, 4 PR 
14 CR 
Abbreviations: na-notavailable; MM-metastatic melanoma; HNSCC-head and neck squamous cell carcinoma; 
RCC-renal cell carcinoma; CR-complete response; PR-partial response. 
' η (eval)-number of patients (number of évaluable patients, if this number was less than the number of included 
patients) 
b
 response was defined as a complete clearing of cerebrospinal fluid tumor on 2 sequential weekly lumbar punction 
cells six patients had a PR47. Hayes et al. treated 19 patients after surgery w i t h IL-2 and LAK cells; 
after f in ishing the immunotherapy all patients were offered chemotherapy, including responders. 
They obtained one CR and two PR during immunotherapy and one addit ional CR 14 months after 
stopping chemotherapy4 ' . The median survival was 12 months, which was longer than in a 
simultaneously treated (wi th only chemotherapy) patient population w i t h a survival of only 6 
months. However, this does not replace a randomised study. Toxicity consisted mainly of 
neurological symptoms due to temporary cerebral oedema. Significant biologic changes, 
characterised by a regional eosinophilia, and extensive lymphocytic in f i l t ra t ion assessed by 
immunohistochemistry, were correlated w i t h a better survival. In an update of this study six 
out of 28 treated patients had a long-term survival of greater than 2 years50. 
Another approach in recurrent malignant glioma is treatment w i t h autologous stimulated 
lymphocytes w i t h or w i thou t LAK cells and IL-251·52. Response rates were not exactly given. 
There were no major side effects. The given survival data are hardly to interpret. Recently ex 
vivo expanded autologous tumor-specific Τ lymphocytes were locally injected in 10 patients 
w i t h recurrent malignant gliomas. Five patients showed a response5 3. 
Nitta et al. described treatment w i t h LAK cells pre-incubated by bispecific ant ibody 5 4 (table i ) . 
The antibody consisted of an anti-CD3 mAb chemically conjugated w i t h an anti-glioma Ab. In 
10 treated patients four PR were found. In four additional patients a high-density area appeared 
at the site of the surgical resection, what probably was a good sign, because in two of those 
patients a biopsy from this area showed necrosis of tumor cells. There was no toxicity. 
In a small interesting phase I / I I study tumor lysate-pulsed dendrit ic cells were intratumorally 
and intradermally administered in seven patients w i t h recurrent disease. It was safe and 
ant i tumor and immune effects were detected 5 5 . 
One study used IFN-ß in 20 patients w i th no response56 (table i ) .The major di f f iculty wi th this 
form of therapy was a problem w i th the Ommaya reservoir (obstruction or infect ion). 
Summarising, in malignant glioma in most phase I I studies no évaluable disease was present. 
The effect of therapy was evaluated on clinical improvement and survival. Interpretation of 
these study parameters is impossible in phase I I studies. In most studies no investigations were 
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performed to elucidate potential effector mechanisms The results obtained so far, do not justify 
a phase I I I study 
Leptomemngeaf metastases 
In one study intraventricular injection of IL-2 into patients with leptomenmgeal carcinomatosis 
(from adenocarcinoma of the lung or malignant melanoma) induced release of secondary cytokines, 
soluble IL-2 receptor and neutrophilic leukocytes, sustained presence of lymphocytes, and decrease 
of malignant cells m the cerebral fluid5 7 There is no place for this treatment m daily practice 
INTRAPLEURAL ADMINISTRATION 
Intrapleural immunotherapy was studied in two categories of patients first, in patients with 
pleural mesothelioma and second, in patients with malignant pleural effusion mainly due to lung 
and breast cancer and sometimes other cancers In intraperitoneal tumor models intracavitary 
administration of IL-2 can induce very high numbers of LAK cells in the peritoneal excudate5' 
The interferons have an antiproliferative effect on tumor cells including mesothelioma and IFN-γ 
is a potent activator of macrophage cytotoxicity against tumor cells 
Pleural mesothelioma 
Pleural mesothelioma is an incurable disease Intensive treatment with surgery, radiation therapy 
or chemotherapy has no proven effect on survival In pleural mesothelioma IFN-γ or IL-2 was 
administered locoregionally through a thin catheter or Port a-cath system Response rates 
(measured on a CT scan of the chest and evaluated according to the criteria of the World Health 
Organisation) were between 19 and 54% 5 9 6 3 , with a median time to progression of 12 to 15 
months"163 (table 1) Toxicity was mild, except on high dose-levels and consisted of catheter 
infection, fever and flue-like symptoms61 Patients with a low tumor load had a higher response 
rate62 The level of induced TNF-a and LAK cell activity were not predictive for response61 In a 
phase Π study with the combination of activated macrophages and IFN-γ the response rate was 
very low64 In conclusion IL-2 appears to have anti-tumor activity m pleural mesothelioma Future 
studies are required to see if this treatment will prolong survival However, mesothelioma is a 
very rare disease, which will be a problem for performing a phase I I I study 
Malignant pleural effusions 
In the palliative treatment of malignant pleural effusions due to carcinomas of lung, breast or 
other, IL-2, IFN-ß or IFN-a was administered mtrapleurally6568 Response rates (disappearance 
of fluid effusion) differed between 38 and 82% (table 1) In most responders the cytology of the 
effusion became negative The response duration ranged between 2 and 10 months68 Toxicity was 
mild After IL-2 administration induction of LAK cells was only seen m responders65 Rosso et al 
observed all the responses in patients with an effusion volume <1000 ml67 Surprisingly, an 
increased ratio of tumor cells to malignant effusion-associated mononuclear cells and the 
presence of CD8+ Τ lymphocytes within the malignant effusions were positive correlated 
with a response after treatment with IFN-a68 This form of treatment has never been tested 
m a randomised study versus the standard approach, 1 e , chemical pleurodesis with intrapleural 
installation of nitrogen mustard, bleomycin, tetracycline or talc With these drugs responses 
occurred m 30-91% of the cases Using the locoregionally immunotherapy instead of the 
standard therapy has showed no clear benefit and there is no place for this treatment in 
daily practice 
OVARIAN CARCINOMA 
In ovarian cancer residual disease after chemotherapy is a great problem, with limited chance 
of cure The disease is very often limited to the intraperitoneal space Residual ovarian cancer or 
recurrent ascites has been treated with several intraperitoneal (ι ρ ) immunotherapeutical agents, 
because in the intraperitoneal space the cytokine or immune cells can be brought in direct 
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contact with tumor cells. Most responses in ovarian cancer are surgically documented. 
Corynebacterium parvum i.p. (a bacterial component) induced a rather profound local reaction 
and its toxicity prevented more widespread testing69. Another way of non-specific treatment was 
the administration of viral oncolysates70 (table i ) . Humoral responses to TAAs and viral antigens 
were observed in patients demonstrating clinical activity. 
On the other hand, IFN-a was locally well tolerated but had significant systemic side effects. It 
has shown activity in ovarian cancer patients with very small volume, i.e., minimal residual 
disease (MRD, microscopic disease or tumor nodules <5 mm) after first line chemotherapy71-72 
(table i ) . Survival data were not given. NK cells obtained from the i.p. cavity revealed an 
increased cytotoxicity in most patients71. However this increased NK lysis did not correlate 
with the individual tumor response73. There has been substantial evidence to suggest synergy 
between various interferons and cytotoxic agents, i.e., cisplatin74. Therefore IFN-a was given 
in combination with cisplatin in three studies. In two studies the response rate (RR) of the MRD75 
or malignant ascites76 was approximately 50%, but in the third only 7%7 7. In this last study most 
patients had extensive cisplatin-resistant carcinomatosis (table i ) . 
Based on two pilot studies with IFN-γ i.p.78·79, which showed an increased cytotoxicity of tumor-
associated macrophages, secondary release of cytokines and a marked increase of MHC class I I 
molecules, a large phase I I study was performed80. One hundred eight patients with residual 
disease at second-look laparotomy were treated with IFN-γ i.p.. Of 98 assessable patients, 32% 
achieved a surgically documented response, with a median duration of 20 months (table i ) . 
The age of the patient and size of residual tumor were significant prognostic factors for the 
réponse to IFN-γ. Adverse events included fever, flu-like syndrome, neutropenia, and liver 
enzyme disturbances. No significant peritoneal fibrosis was noted. Controlled prospective 
trials are required to determine the place of IFN-γ i.p. in ovarian cancer. 
IL-2 was given in a number of studies, sometimes together with LAK cells81·82, with tumor 
infiltrating lymphocytes (TIL)83, with IFN-γ84, or as single agent85 (table i ) . Toxicity of IL-2 i.p. 
was rather high, with intraperitoneal fibrosis being the greatest problem. Other toxicity included 
abdominal pain secondary to accumulation of ascites and systemic effects, i.e., fever, nausea and 
vomiting and diarrhoea61·82. LAK cell activity was increased intraperitoneal and to a lesser degree 
in the peripheral blood81. Edwards et al. compared two schedules of IL-2 i.p.; IL-2 was better 
tolerated as a weekly infusion as compared with a 7-day infusion85. The RR was 26%. In this 
phase I I study a prolonged survival was suggested, but only a randomised trial can address 
this question. In this study catheter infection was the most important toxicity. 
Canevari et al. administered to patients with advanced ovarian carcinoma autologous, ex vivo 
expanded Τ lymphocytes re-targeted with bi-specific (bs) Mab OC/TR, combined with soluble 
OC/TR and low dose IL-2 i.p.'6. The bs-Mab OC/TR is specific for CD3 on Τ lymphocytes and for 
a high affinity folate-binding protein (M0vi8) which is overexpressed by about 90% of ovarian 
carcinomas87. The supposed mechanism of action is probably based on an initial bispecific 
Mab-retargeted T-cell response directed against folate binding protein-positive cells, which in 
turn triggers a non-specific inflammatory reaction86. They observed only local anti-tumor effects, 
with a RR of 23% in 26 évaluable patients and disappointingly no systemic anti-tumor effects. 
This matched with the observation that the treatment resulted in substantial local 
immunomodulation but virtually no systemic immunomodulation88. 
In summarise, it can be stated, that in ovarian cancer, response rates differed between 0 and 
53%, with also the occurrence of complete responses. Although the number of treated patients 
is sometimes high, a phase I I I study to identify a possible survival advantage has not been 
performed. Relatively few investigations have been performed for searching to the effector 
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mechanisms. It is not clear if IFN-γ is superior to other intraperitoneal immunotherapeutics, 
for example IFN-a, but the data presented are challenging. Therefore IFN-γ might be a candidate 
for further investigation. 
DIRECT GENE TRANSFER TO OTHER SITES 
Direct intratumoral gene transfer or gene therapy offers a novel approach to augment tumor 
cell immunogenicity while minimising systemic toxicities. The published clinical studies of gene 
therapy influencing the immune system transferred an HLA-B7 gene, an IL-2 gene or IFN-γ gene 
intratumorally (table i).The differences in vectors will not be discussed, because it is beyond the 
scope of this review. 
The expression of MHC class I molecules is often decreased or undetectable in tumors. However, 
these molecules are necessary for TAA-recognition and activation of CD8+ CTLs. In an animal 
model it was shown that intratumoral injection of allogeneic MHC genes into murine tumors 
resulted in induction of CTLs against tumor cells8». Nabel et al. published the first clinical results 
in 5 patients with malignant melanoma (MM) treated with intratumoral injections of an 
allogeneic MHC class I gene HLA-B7, in a cationic lipid vector90. Since than, six other phase I 
studies (melanoma, renal cell carcinoma, colon cancer, head and neck cancer (see above) or other 
cancer) are published40·9195 (table 1). In post-treatment biopsies HLA-B7 was demonstrated in the 
majority of the patients in all studies. However, HLA-B7-reactive cytotoxic T-lymphocytes (CTLs) 
were only found in the minority of treated patients. The treatment was safe, feasible and 
associated with minimal toxicity (related to technical aspects of the injection or biopsies). There 
were responses in head and neck cancer, lung cancer and MM, both in lesions treated with the 
gene, as exceptionally in distant lesions. In a phase I I study intralesional gene transfer of HLA-B7 
and ß2-microglobulin was administered in 52 patients with metastatic melanoma96. Regression in 
the injected lesion was 18% and two PRs were seen. 
The other approach is direct gene transfer of an IL-2 DNA lipid complex in the tumor. In animal 
models, tumors containing the IL-2 gene showed a significantly more potent stimulus for the 
immune system in comparison to untransduced cells. Intratumoral injection of the murine 
equivalent of this IL-2 gene showed complete tumor regression mediated by CD8+ cells'7. Calanis 
et al treated 74 patients with IL-2 DNA lipid complex98. There were three PR in RCC or MM and 
there was regression of the injected tumor in another nine patients. Toxicity was mild and existed 
mainly of constitutional symptoms. The IL-2 plasmid was detected in post treatment samples of 
29 of 46 evaluated patients. Post treatment biopsy specimens showed an increased IL-2 
expression and infiltration of CD8+ cells. One other phase I study used an adenovector-mediated 
gene delivery of IL-2 in subcutaneous localisations of melanoma or breast cancer99. Local 
inflammation was observed at the site of injection in 60% of the patients. The gene expression in 
tumor biopsies was present in most cases. There were no clinical responses, but six patients had 
an incomplete local tumor regression at the site of the injection. 
One study described the use of an IFN-γ retroviral vector administered intratumorally100. No 
toxicity was observed. IFN-γ expression was confirmed in only three of 10 harvested tumor 
samples. No responses were seen. A phase I study with intratumoral injection of an adenovirus 
encoding interleukin-12 (IL-12) in 22 patients with advanced digestive tumors showed that it 
was feasible and well tolerated. In one patient with hepatocellular cancer a response was seen101. 
Almost all the above-mentioned trials with gene therapy were phase I trials. The main purpose 
was to determine feasibility and safety of the intratumoral gene delivery. Patients were treated at 
different dose-levels. So, the response rate must be established in phase I I studies in future. In 
these studies much more emphasis has been given to elucidate the local effector mechanisms 




One phase I study was performed with inhaled IL-2 (table i ) 1 0 2 . Reversible airway irritation 
causing a non-productive cough represented the dose-limiting toxicity. Posttreatment 
bronchoalveolar lavage showed an activated lymphocyte phenotype with increased HLA-DR 
expression. Other studies in patients with metastatic renal cell carcinoma with inhaled IL-2 
were always done in combination with systemic IL-2 and/or IFN-a s.c. and showed low 
toxicity 1 0 3 1 0 5 . Despite the large number of patients treated, unfortunately no randomised 
phase I I I study has been published. Hence, the true value of the locally inhaled IL-2 is still 
questionable. 
Ascites 
Intraperitoneal immunotherapy was given for refractory malignant ascites due to metastatic 
spread of carcinomas of different origin (i.e., gastrointestinal, ovarian, breast, uterus) as palliative 
treatment. The number of responders (disappearance of ascites) was in all studies high (42-97%) 
(table i)»2.i<»-i09. The disappearance of cancer cells, as determined by cytology, was 86% in patients 
treated with IL-2 and OK-432. Improvement of performance status and clinical symptoms were 
observed in responders. After IL-2 and OK-432 administration an increase of cytotoxic activity of 
CD4+ cells was seen107. In responding patients after combination treatment with TNF-a and 
IFN-γ it was shown that an increase of peripheral NK activity occurred108. 
The standard treatment for patients with ascites is diuretics and/or relieving paracentesis with 
usually a moderate result. The studies with locoregional therapy showed disappearance of the 
ascites in the majority of patients. Toxicity was higher than with standard therapy. At this 
moment it is unclear if it is a good palliative therapy. 
Hepatocellular carcinoma or metastases in liver 
Intrahepatic immunotherapy can be given by hepatic artery infusion. Both in hepatocellular 
carcinoma and in case of liver metastases (mostly of colon carcinoma) locoregional immuno­
therapy as a single treatment is seldom given and there are only case reports published110-113. 
Locoregional combination immuno-chemotherapy has been given, but because it is combination 
treatment the relative contribution can only be established in randomised trials. Based on the 
present anecdotal positive results no conclusions can be drawn 1 1 4 1 1 6 . Rat experiments, performed 
after the earlier mentioned clinical studies, indicate a rationale for IL-2 pre-treatment followed by 
chemotherapy. In rat it was shown that the hepatic extraction rate of 5-FU was increased after 
administration of IL-2 1 1 7. 
In conclusion, there is far to less evidence that local immunotherapy is effective in 
hepatocellular carcinoma or liver metastases. Furthermore, there were no hard data given 
to use combination treatment of locoregional immuno- and chemotherapy in the above 
mentioned studies. 
Pancreatic carcinoma 
No studies have been published where locoregional immunotherapy has been given as single 
modality. There are studies in irresectable and resectable pancreatic carcinoma in which a 
combination of immunochemotherapy has been given11'·119. However, the rationale for combining 
these treatments is not well-founded, neither by in vitro investigations, nor by animal 
experiments. In two randomised studies the patients who have been treated after surgery 
(curative or palliative surgery) with IL-2 and IFN-γ in combination with chemotherapy had an 
improved survival compared with those who had no additional treatment after surgery11'. 




D I S C U S S I O N 
In this review the clinical studies in which locoregional immunotherapy was administered to patients 
w i t h cancer were discussed. Most studies used immunotherapy that increased specific or non-specific 
immune functions or both, i.e., IL-2 or the interferons. Adoptive cell transfer therapy was also used, 
mostly malignant glioma and ovarian carcinoma. The motive for using adoptive cell transfer therapy 
in malignant gliomas is that the central nervous system is an immunologically privileged site. 
After many decades of locoregional immunotherapy, none of the above described therapies has 
developed t o a standard therapy in patients w i t h cancer. Reasons therefore are that in most 
cancers, except in ovarian carcinoma, the response rates were low. Some of the therapies, i.e., 
transfer of TIL or LAK cells, are t ime consuming and very expensive. Although a longer survival in 
treated patients compared w i t h historical controls was suggested in a number of the reviewed 
articles, this can only be shown in a prospectively randomised phase I I I study. Such studies are 
hardly performed w i t h the abovementioned treatments. Toxicity was always lower than w i t h 
systemic t reatment, but nevertheless present. 
The most important reason t o give immunotherapy locoregionally is to get a higher concentration 
of the administered drug in the tumor, to attract or activate the effector cells. However, only in a 
l imited number of the reviewed studies, mainly in HNSCC and in the gene transfer studies, 
investigations were done to look for the effector mechanism locally and/or systematically. 
Histological examinations at the site of the tumor have its anatomical l imitat ions, but is essential 
to get insight in the events triggered in and around the tumor. Repeated cytology might be an 
alternative. Furthermore, i t is known, t h a t immunosuppression at the site of the tumor is 
present. The tumor has many escape mechanisms to prevent recognition by the immune system, 
or in case of T-cell act ivat ion prevent effective k i l l i n g 1 2 0 . The level and the reversibility of the 
immune dysfunction before and during immunotherapy are very important. In none of the 
reviewed studies these tumor related factors are regarded. 
It is recommended that in future clinical trials in cancer patients treated w i t h locoregional 
immunotherapy, both the locoregional immunodysfunction and the effector mechanisms involved 
wi l l be studied. This wi l l provide a better insight in the reasons of clinical (non)responsiveness of 
cancer and lead to a better selection of patients who wi l l benefit from locoregional 
immunotherapy. Furthermore local investigations may lead to a better insight in the potential of 
systemic therapy. Studies should be performed in an optimal experimental sett ing combining both 
clinical and laboratory expertise. 
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A B S T R A C T 
The safety and tolerabi l i ty of recombinant human interleukm-12 (rhlL-12) administered 
subcutaneously (s.c.) were evaluated in patients w i t h advanced cancers. Men and women aged 
> 1 8 years were enrolled in an open-label, dose-escalating phase I study. Histologic or cytologic 
diagnosis of advanced malignancy, w i t h residual, recurrent, or metastatic disease w i t h o u t 
standard curative therapy, life expectancy > 1 2 weeks, adequate hematopoietic, renal, and hepatic 
f u n c t i o n , and Karnofsky performance status score > 7 0 were required. Safety was assessed in all 
patients Tumor size was measured before the study, every 8 weeks, and at the final visit Sixty 
patients w i t h malignant melanoma ( M M ) , renal cell carcinoma (RCC), or other cancers received 
and tolerated rhlL-12 s.c. at once-weekly dosages of 30 t o 2100 ng/kg. All discontinuations 
resulting from adverse events (n=4) occurred at weekly doses >750 ng/kg 
Nine patients completed the study. Twenty-six patients who received rhlL-12 died because 
of disease progression, none was considered to be rhlL-12-related Forty-three patients 
wi thdrew because of disease progression. Two patients had a minor response (MR) one w i t h 
RCC receiving 900 ng/kg and one w i t h MM receiving 1800 ng/kg There were no complete or 
partial responses. Subcutaneous rhlL-12 (30-2100 ng/kg weekly) was well tolerated in a variety 
of advanced cancers 
I N T R O D U C T I O N 
Recombinant human mterleukm (rhlL)-12 is a heterodimenc, pleiotropic T-lymphocyte g r o w t h 
factor that has demonstrated preclinical ant i tumor efficacy primarily m murine cancer models, 
including the B16 melanoma and RENCA renal adenocarcinoma models 1 6 Phase I studies m 
patients w i t h advanced malignancies, and a phase I I study demonstrated modest overall efficacy 
profiles w i t h degrees of safety and tox ic i ty ranging from acceptable t o severely treatment-
l imi t ing adverse events (AEs) and laboratory t o x i c i t i e s 7 1 7 
Imbalances m type-1 and type-2 helper T-lymphocyte ( T h l and Th2) populations have been 
implicated m the disease courses of malignant melanoma (MM) and renal cell carcinoma (RCC) 1 8 2 0 . 
IL-12 mediates t u m o r - m f i l t r a t m g lymphocyte a c t i v i t y 2 1 2 2 , promotes T h l and natural killer (NK) 
cell responses1 1 1 7, inhibits tumor angiogenesis m a variety of cancers2 3 2 e , including metastatic 
renal cell carcinoma (RCC)2 5·2 7, and potentiates NK cell response2 9, which may also relate to 
the inhibi t ion of tumor metastases 2 6 3 0 . Increases m mterferon-gamma (IFN-γ) production in 
response t o rhlL-12 administrat ion have been pivotally linked by preclinical2 and clinical 
e v i d e n c e 7 6 1 0 1 2 · 1 7 2 1 3 1 3 3 t o the ant i tumor act iv i ty of rhlL-12, d iminut ion m circulating 
concentrations of both IFN-γ and IL-12 has been demonstrated upon continued rhlL-12 
t r e a t m e n t 7 8 1 1 3 4 · 3 5 . Serum concentrations of other cytokines, most prevalently IL-10, IL-6, 
tumor necrosis factor-alpha (TNF-a), and neopterm have also been demonstrated to increase 
as part of the host immune response that follows rhlL-12 administrat ion 8 " 1 3 1 5 3 1 3 6 3 7 . 
The present phase I study evaluated the safety and tolerabi l i ty of weekly subcutaneous (s c.) 
protein therapy w i t h rhlL-12 m the treatment of patients w i t h residual, recurrent, or metastatic 
malignancies that currently have no standard curative therapy. 
M A T E R I A L S A N D M E T H O D S 
S T U D Y D E S I G N A N D T R E A T M E N T S C H E D U L E 
We conducted a phase I, open-label, dose-escalating, nonrandomized, mult icenter outpat ient 
study of rhlL-12 administered by weekly s.c. injection t o patients w i t h advanced cancers. 
Men and women aged > 1 8 years were recruited at 3 centers m France and 1 center in the 
Netherlands who had 1) a histologic or cytologic diagnosis of, recurrent, or metastatic disease 
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for which there was no standard curative therapy; 2) life expectancy of at least 12 weeks; 
3) adequate hematopoietic, renal, and hepatic function; and 4) Karnofsky performance status 
score >70. Women of childbearing potential and men agreed to use adequate contraception 
(hormonal or barrier method of birth control) before study entry and for the duration of study 
participation. The study protocol and proposed conduct were approved by institutional review 
boards or human ethics committees in France and the Netherlands. Each patient gave signed 
informed consent before enrollment in the study. The study was conducted in accordance with 
the Declaration of Helsinki and its amendments. 
Patients were evaluated to receive treatment with rhlL-12 at dosages ranging from 30 ng/kg to 
2100 ng/kg for 8 weeks or until there was disease progression or toxicity associated with rhlL-12. 
The planned study duration was a maximum of 32 weeks, for any patient who had an objective 
response to treatment with rhlL-12 or stable disease (SD). With subsequent study protocol 
amendments, up to 24 additional weeks of rhlL-12 treatment could be administered. All 
patients participated in the study between February 1996 and April 1998. 
A 21-day screening period was followed by weekly (±2 days) s.c. injections of rhlL-12 for 
8 weeks. The final visit was conducted within 3 weeks of the last rhlL-12 dose. 
SAFETY ASSESSMENTS 
Safety analyses included all patients who received at least one dose of rhlL-12. Safety was 
assessed using incidences of AEs, in addition to results of physical examinations, serum 
chemistry, and hematology laboratory tests. Toxicity grading of AEs used the modified National 
Cancer Institute (NCI) Common Toxicity Criteria Scale. Dose-limiting toxicities (DLTs) were 
defined as AEs >NCI grade 3, regardless of attribution to treatment; investigators were to assess 
the etiologies of all DLTs. 
Safety was evaluated for the first cohorts of three patients each (30 and 100 ng/kg) after the 
initial four weeks of treatment. Subsequent cohorts of six patients each were then enrolled at 
dose levels of 300, 450, 600, 750, 900, 1200, 1500, 1800, or 2100 ng/kg rhlL-12. Dose escalation 
or maintenance was implemented according to the following criteria: 
1 If 1 or 2 of 3 patients in the 30 or 100 ng/kg rhlL-12 cohort experienced a DLT, another 
3 patients were entered at the same dose. 
2 If only 1 or 2 of 6 patients in the 300, 450, 600, 750, and 900 ng/kg cohorts experienced 
a DLT, escalation to the next dose occurred. 
3 If 3 or more of 6 patients in the 300, 450, 600, 750, and 900 ng/kg cohorts experienced 
a DLT, this dose was considered the toxic dose level, and the previously tested dose was 
defined as the maximum tolerated dose (MTD). 
Incremental additions of higher-dose cohorts (1200, 1500, 1800, or 2100 ng/kg) were based on 
the observations that DLT had not occurred at lower doses during the study; hence, the MTD 
could only be determined by adding patients at progressively increasing doses. 
No dose escalation was permitted within a cohort. Any patient who experienced a reversible 
DLT that was determined to be related to rhlL-12 administration was allowed additional 
rhlL-12 treatment at the next lower dose level. 
EXPLORATORY EFFICACY MEASUREMENTS 
Because this was primarily a safety study, formal efficacy analyses were neither planned nor 
conducted. Tumor status was evaluated by sequential measurements obtained at screening, 
after every 8 weeks of treatment, and at the final visit, from computed tomographic or plain 
radiographic images or by palpation. 
All objective responses were evaluated by 2 or more observations >4 weeks apart, measuring the 
increase or decrease in the sum of the products of the perpendicular diameters of all measured 
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table 1 Patient characteristics. 

















' Adenoid cystic carcinoma, Bartholin's gland (n=i); Uterine sarcoma (11=2); Pubic sarcoma (n=i); 
Hypopharynx carcinoma (n=i); Ovarian carcinoma (n=i). 
table 2 RhlL-12 exposure by number of doses per cohort. 



































































































lesions from baseline; any response or stable disease precluded the appearance of any new lesion 
and existing lesion progression. Complete response (CR) signified disappearance of all known 
disease; partial response (PR) was a >50% decrease in the size of all measured lesions; minor 
response (MR) was a >25% decrease in the size of all measured lesions; stable disease (SD) was 
a <25% increase or a <25% decrease from baseline in the size of all measured lesions; progressive 
disease (PD) was any increase >25% in the size of one or more measurable lesions or the 
appearance of new lesions. 
Karnofsky Performance Status scores and addit ional tumor measurement data were also evaluated 
for each patient. 
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Abbreviations: SD-stable disease; MR-minor response 
P H A R M A C O T I N E T I C A N D P H A R M A C O D Y N A M I C A N A L Y S I S 
Assays of serum IL-12, IL-12 antibodies, interferon-gamma (IFN-γ), IL-6, IL-10, neopterin, and 
tumor necrosis factor-alpha (TNF-a) levels, were performed. Serum IFN-γ, IL-12, and antibody 
data were collected from 20 patients treated w i t h 100 ng/kg , 300, 450, 600, 750, 900, 1200, 
or 1500 ng/kg rhlL-12. Serum levels of IL-6, IL-10, neopterin, and TNF-a were measured in a 
smaller cohort (n=8) that received doses of 450 to 1500 ng/kg rhlL-12. 
S T A T I S T I C A L A N A L Y S I S 
Changes from baseline in tumor measurements were summarized for each patient. Statistical 
comparisons were performed w i t h i n cohorts using paired t tests. 
R E S U L T S 
Forty patients w i t h RCC, 14 patients w i t h M M , and six patients w i t h primary tumors of other 
histologies were treated. All patients had some type of local or distant metastasis. 
Table ι summarizes demographic information for all patients who participated in the study, including 
prior t reatment history (chemotherapy, radiat ion, or surgery), and primary tumor type. Cohorts 
of 3 patients each were treated w i t h 30 or 100 ng/kg rhlL-12. Cohorts of 6 patients each were 
treated w i t h 300, 450, 600, 750, 900, 1500, or 1800 ng/kg rhlL-12. Seven patients participated 
in the 1200 ng/kg rhlL-12 cohort and five patients participated in the 2100 ng/kg rhlL-12 cohort. 
Treatment continued for 8 weeks or unt i l rhlL-12-related tox ic i ty or disease progression occurred. 
Table 2 summarizes rhlL-12 exposure by number of doses. Thir ty patients received five to eight 
doses of rhlL-12, while nine patients received 24 weekly doses. One 58-year-old white man was 
screened but died because of disease progression and did not receive rhlL-12. 
Table 3 summarizes the mean number of days on therapy for patients treated at each dose level. 
Patients were evaluated for response every 8 weeks. Patients who did not exhibit disease 
progression, and who were tolerating therapy, were continued on weekly rhlL-12. There appears 
t o be a dose-response trend w i t h less than 33% of patients having stable disease for 2 evaluations 
(16 weeks) at doses less than 750 ng/kg and 40% or more having stable disease for at least 
16 weeks at doses of 900 ng/kg and higher. While no objective responses were observed, 
t w o patients treated at the 900 ng/kg and 1800 ng/kg levels had a minor response. 
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A 60-year-old white man with a primary diagnosis of RCC received 24 doses of rhlL-12 at 900 
ng/kg for 170 days. He had 2 metastatic lung tumors, each with 2 stable measurements, followed 
by a final measurement 8 weeks later at which both tumors had shrunk (32% decrease). He was 
still alive at his last follow-up observation (November 2003). 
A 69-year-old white woman with primary melanoma of the left arm, with locally metastatic 
cutaneous melanoma in addition to left axillary lymph node metastases, received 24 doses of 
rhlL-12, at 1800 ng/kg, for 186 days. She also had one metastatic tumor on the left hand. Both 
tumors increased in size at the second measurement, then decreased in size by 38% at the third 
measurement. 
Twenty-six patients who received rhlL-12 died because of disease progression at intervals ranging 
from 2 days to 83 weeks after discontinuation from the study. None of the deaths was considered 
by the investigator to be related to treatment with rhlL-12. Of the 26 patients who died, 25 had 
discontinued rhlL-12 treatment because of disease progression; the remaining patient had 
completed the study. 
SAFETY OF IL-12 
The dosages used in this study (weekly s.c. injections from 30 to 2100 ng/kg rhlL-12) generally 
were well tolerated. Hence, these findings were insufficient to determine a clear MTD for rhlL-12 
administered weekly s.c. to these patients. There was a tendency for more severe adverse events 
at doses of 1200 ng/kg and higher. 
No rhlL-12-related deaths occurred during this study. 
All patients experienced at least one AE during the study, and all had an event attributed to treat-
ment with rhlL-12. In general, the frequency and intensity of rhlL-12-related AEs increased with dose. 
All discontinuations for which AEs were cited as the primary or sole reason for withdrawal (n=4) 
occurred at weekly doses >750 ng/kg of rhlL-12. These AEs included grade 4 elevated aspartate 
aminotransferase (AST) and grade 3 elevated alanine aminotransferase (ALT) levels in the same 
patient, grade 4 bilirubinemia, grade 3 shoulder arthrosis, and grade 2 asthenia. All of these AEs 
were likely related to treatment with rhlL-12. 
Table 4 summarizes the incidences of all AEs reported by >20% of patients who received rhlL-12. 
The most commonly reported AEs (regardless of relationship to rhlL-12) were lymphopenia, 
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Abbreviations: MR-minor response; n.a.-not available 
neutropenia, fever, asthenia, headache, nausea, and v o m i t i n g . 
Fifty-nine (59) patients had at least one grade 3 or 4 laboratory AE during the study. The most 
commonly reported grade 3 or 4 laboratory AEs were lymphopenia (59 patients), neutropenia 
(53 patients), and leukopenia (8 patients). AEs of grade 3 or higher related to impairment of liver 
funct ion (i.e., elevated alkaline phosphatase, bi l i rubin, AST, or ALT) or renal function (creatinine) 
occurred in 6 patients. 
Nonlaboratory grade 3 or 4 events that occurred in more than 1 patient were fever, asthenia, 
diarrhea, malaise, chest pain, and dyspnea. Previously reported severe laboratory toxicities, 
such as agranulocytosis and hemolytic anemia 1 9 , were not observed in this study. 
P H A R M A C O K I N E T I C S O F IL-12 A N D P H A R M A C O D Y N A M I C RESPONSES 
IL-12 and IFN-γ 
Table 5 presents comparative pharmacokinetic (IL-12) and pharmacodynamic (IFN-γ) data. Peak 
plasma concentrations and areas under the plasma concentration-time curves unti l the t ime 
points of last quantif iable concentrations ( A U C 0 . T ) are shown for IL-12 and for IFN-γ response to 
IL-12 administrat ion, at study week l . T h e number of days on therapy is shown for each patient. 
Much interpatient variabil i ty was observed in regard to which cytokines were induced after 
rhlL-12 administrat ion (table 5). Two patients who received 900 and one who received 1500 
ng/kg rhlL-12) developed rhlL-12 antibodies. 
At the beginning of this study, concentrations of IL-12 and IFN-γ were below the limits of detec­
t ion (80 pg/mL and 25.6 pg/mL, respectively), but increased to detectable levels w i th in 24 hours 
after rhlL-12 administrat ion at week 1. In 13 of 19 patients w i t h data, detectable levels of IFN-γ 
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were observed within 8 hours. Maximal IFN-γ response during week 1 occurred within 48 hours 
for patients given <750 ng/kg rhlL-12, and as late as 72 hours after dose administration m 
patients given >750 ng/kg rhlL-12. Of note, by week 6 the maximum peak IFN-γ concentrations 
had decreased by >93% of corresponding values at week 1 in all cohorts receiving >750ng/kg 
rhlL-12 (not shown). 
As evidenced by AUC 0 T, total exposure to exogenous and endogenous IL-12 generally tended to be 
higher at week 1 in patients who received >750 ng/kg These cohorts tended to have maintained 
stable disease and stayed on therapy longer than lower-dose cohorts (table 3) 
IL-6 and IL-10 
IL-6 concentrations were rarely detectable. IL-10 concentrations frequently exceeded the level of 
detection on the day of initial rhlL-12 administration, with elevations typically persisting for 3 
to 5 days Concentrations of IL-10 consistently peaked a second time, at days 36 to 40, to levels 
ranging from 40 to 110 pg/mL, generally paralleling increases in IFN-γ (not shown) 
Portielje and associates37 reported statistically significant increases m IL-10 concentrations in 
11 patients receiving 500 ng/kg rhlL-12 and in 4 patients receiving 1000 to 1250 ng/kg rhlL-12 
compared with baseline, and reported similarly concurrent peaks in IFN-γ approximately 50 to 
75 days after initial rhlL-12 administration. 
TNF-α and neopterin 
Concentrations ofTNF-a never exceeded the limit of detection (49 pg/mL) m the 8 patients 
in whom it was analyzed m the present study. Increases of two to five fold or greater m the 
induction of TNF-a messenger RNA was observed in peripheral whole blood samples in our 
subcohort study, but none occurred at rhlL-12 doses above 1200 ng/kg During follow-up, no 
toxicity was observed in connection with these increases31 TNF-a and IL-2 fluctuations have 
been implicated m immunocompetence and response in advanced RCC patients, as have levels of 
other cytokines in relation to prediction and variability of individual response3' 
Neopterin levels were elevated at baseline m most patients tested m the present study 
(consistent with subcohort), and increased further after rhlL-12 administration, a clinical finding 
that has also been previously reported1 0 1 3 
Of the two patients with MR, only one had data for IFN-γ, IL-10, and neopterin (patient 02-0019 
with RCC, 900 ng/kg cohort). All of these values showed sustained responses at the week 6 
measurement m this patient (166 pg/mL IFN-γ and 110 pg/mL IL-10 on day 37, followed by a 
peak concentration of 177.7 pg/mL neopterin on day 40) Taken together, these were the highest 
sustained values of all patients with week 6 data for all 3 parameters 
DISCUSSION 
Cytokine therapy with rhlL-12 has been previously evaluated in several phase I and phase I I study 
designs. The mam difference in the present phase I study is the magnitude of single weekly 
rhlL-12 doses used, which, through the maximum dose level (2100 ng/kg), was considerably 
greater than those used in similar clinical studies (typically 500-1000 ng/kg)7 9 
Using weekly s.c. administration, the present study did not determine a MTD for this dosage 
schedule of rhlL-12. These data suggest a weekly s.c dosing schedule was better tolerated and 
substantially higher doses of rhlL-12 could be administered for up to 32 weeks. 
The relationship between the administration of rhlL-12 and IFN-γ is well described in the clinical 
oncology setting7 e'12. IFN-γ concentrations have also been related to overall efficacy of the T-cell 
antitumor response2139. Some study results suggest that rhlL-12 therapy induces production of IFN-γ, 
IP-10, and other cytokines within the RCC tumor bed as well as by circulating mononuclear cells32. 
A relatively consistent pattern, as observed in this study, involves an initial rise of IFN-γ levels 
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after rhlL-12 administration, followed by a blunting or fall-off after continued therapy11 Collob 
and associates7 have further categorized IFN-γ induction into separate patterns among RCC and 
melanoma patients who had a response to rhlL-12 therapy, compared with those who had SD or PD 
We have previously reported a heterogeneity of cytokine response that is independent of rhlL-12 
dose31, suggesting the possible importance of interpatient variability regarding clinical response 
to rhlL-12 Low sample numbers at each dose level in this cytokine analysis (n=21) and in the 
present study (n=18 analyzed for IFN-γ response) did not allow clinically meaningful assessment 
of any dose-response relationship 
Between week 1 and week 6, the well-described blunting or downregulation of IFN-γ response 
also occurred with patients in this study The data m (table 5) suggest that elevation in IFN-γ 
levels, by itself, has limited predictive value for tumor response over this study duration 
We previously observed a downregulatmg effect of IL-10 on IFN-γ levels and attributed it possibly 
to increases in soluble IFN-γ receptor after repeated IL-12 administration31, or to an acquired 
defect in lymphocyte IFN-γ production in response to IL-127 It is also possible that the lack of 
long-term IFN-γ elevation is due to a suppressive effect by IL-10 on macrophage activation 
Consistently with these and other findings1 1 3 7, despite the biphasic and concurrent rises in IL-10 
and IFN-γ from week 1 to week 6, IFN-γ levels m the present study generally dropped below 
quantifiable limits after several days 
The dramatic increases m IFN-γ and neopterin that occurred after rhlL-12 administration suggest 
induction of macrophage-produced components, in response to rhlL-12 administration As with 
IL-10, neopterin concentrations remained elevated, and measurements at weeks 5 and 6 exceeded 
baseline levels Peak neopterin concentrations increased with the dose of rhlL-12, which is 
generally consistent with reports m the l i terature 8 1 3 4 0 4 1 , although a dose-response relationship 
has not been uniformly reported10 
These observations support the hypothesis that effective rhlL-12 therapy may require higher 
dose levels than those previously used, or at least a more efficient mode of delivering active 
IL-12 to tumor or tumor bed Collob and associates have also advanced the need for chronic 
administration of rhlL-12 to induce tumor regression, particularly in patients who mount a 
sustained (but not necessarily large) IFN-γ response7 
Most patients (43 total) withdrew from our study because of disease progression 
Discontinuations that were solely or primarily AE-related (four patients) mostly involved 
laboratory value abnormalities (elevated AST and ALT, bilirubmemia), arthrosis (which the patient 
reported as being present before study entry and worsening thereafter), or asthenia, all were 
attributed to treatment with rhlL-12 administered s c 
Similarly (and not unexpectedly), almost all patients (59 total) had at least one grade 3 or 4 
laboratory toxicity during the study In most cases, such elevations in laboratory parameters 
were not accompanied by clinical signs of patient morbidity Overall, these findings suggest an 
acceptable general systemic tolerability profile for once-weekly s c rhlL-12 
Other phase I and in vitro studies m similar cancers suggest that individualized host response is 
a critical component of clinically relevant antitumor activity4 2 4 6 
Individual patient serum IL-12 levels have been significantly associated with survival prognosis m 
RCC4749, and increased upon induction by IL-2S0-51 Reduced serum IL-12 levels frequently coexist 
with disease progression and relapse, and increased levels of vascular endothelial growth factor52 
The present study demonstrated that weekly rhlL-12 dosage was well tolerated Although no 
patient had a complete or partial response to treatment with rhlL-12, two patients treated with 
dose levels of 900 ng/kg or higher had a minor response Further, there was a trend for a greater 
mean duration of rhlL-12 therapy for patients who received dose levels of 750 ng/kg or higher 
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Moreover, the percentage of patients who received at least 16 weeks of rhlL-12 therapy was 
increased as the dose level of rhlL-12 increased. Patients with advanced cancer who typically 
enroll into phase I studies are often noted to have progressed at the f i rst restaging evaluation 
(8 weeks in the present study). Taken together, these data suggest that chronic administrat ion of 
rhlL-12 s.c. on a weekly schedule may be a useful adjunct to other cancer therapy. 
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The aim of this study was to evaluate the tolerabihty of mtratumoral (i.t ) administered 
recombinant human interleukin-12 (rhlL-12) in patients with head and neck squamous cell 
carcinoma. Six patients were treated once a week at two dose levels of 100 ng/kg or 300 ng/kg, 
respectively, up to 24 weeks. The primary endpomt was to assess the toxicity and safety of i.t. 
injected rhlL-12 in HNSCC patients; the pharmacokinetics and pharmacodynamics of rhlL-12, and 
any evidence of antitumor effect were also determined. 
Toxicity was mild, with prolonged grade 4 lymphopenia observed in only one patient No dose 
limiting toxicities occurred. In all 6 patients the rhlL-12 was detectable m plasma within 30 
minutes. Significant reductions m absolute number of peripheral blood lymphocytes and all 
lymphocyte subsets, especially cytotoxic Τ cells and NK cells, were observed that were maximal 
between 12-24 hours. Maximal plasma concentrations of mterferon-yand IL-10 were detected 
after 12 hours. A real-time semi-quantitative PCR analysis in peripheral blood mononuclear 
cells (PBMCs) showed a mean increase of mRNA encoding IFN-γ of 2 2 times relative to the 
pre-treatment sample. An unexpected, significant decrease of 80% m T-bet mRNA , a Τ helper 1 
transcription factor, was detected after 12 hours, with normalization after 48-72 hours. No 
complete or partial responses were observed In one patient a 40% regression of a tumor lesion 
was noted. 
In conclusion, rhlL-12 at these dose levels and schedule was well tolerated and resulted m 
measurable immunological responses. 
INTRODUCTION 
Head and neck squamous cell carcinoma (HNSCC) provides an excellent model to study the effects 
of locoregional immunotherapy, such as cytokines. HNSCC is characterized by the occurrence of 
regional lymph node metastases and therefore a regional lymph node dissection, together with a 
resection of the primary tumor is frequently the treatment of choice Furthermore, HNSCC is an 
immunogenic tumor, as demonstrated by a variable amount of infiltrating lymphocytes and other 
immune cells susceptible for activation by e.g interleukin-2 (IL-2) treatment1 Several kinds of 
immunodysfunction, starting at the site of the tumor and eventually generalized, have been 
reported25. Immunotherapy given pre-operatively, allows to study the effects both m the primary 
tumor and m the (draining and non-draining) lymph nodes. In approximately 50% of patients the 
primary tumor is accessible for local injection. 
In the past the therapeutic effects of locoregional IL-2 administration in HNSCC have been 
studied extensively Locoregional immunotherapy may be preferred over the systemic 
administration for the following reasons. In animal models", it has been shown that with 
locoregional IL-2 higher concentrations of IL-2 are achieved at the site of the tumor with less 
toxicity compared to systemic treatment. Furthermore, after local administration IL-2 has 
preferential access to the draining lymph nodes Mattijssen et al showed in a syngeneic guinea-
pig line-10 tumor model that i.t. (and not pen-lymphatic) administration of polyethylene-glycol-
modified IL-2 (PEC-IL-2) resulted in the cure of animals with palpable experimental tumors and 
regional lymph node micrometastasis. Moreover, protective systemic antitumor activity was 
induced10. In a phase I I study in HNSCC patients the effect of 1 t. injection of PEC-IL-2 was 
evaluated. It was feasible, however, the objective response rate was only 6%" 
lnterleukin-12 (IL-12) is a heterodimeric cytokine, which consists of two disulfide-lmked subumts, 
1 e , IL-12p40 and IL-12p3512. IL-12 has a wide range of biological activities1 3 1 4 It stimulates the 
proliferation and activation of cytotoxic Τ lymphocytes and NK cells and induces the production 
of a number of other cytokines, especially IFN-γ, but also TNF-a and CM-CSF1S16. IL-12 is the key 
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cytokine in the induction of Τ helper 1 ( T h l ) responses and thereby cellular i m m u n i t y 1 7 
Furthermore, IL-12 inhibits angiogenesis 1 8 1 9 . In experimental murine tumor models IL-12 has 
antineoplastic a c t i v i t y 2 0 2 1 . In cancer patients w i t h various tumor types six phase I s tudies 2 2 2 7 
and one phase I I s tudy 2 ' have been performed w i t h either intravenous (ι ν ) or subcutaneous 
(s.c.) administrat ion of recombinant human IL-12 (rhlL-12) Toxicity was very dependent on the 
schedule of admin ist rat ion 2 8 " . Some clinical responses were observed. However, IFN-γ production 
induced in vivo by rhlL-12 was attenuated rapidly w i t h consecutive cycles, which indicates that 
the biological response to rhlL-12 is down-regulated during t h e r a p y 2 2 2 4 
The primary objective of this study was to assess the toxic i ty and safety of ι t . injected rhlL-12 at 
t w o dose levels in patients w i t h recurrent HNSCC Our treatment schedule was based on an earlier 
s.c. study, m which biological act iv i ty was demonstrated at the t w o dose levels used3 0. The 
secondary objectives were the assessment of clinical activity, the pharmocokmetics (PK) of 
rhlL-12 after i.t. administrat ion, and the pharmacodynamic (PD) effects on leukocyte subsets and 
cytokine profiles m peripheral blood. We have also investigated the effect of rhlL-12 in vivo on the 
expression level of mRNA of T-bet (T-box expressed in T-cells) and c-Maf. T-bet is a recently described 
Thl-specific transcription factor that controls the expression of IFN-γ3 1.T-bet expression correlates 
well w i t h IFN-γ expression m T h l cells, NK cells and B-cells. It redirects effector Τ helper 2 (Th2) 
and Τ cytotoxic 2 (Tc2) cells into the T h l and Τ cytotoxic 1 (Tel) pathway by inducing a str iking 
increase m production of IFN-γ, and a repressed production of IL-4, IL-5, and surprisingly also IL-2 
IL-12 induces an increase in levels of T-bet RNA and protein in v i tro 3 1 c-Maf is a Th2-specific 
transcription factor It regulates the expression of the keyTh2 cytokine interleukin-43 2 
P A T I E N T S A N D M E T H O D S 
P A T I E N T S E L E C T I O N 
All patients had histologic proof of recurrent HNSCC w i t h either local recurrence or subcutaneous 
or lymph node metastases, not amenable for curative surgery or radiotherapy The tumor had to 
be accessible for local injections w i t h a diameter not exceeding 5 cm. Further el igibi l i ty criteria 
included age between 18 and 75 years, WHO performance score 0-2, life expectancy of >3 months, 
adequate renal funct ion (serum creatinine, < 1 5 times normal), adequate hepatic function (serum 
bi l i rubin, < 1 5 times normal, ALT and AST, < 2 times normal), normal serum calcium ( < 1 1 mg/dl), 
serum hemoglobin > 9 g/dl , granulocytes > 1 5 0 0 /pi and platelets > 1 0 0 , 0 0 0 / p l . A maximum of 
t w o previous systemic treatments either w i t h chemotherapy, biologic modifiers or hormonal 
therapy, was allowed provided a treatment-free interval of at least 6 weeks Systemic 
corticosteroids were not allowed. Patients w i t h major concurrent disease were excluded, as were 
patients known t o be positive for HIV or hepatitis Β surface antigen All patients gave w r i t t e n 
informed consent. The study was approved by the local regulatory commit tee. 
S T U D Y D E S I G N A N D T R E A T M E N T S C H E D U L E 
The study was a single center, open-label, non-randomized phase l b study RhlL-12 was supplied 
by Wyeth (Cambridge, MA, USA) and administered by ι t . injection RhlL-12 was administered 
at t w o dose levels of 100 ng/kg and 300 ng/kg body weight , respectively, by multiple i.t. 
injections. Patients were treated once weekly for a period of eight weeks. After 8 weeks patients 
were evaluated for response. Patients w i t h o u t disease progression or dose-limiting toxic i ty (DLT) 
could receive up to 24 injections of rhlL-12 i.t.. The f irst inject ion was given as in-patient 
t reatment. All of the remaining doses were administered on an outpat ient basis, w i t h an 
observation period of 1 hour after each in ject ion. 
Toxicity was assessed using the National Cancer Inst i tute Common Toxicity Criteria Version ι DLTs 
were defined as drug-related grade 3 or 4 toxicity, w i t h the exception of lymphopenia If no DLT 
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occurred in 3 patients at 100 ng/kg, the dose was escalated t o 300 ng/kg If one of three 
patients experienced a DLT, three more patients were added to this dose level, and dose 
escalation was only allowed if < 2 / 6 patients experienced DLT at 100 ng/kg 
Before start of the study all patients underwent a complete medical history, physical 
examination, electrocardiography, hematology and blood chemistry tests, dipstick urinalysis, 
occult blood test in stool, chest X-ray, and evaluations of disease parameters by CT scan. 
Patients were monitored by physical examination, complete blood count, and serum chemistry 
before each weekly in ject ion. Disease parameters were evaluated after each treatment period of 
8 weeks by CT scan. WHO criteria for response were used 
P H A R M A C O K I N E T I C A N D P H A R M A C O D Y N A M I C S A M P L I N G A N D P A R A M E T E R S 
Venous blood was collected in week 1 and week 6 Whole blood samples anticoagulated in EDTA 
and citrate were obtained for determination of total and differential leukocyte counts, separation 
of peripheral blood mononuclear cells (PBMCs) by Percoli density centr i fugation and immuno-
phenotypic analysis before and after 4, 12, 24, 48, 72 and 96 hours Plasma was obtained for a 
determination of serum cytokine levels before and after 0.5, 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours 
The total number of leukocytes and differential leukocyte counts were determined on the Advia 
120 (Bayer) Plasma IL-12p70 and IL-12p40 were measured in an enzyme-linked immunosorbent 
assay (ELISA) as previously described3 3 For measuring of IFN-γ and IL-10 ELISA kits were used 
(Sanqum Reagents, the Netherlands). They were standardized w i t h the standards of the National 
Inst i tute for Biological Standards and Control (NIBSC). 
After Percoli density centr i fugation the PBMCs were incubated w i t h monoclonal antibodies 
(mAb) and stained indirectly w i t h FITC and/or PE The fol lowing mAbs (and clones) were used 
CD3 (T3b), CD4 (RIV7), CD8 (WT82), CD20 (B9E9) and CD56 (NBL-l) Thereafter the PBMCs 
were analyzed by f low cytometry using a FACScan of Becton Dickinson (Mountain View, CA) 
Total RNA of PBMCs was extracted using Tnzol Reagent (Life Technologies, Ine ). Reverse 
transcription was performed using 5 μ g total RNA, random hexamers and Mo-MLV reverse 
transcriptase (Life technologies, Inc.) Pre-developed assay reagents (PDARs) (PE Biosystems) were 
used for determination of IFN-γ, IL-10, IL-12p35 and IL-12p40 A PDAR (PE Biosystems) was used 
for determination of a housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (CAPDH) 
Taqman probes forT-bet, c-Maf and phorphobilmogen deaminase (PBCD), a housekeeping gene, 
were synthesized by PE Biosystems (Branchburg, New Jersey). The sequence of the primers and 
probes ofT-bet, c-Maf and PBCD used in this study are given in table 1. Real-time sequence 
quant i tat ive analysis was performed as described before 3 4 At several t ime points the amount 
of mRNA of cytokines or transcription factors was normalized to CAPDH and calculated relative 
to the amount of target present before start of rhlL-12. A cycle t ime (Cr) of less than 35 cycles 
was established as meaningful. 
R E S U L T S 
P A T I E N T C H A R A C T E R I S T I C S 
A total of six patients were entered in the study: five males and one female, w i t h a median age 
of 57 years (range, 28-70). The median WHO performance was 1 (range, 0-2) Tumor sites were: 
larynx (n=3), oral cavity ( n = l ) , nasopharynx ( n = l ) and oropharynx ( n = l ) . All patients had prior 
surgery and local radiotherapy None of the patients had received prior systemic treatment The 
rhlL-12 was administered at the site of a local recurrence in 2, and m regional lymph node 
metastases in 4 patients. In one of these 4 patients the rhlL-12 was injected m 2 lymph node 
metastases. The volume of the injected rhlL-12 varied between 0.26 and 0 64 ml , dependent 
of the dose level and the weight of the patient. In some patients rhlL-12 was injected under 
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table ι Primers and probe used for real-time q u a n t i t a t i v e PCR analysis. 
5' p r i m e r 3' 
T-bet TCATTTCCCAAACTAAACCTCACA 
TCTGGCTCTCCGTCGTTCAC 








table 2 Pharmacokinetic data: mean (± SD) PK parameters at dose levels 100 ng/kg and 300 ng/kg in week 1 and week 6. 
100 ng/kg 
week 1 (n=3) week 6 (n=2) 
Cm»(pg/ml) 362 (74.7) 763 (62.2) 
T
m
„ ( h ) 3 (1.4) 0.5 (0) 
ttflh) 6 8 (0.1) 5.1 (0.4) 
AUC(pgxh/ml) 4361 (1199) 6045 (2068) 
300 ng/kg 










ultrasound guidance. Three patients received 100 ng/kg and three patients 300 ng/kg i.t.. 
The median number of injections per patient was 9 (range, 3-24). 
T O X I C I T Y A N D C L I N I C A L RESPONSE 
Toxicity was mi ld. Fever grade 2 was seen in all patients, generally occurring 8 to 12 hours after 
the f irst in ject ion. In all patients fever was minimal or absent after subsequent injections, w i t h 
the exception of one patient who had fever after each of the 24 injections. No DLTs were 
observed. Before start of the rhlL-12 injections all patients had a lymphopenia w i t h a mean 
number of lymphocytes of 697/pl (range 600/pl to 1300/pl). At baseline t w o out of five patients 
had lymphopenia equivalent w i t h a grade 2 and three patients w i t h a grade 3 lymphopenia. After 
the f irst injection in four of five patients a temporary lymphopenia grade 4 (<500/pl) was seen, 
and in one patient a grade 2 (500-900/μΙ). In one patient (at 100 ng/kg) the grade 4 
lymphopenia was prolonged and present most of the t ime during his 24 weeks of treatment. 
No infections were observed. No other grade 2, 3 or 4 toxicit ies were observed. Two patients 
experienced local i tching at the site of the inject ion. 
No partial or complete responses were seen. One patient received only 3 injections due to early 
progression. In t w o patients, who were rapidly progressive before start of the rhlL-12 
administrat ion, a stabil ization of the disease for 10 (at the 100 ng/kg) and 12 months (at the 
300 ng/kg) was observed w i t h a reduction in tumor size of 40% in one of these patients. 
R H I L - 1 2 P H A R M A C O K I N E T I C S 
Results of the pharmacokinetic studies are shown in table 2. PK analysis after the init ial injection 
was performed in five of six patients. One patient treated at 300 ng/kg was not analyzed as 
leakage of IL-12 from the injected tumor was seen probably due to ulceration and necrosis. In all 
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table 3 Effects of rlL-12 i.t. therapy on PBL subsets of cancer patients. Values are the mean ± SD of the absolute number 
(cells/μΙ) of total lymphocytes or lymphocytes expressing CD3 (total Τ cells), CD4 (Th cells), CDS (cytotoxic Τ cells), 
CD20 (B cells) or CD56 in the absence of CD3 (NK cells) in peripheral blood drawn just before, and 4, 12, 24, 48, 72 

























































patients IL-12 was detected in plasma 30 minutes after rhlL-12 injection. In three of four 
patients the area under the curve (AUC) and the maximal concentration (CmaJ increased in 
week 6 in comparison with the first injection. For all injections the mean ti/, as measured in 
plasma was 7.2 hours (range, 5.4-9.6). 
PHARMACODYNAMICS 
Effects on leukocyte subsets 
Before rhlL-12 treatment, most patients showed a low to normal absolute number of lymphocytes 
in the peripheral blood (table 3). Significant reductions in absolute peripheral blood lymphocytes 
(PBL) counts were seen, within 4 hours after administration of rhlL-12.The maximal decrease 
was observed after 12 or 24 hours, followed by a gradual increase from 48 till 96 hours and 
normalization at 168 hours. A decrease was seen in all lymphocyte subclasses, but was most 
pronounced in NK cells and cytotoxic Τ cells. No differences in lymphocyte or lymphocyte subclass 
reductions were observed between the two dose levels or between week 1 and 6. In one patient 
who received rhlL-12 for 24 weeks the same reductions in all subclasses were observed in week 
22 (data not shown). 
The number of monocytes decreased with approximately 50% in week 1 in most patients, but 
not in week 6. The number of eosinophils remained stable. 
Effects on plasma cytokine levels 
The effect of rhlL-12 on the plasma levels of IFN-γ and IL-10 was analyzed (figure 1). After 4 
to 8 hours an increase of IFN-γ was seen in five of six patients with peak concentration occurring 
at 12 hours. After 24 hours the level of IFN-γ decreased with normalization at 48 hours. The mean 
maximal concentration was 65.1 pg/ml (range, not detectable (n.d.) to 158 pg/ml). No 
significant correlation was observed between the doses of IL-12 injected or the IL-12p70 plasma 
level and the amount of IFN-γ produced. In three of four patients the IFN-γ production measured 
in the plasma was somewhat lower in week 6 compared to week 1. 
IL-10 production followed the same pattern as for IFN-γ in each patient. An increase of IL-10 was 
first detected after 4 to 8 hours, and reached its maximum after 12 hours (in one patient after 
24 hours). A decrease was seen after 24 hours and normalization after 48 hours. The mean 
maximal concentration was 27.4 pg/ml (range, n.d. to 63 pg/ml). Again, no correlation was 
observed between the two doses of rhlL-10 or the amount of IL-12p70 in plasma and the level 
of IL-10. There was no apparent correlation between the plasma levels of IL-10 and IFN-γ. In 
week 6 the IL-12 production was comparable to week 1. 
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figure ι Plasma level of IFN-γ and ILIO after administration of rhlL-12 i.t. in week 1. The results shown are the mean and the 
SEM of five patients. 
120 
IFN-γ (pg/ml)
 1 0 0 IL-10 (pg/ml) 
time after IL-12 i.t. (hours), in week ] 
36 48 
time after IL-12 i.t. (hours), in week ι 
Effects on mRNA of cytokines and transcription factors 
To determine the expression of mRNA of certain cytokines and t w o transcription factors, we 
performed a semi-quantitative PCR analysis on five of six patients. In some cases it was not 
possible to process the samples for RT-PCR due to the low number of PBMCs after 12 or 24 hours. 
Four hours after rhlL-12 administrat ion the amount of mRNA encoding IFN-γ present in PBMCs 
showed a mean increase of 2.2 times (range, 0.8-4.2) relative to the pre-treatment sample. After 
12 hours the IFN-γ mRNA expression was returned t o baseline values (figure 2). 
The mRNA encoding IL-10 did not increase, except in one patient who expressed the highest level 
of IFN-γ mRNA. In this patient IL-10 mRNA was increased 2.8 times after 4 hours to a maximum 
of 5.2 times after 72 hours (figure 2). 
The IL-12p35 mRNA showed an increase in three patients w i t h a maximum after 12 or 24 hours 
and decreasing after 48 hours (figure 2). The expression of IL-12p40 was too low for reliable 
measurements (data not shown). 
As IL-12 induces IFN-γ gene transcript ion, we decided to measure the mRNA encoding a T h l and 
a Th2 transcription factor. Surprisingly, the mRNA of T-bet, a T h l transcription factor essential for 
IFN-γ gene transcript ion, decreased in all five patients, start ing after 4 hours. After 12 hours only 
20% (range, n . d . t o 30%) of the init ial amount of mRNA of T-bet was present. The T-bet mRNA 
levels returned to normal after 48 or 72 hours (figure 3). Also c-Maf mRNA, a Th2 transcription 
factor, showed a decrease in most patients, but this decrease was less pronounced than for T-bet 
mRNA (figure 3). Therefore, we calculated a T h l / T h 2 transcript ion factor ratio by determining 
the T-bet/c-Maf rat io. In all patients this ratio decreased after IL-12 treatment w i t h a mean 
decrease of 0.7 (figure 3). 
DISCUSSION 
We have studied various aspects of i.t. administrat ion of rhlL-12 in HNSCC patients. A schedule 
of 100 ng/kg or 300 ng/kg, given once weekly, was well tolerated. No DLTs occurred. There are 
three explanations for the low toxicity. First, we administered a relative low dose of rhlL-12, when 
62 
Chapter 4 
figure 2 Semi-quant i tat ive mRNA of IFN-γ, IL-10 and IL-12p35 of PBMCs of peripheral blood after a d m i n i s t r a t i o n of rhlL-12 i.t.. 
The results shown are the mean and the SEM of f ive pat ients in week 1. 
time after IL-12 i.t. (hours) 
1 1 
48 72 96 
time after IL-12 i.t. (hours) 
IL-12p35 
time after IL-12 i.t. (hours) 
compared with the maximum tolerated dose of i.V. (500 ng/kg)22·23·25-27 or s.c. (1000 to more 
than 2100ng/l<g)24'26 administration. Second, the route of administration of rhlL-12 was i.t., 
so loco-regional. In studies, using intravenous dose-levels of 100 and 300 ng/kg22, much more 
grade 2 and 3 toxicities were seen. In two s.c. studies no or some grade 2 or 3 toxicity was seen 
at this dose-level24·27. Therefore, this i.t. route of administration is less toxic than the i.v. route 
and possibly less toxic than the s.c. route. Third, it is known that these patients do have a 
compromised immune system as is reflected in the low normal basal number of lymphocytes. 
This may result in a diminished secondary cytokine release, leading to decreased toxicity. 
In this limited number of six HNSCC patients we saw some clinical activity. In two patients a 
long-lasting stable disease (SD) was observed, with a reduction in tumor size of 40% in one of 
these patients. 
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figure 3 Semi-quantitative mRNA of T-bet, c-Maf and the T-bet/c-Maf ratio per patient of PBMCs of peripheral blood after 
administration of rhlL-12 i.t.. The results shown are the mean and the SEM of five patients in week 1. 
T-bet c-Maf 
relative to t=0 
time after IL-12 i.t. (hours) time after IL-12 i.t. (hours) 
T-bet/c-Maf 
relative to t=0 J Q 
time after IL-12 i.t. (hours) 
In all patients IL-12 was already detectable in plasma 30 minutes after i.t. administrat ion. This is 
in accordance w i t h the observation of Mattijssen et al. w i t h PEC-IL-210. As shown in previous 
studies the IL-12 measured in plasma was mainly rhlL-12, but the induction of IL-12 mediated 
through IFN-γ cannot be excluded. When we compare our PK data w i t h i.v.22 or s.c.2 3·2 4·2 6 
administration of rhlL-12, the AUC and Cmax is higher after i.v. and lower after s.c. administration, 
respectively, compared w i t h i.t. administration. Our f inding of an increment in AUC from week 1 to 
week 6 in three of four patients is in contrast w i t h the results of Portielje et al.2 · who described 
a reduction in AUC after repeated s.c. administrat ion. This may be explained by an intrinsic effect 
of IL-12 on the tumor vasculature. rhlL-12 is an inhibitor of tumor neo-angiogenesis in mouse 
models" . The effects of IL-12 on pre-existing vessels in larger human tumors are less known. The 
increased AUC after i.t. administrat ion in week 6 may possible be due t o a leakage of the rhlL-12 
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out of the tumor into the vessels and circulation. 
When the induction of IFN-yand IL-10 is compared between the i.t. and i.v. or s.c. administration 
of rhlL-12, most23·25-27, but not all24 results, show higher IFN-γ peak concentrations and 
comparative IL-10 peak concentration23·27. After 6 injections of rhlL-12 i.t. the IFN-γ production 
appeared to diminish in contrast to the IL-10 production which remained the same, suggesting 
different mechanisms of induction of IFN-γ and IL-10 after rhlL-12 administration. 
The number of lymphocytes and lymphocyte subsets rapidly declined after rhlL-12 administration 
and this was most prominent for NK and cytotoxic Τ cells. In some patients only 10% of these 
cells was present in circulation after 12 to 24 hours. This decrease of lymphocytes was the same 
in week 1 and week 6. In one patient the effect was still present after 22 weeks. After rhlL-12 i.t. 
administration the magnitude of comparable results have been reported for i.v. and s.c. 
administration of rhlL-1223'25. 
For the interpretation of our data on mRNA of cytokines and transcriptionfactors, it is important 
to realize that rhlL-12 changes the percentage of Τ helper cells, cytotoxic Τ cells, B-cells and NK 
cells over time. After 4 hours we measured a slight increase in IFN-γ mRNA. We found no 
differences in the mRNA of IL-10, except in one patient. This low expression may be explained by 
the fact that the highest induction of IFN-γ and/or IL-10 occurs in the regional lymph nodes and 
not in the circulation. Alternatively, the PBMCs, in which expression of the mRNA of IFN-γ and/ 
or IL-12 is induced, may leave the circulation. 
Our data on the concentration of IL-12 subunits showed more IL-12p35 expression after 12 hours. 
The expression of IL-12p40 was below the detection limit, both before and after rhlL-12 
treatment. The induction of IL-12p35, the rate limiting subunit, may reflect a real increase in 
PBMCs, which produce more IL-12p35 after stimulation with rhlL-12, or the remaining cells in 
circulation, i.e., B-cells, have relative more expression of mRNA of IL-12p35. 
Interestingly, a distinct and reproducible decrease in the mRNA level of T-bet was detected after 
rhlL-12 i.t. administration in each patient, both in week 1 and in week 6. This effect was maximal 
at 12 to 24 hours and coincided with the decrease in total lymphocytes. c-Maf showed a similar 
decrease over time, although much less pronounced compared to T-bet. The T-bet/c-Maf ratio, 
which may be indicative for the Thl/Th2 balance, showed a decrease in all patients. This 
apparent contradiction may be explained that we may have missed a possible peak in T-bet gene 
expression, occurring prior to our first sampling time. The maximal increase of IFN-γ mRNA was 
detected after 4 hours and of plasma IFN-γ after 12 hours. Thus, an upregulation of T-bet could 
have occurred prior to our 4-hour sampling time. This is supported by data from Lighvani et al.3 5, 
who found a rapid induction of T-bet expression in vitro and in a murine model in vivo. A second 
hypothesis is that the T-bet positive (Thl) cells become adherent to the blood vessel wall and 
preferentially leave the circulation. It has been previously reported that in the process of 
inflammation the recruitment of Thl and Th2 cells into peripheral tissues is different. Expression 
of selectin ligands occured preferentially on Thl cells and these cells are recruited to sites of 
inflammation36. IL-12 was shown to upregulate Τ cell adhesion37 and induce interferon^inducible 
protein 10 (IP-10), that recruits Thl cells38. Collectively, our findings of the decrease in 
lymphocyte numbers together with the decrease in the T-bet/c-Maf ratio suggest that especially 
T-bet expressing Tel cells and NK cells rapidly extravasate after rhlL-12 treatment. This is 
confirmed by preliminary results of our ongoing study, with rhlL-12 given prior to surgery in 
non-pre-treated HNSCC patients, which show an enlargement of the regional lymph nodes and 
increase in T-bet expression locally. 
In summary our data demonstrate that the weekly i.t. administration of rhlL-12 is feasible and 
safe at doses of 100 ng/kg and 300 ng/kg. Its main biological effects are a transient reduction 
65 
in the number of lymphocytes and all lymphocyte subsets, especially NK and cytotoxic Τ cells, 
induct ion of plasma IFN-γ and IL-10, and a decrease in T-bet mRNA in PBMCs in peripheral blood. 
In a subsequent study the same doses and schedule are being applied in non-pre-treated HNSCC 
patients before surgery. That study wil l provide further insight in the effects of rhlL-12 on 
immunological parameters in the primary tumor and the regional lymph nodes. 
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lnterleukin-12 is an anti-angiogenic and antitumor agent m many transplanted murine tumor 
models. In a previous clinical study in head and neck squamous cell carcinoma patients treated 
with recombinant human IL-12 the tumor turned pale, after an initial reddening. The aim of 
this study was to investigate the effects of recombinant mouse IL-12 on the vasculature, blood 
perfusion, hypoxia and proliferation of tumor cells in an implanted human head and neck 
squamous cell carcinoma xenograft tumor, with a relatively large diameter, in Balb/c nu/nu 
mice over time. 
Established human squamous cell carcinoma xenograft tumors were mtratumorally injected for 
3 days with either 200 ng rmlL-12 or PBA. Mice were sacrificed at 4 different time points (between 
8 hours and 8 days after the last injection), after administration of Pimomdazole, BrdUrd and 
Hoechst 33342 The tumor sections were quantitatively analysed with a semi-automatic method 
based on a computerised digital image analysis system, after immunohistochemical staining 
Despite a faster and higher upregulation of anti-mouse ICAM-1 in the IL-12 treated tumors, no 
significant differences in vascular density, perfusion fraction, hypoxic fraction, and BrdUrd 
labelling index were detected between IL-12 treated tumor and control tumors. 
We suggest that the mam reason why the observation made in humans could not be confirmed in 
this mice study is the combination of a lack of possessing an intact immune system m the Balb/c 
nu/nu mice and a relatively large tumor with probably a lot of mature vessels. 
INTRODUCTION 
lnterleukin-12 (IL-12) has antineoplastic and anti-metastatic activity in many experimental mouse 
tumor models12. This can be explained by a wide range of biological activities of IL-123*. IL-12 
stimulates the proliferation and activation of cytotoxic Τ lymphocytes and NK cells and induces 
the production of several cytokines, such as IFN-γ, TNF-a and CM-CSF56 IL-12 is the key cytokine 
m the induction of Τ helper 1 responses and thereby m cellular immunity7 Furthermore, IL-12 
inhibits angiogenesis1", which is mediated by the CXC chemokmes, interferon-inducible protein-10 
(IP-10) and monokine induced by interferon-γ (Mig), both upregulated by IFN-γ'12 
Most studies concerning the effect of IL-12 on inhibition of angiogenesis are performed in 
small tumors. The in vivo assays used include the mouse corneal angiogenesis assay', sponge 
implantation", a matngel assay914-17, an mtradermally tumor suspension assay18, and the 
inoculation of tumor cells subcutaneous m a skinfold chamber" In some studies the vascular 
effects of IL-12 in larger tumors was studied by measuring vessel density 1 2 2 0 2 1 or by analysis 
of tumor blood flow with Doppler ultrasound22. All the mentioned studies showed inhibition of 
neovascularization after IL-12 treatment. 
Recently, m a phase lb study we treated six patients with recurrent or metastatic head and 
neck squamous cell carcinoma, with relatively large tumor volumes (diameter between 1 and 5 
centimetres), with recombinant human IL-12 (rhlL-12)23. RhlL-12 was administered mtratumorally 
once a week. In four of five évaluable patients the colour of the tumor changed during the course 
of treatment. Initially, a reddening of the tumor was seen After 3 to 5 weeks the tumor developed 
a more pale appearance, suggesting a vascular effect. 
In view of this observation the aim of the present study was to investigate the micro-
environmental effects of recombinant mouse IL-12 (rmlL-12) mtratumorally m an implanted 
human tumor model. Our hypothesis was that after the start of treatment with IL-12 first an 
increase in perfusion occurs, allowing the accumulation of immune cells (e.g. natural killer (NK) 
cells) m the tumor, followed by the inhibition of angiogenesis and effects on existing vessels, 
which eventually may lead to tumor shrinkage To test this hypothesis, the effects of rmlL-12 
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mtratumorally (ι t ) administered on the vasculature, blood perfusion, hypoxia and proliferation in 
a human head and neck squamous cell carcinoma xenograft in nude mice were analysed over t ime 
M A T E R I A L S A N D M E T H O D S 
M I C E , T U M O R S A N D T R E A T M E N T W I T H R E C O M B I N A N T M O U S E IL-12 
Five to six week-old-female Balb/c nu/nu mice maintained m a specific-pathogen-free unit m 
accordance w i t h inst i tut ional guidelines were used in the experiments Tumor line SCCN1J3, 
derived from a moderately to well dif ferentiated human squamous cell carcinoma from the larynx, 
was used Tumors were passaged when they reached a diameter of 1 0 cm Viable 1 mm 3 tumor 
pieces were implanted subcutaneously m the r ight hind leg of the mice 
When the tumors reached a diameter of 6-8 mm the treatment w i t h mouse rlL-12 (R&D Systems, 
Minneapolis, USA) was started During 3 consecutive days (day 1, 2, 3) half of the tumors (n=25) 
were injected w i t h 200 ng rmlL-12, di luted m 20 pi sterile phosphate-buffered saline (PBS) 
containing 2% bovine serum albumin (BSA), mtratumoral ly (1 t ) Control tumors (n=25) were 
injected w i t h 20 pi PBS/BSA 0 1% 1 t 
Approval of the local ethical committee for animal use was obtained for these experiments 
A D M I N I S T R A T I O N O F M A R K E R S OF H Y P O X I A , P R O L I F E R A T I O N , A N D P E R F U S I O N A N D T I M E S C H E D U L E 
As a marker of hypoxia, pimomdazole hydrochloride l-[(2-hydroxy-3-piperidinyl) propyl]-2-
mtroimidazole hydrochloride (Natural Pharmaceuticals, International Ine , Belmont, MA, USA) 
was u s e d 2 4 2 5 Pimomdazole hydrochloride was administered intravenously (ι ν ) at a dose of 80 
mg/kg m a volume of 0 1 ml saline The S-phase marker bromodeoxyuridme (BrdUrd) (Sigma, 
St Louis, MO) was given mtrapentoneally at 500 mg/kg in a volume of 0 5 ml saline As a marker 
of tumor blood perfusion the fluorescent dye Hoechst 33342 (Sigma), dissolved in saline, was 
given ι ν at a dose of 15 mg/kg m a volume of 0 1 ml Pimomdazole was injected 60 mm, 
BrdUrd 15 mm and Hoechst 33342 one minute before ki l l ing the animals 
The mice were sacrificed at 4 different t ime points on day 3 (8 hours after the last 
administrat ion of mouse rlL-12), on day 4, on day 8 and day 11 After weighing, tumor 
excision specimens were immediately stored in l iquid nitrogen 
I M M U N O H I S T O C H E M I S T R Y 
Complete tumor sections of 5 pm thickness were cut and stored at -80 o C unt i l stained From 
each tumor, one tissue section was stained and analysed for perfusion, hypoxia and endothelial 
structures A consecutive tissue section was stained and analysed for perfusion, proliferation and 
all nuclei A th i rd tumor section was stained w i t h hematoxylin and eosm (H8tE) to distinguish 
viable from necrotic and non-tumor tissue Finally, in 7 IL-12 treated and 7 control tumors a 
forth tumor section was used for ICAM-1 expression 
After thawing, the sections were fixed in cold acetone (40C) for 10 mm and air dried The Hoechst 
33342 signal was recorded prior to immunohistochemical staining Between all consecutive steps 
of the staining procedure the sections were rinsed three times for 5 minutes in PBS Unless 
otherwise stated all antibodies were di luted m PLD polyclonal l iquid di luent (Euro DPC) 
Endothelial structures and pimomdazole 
Prior to the immunohistochemical staining procedures non-specific binding of the mouse 
antibodies was prevented by blocking w i t h the M 0 M-kit™ (Vector Laboratories, Ine ) overnight 
at 40C Monoclonal l iquid di luent (MLD, Euro-DPC, Breda) pre-mcubation was performed for 
2 mm at room temperature The tissue sections were incubated 45 mm at 370C w i t h rabbit ant i-
pimomdazole ant iserum 2 4 di luted 1 200 in undiluted 9F1 rat monoclonal to mouse endothelium 
(Department of Pathology, UMC Nijmegen, Nijmegen, The Netherlands)2 6 The sections were then 
incubated for 45 mm at 37°C w i t h tetramethyl rhodamme isothiocyanate (TRITC) conjugated 
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goat anti-rat antibody (Fab2) 1:200 (Jackson Immuno Research Laboratories, West Grove, PA) and 
Cyanine2-conjugated donkey anti-rabbit antibody 1:200 (Jackson Immuno Research Laboratories, 
West Grove, PA). Next the tissue sections were incubated for 45 min at 37°C with TRITC 
conjugated donkey anti-goat fiati), antibody 1:200 (Molecular Probes, Eugene, Oregon). Finally, 
the tissue sections were rinsed and mounted with Fluorostab (ICN Pharmaceuticals, Inc.Cappel). 
BrdUrd 
The DNA in the tissue sections was denatured with 0.2N hydrochloric acid for 10 min. To 
neutralise the pH, the sections were immediately rinsed in 0.1 M Borax for 10 min. M.O.M, 
blocking was performed overnight at 40C and MLD pre-incubation was performed for 60 min at 
room temperature. Then the sections were incubated at 370C for 45 min with Br-3, a mouse 
monoclonal to BrdUrd 1:25, (Caltag Laboratories, San Francisco, CA). Next, the sections were 
incubated for 45 min at 370C with TRITC-conjugated goat anti-mouse 1:200 (Jackson) followed by 
an incubation 45 min at 37°C with donkey anti-goat F(ab')3 TRITC-conjugate 1:200 (Jackson). All 
nuclei were stained with fast blue 1:1000 in PBS for 10 min. Tissue sections were coverslipped. 
/OW-l 
After fixation with dry acetone, sections were air-dried and preincubated for 20 min with 
PBS/0.5% bovine serum albumin (BSA), after which incubation with mAb YN1/1.7 (anti-ICAM-1, 
lgG2b; 2 pg/ml, 60 min, 370C) followed27. After washing 2 times in PBS, sections were incubated 
with biotinylated mouse-anti-rat (MRK-1, Pharmingen, 5 pg/ml, 60 min, RT) in 1% normal 
mouse serum. Subsequently, PBS-washed sections were incubated with Avidine-Biotine 
peroxidase complex prepared as described by the manufacturer (Vector Laboratories ine, 
Burlingame) for 45 min at RT. After rinsing twice with PBS, peroxidase activity was revealed 
using 3-amino-9-ethylcarbazole (AEC, substrate kit, Zymed, San Francisco, CA) as substrate 
resulting in a red colour. After washing in water cells were counterstamed with heamatoxylin. 
This method results in a red staining of cells expressing the ICAM-1 molecule. 
ANALYSIS OF IMMUNOHISTOCHEMICAL MARKERS 
The tumor sections were quantitatively analysed with a semi-automatic method based on a 
computerised digital image analysis system as described before. The hypoxic fraction (HF) was 
calculated as the proportion of the tumor surface stained for the hypoxic marker relative to the 
total tumor surface28. Vascular density (VD) was measured as the number of vascular structures 
per mm229. The perfused fraction (PF) was calculated as the area of vascular structures labelled 
with the perfusion marker Hoechst 33342 divided by the total vascular area30. The S-phase 
labelling index (LI) was calculated as the ratio of the BrdUrd labelled area to the total nuclear 
surface28. 
The expression of ICAM-1 on the endothelial cells and the stroma in the tumors and the 
percentage of necrosis in the tumor was assessed qualitatively. 
STATISTICAL ANALYSIS 
Analysis of variance (ANOVA) was used to assess the differences between the control mice and 
the IL-12 treated mice, and to assess the differences of PF, VD, HF, and LI and at different times. 
Prior to use ANOVA for each of the 8 groups of mice, the Kolmogorov-Smirnov test with Lillifors 
significance correction and Shapiro-Wilk tests were used as tests for normality, whereas the 
Levene statistic was used to test the homogeneity of variance. 
Pearson's correlation analysis and linear regression analysis were used to disclose associations 
between the variables PF, VD, HF, and LI in both control mice and the IL-12 treated mice. 
All statistical analyses were performed with SPSS 10.0 for Windows. 
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R E S U L T S 
G R O W T H , W E I G H T A N D NECROSIS 
In 51 Balb/c nu/nu mice a human squamous cell carcinoma tumor was implanted on the hind leg. 
Twice a week the tumor diameter was measured and the tumor volume was calculated. After 26 
days the size of the tumors ranged from 6 to 8 mm and treatment w i th rmlL-12 i.t. was started 
in 25 mice and PBS/BSA 0 . 1 % i.t. was administered in 25 control mice; one mouse w i thou t 
tumor growth was excluded. 
The mean weights of the tumors and their 95% confidence interval for the IL-12 treated and 
control animals for the four t ime points day 3 (8 hours after the last administration of rmlL-12), 
day 4, day 8 and day 11) are given in f igure i . 
Analysis of variance disclosed that the differences of tumor weight at di f ferent times were not 
signif icant (p=0.05) . Contrary to expectation, the differences of the weight between the IL-12 
treated and control mice for the four t ime points were not signif icant (p=0.49) . 
The percentage of necrosis estimated on a H&.E section ranged between 0% and maximal 15%. 
The median and mean necrosis was 0 and 1% in the control mice and 0 and 2% in the IL-12 
treated mice, respectively, and did not differ between treated and untreated tumors. 
ICAM-1 S T A I N I N G 
Anti-mouse ICAM-1 expression was determined in 7 IL-12 treated and 7 control tumors.The IL-12 
treated tumors showed a faster and higher expression, both in the endothelial cells and stroma, 
compared w i t h the control tumors. After 8 hours the ICAM-1 expression in the stroma was for 
90% positive in the IL-12 treated tumors and only 10 % in the control tumors. So, this implicates 
bioactivi ty of the administered rmlL-12. However, the ICAM-1 expression in the IL-12 treated 
tumors decreased after 4 and 7 days in contrast w i t h the control tumors, in which a mild 
increase of ICAM-1 expression was seen in this t ime period. 
VASCULAR STRUCTURES, PERFUSION F R A C T I O N , H Y P O X I A A N D P R O L I F E R A T I O N 
Figure 2 shows a detail of a combined composite image obtained after the scanning procedure 
of a representative tumor section in a control tumor. Figure 2 A shows the perfused vessels 
(Hoechst), the vessels (9F1) and hypoxic areas (pimonidazole) distr ibut ion (100X magnif ication). 
This shows the relation between the vessels, partly perfused (pink) and the hypoxic areas in the 
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figure 2 Composite binary images of a representative tumor section. The binary image A shows the perfusion (Hoechst, blue), 
endothelium (9F1, red) and hypoxia (Pimonidazole, green) distribution in a tissue section (scanned at lOOx magnification). 
The binary image Β of the consecutive tissue section shows the combination of perfusion and proliferation (BrdUrd, green) 
(scanned at 200x magnification). 
tumor (green). The combination image of Hoechst, 9F1, and BrdUrd (figure 2B) show the spatial 
distr ibut ion of prol iferating cells throughout the tissue section in relation t o perfused and non-
perfused vessels (200x magnif icat ion). 
The perfused f ract ion, vascular density, hypoxic fract ion, and BrdU labelling index for the 
control and IL-12 treated mice for each of the four t ime intervals are given in figures 3. 
ANOVA disclosed no significant differences between control mice and IL-12 treated mice for 
perfusion f ract ion, vessel density, hypoxic fraction and labelling index ( p > 0 . 2 7 ) . 
Obviously, an inverse relation was found between the number of vessels and the hypoxic fraction 
(figure 4), both in the IL-12 treated (Pearson correlation -0.55, p<0.01) and the control mice 
(Pearson correlation -0.85, p<0.01).The difference in correlation between IL-12 treated and 
control mice was not signif icant (p=0.6) . 
DISCUSSION 
In this paper we described the analysis of the microenvironmental effects of rmlL-12 i.t. in a 
human head and neck squamous cell carcinoma xenograft tumor line over t i m e . Our hypothesis 
that IL-12 f irst induces an increase in perfusion, al lowing the accumulation of immune cells 
(e.g., NK cells) in the tumor, followed by an inhibi t ion of angiogenesis or changes in existing 
vessels, which eventually leads t o tumor shrinkage, could not be conf irmed. No signif icant 
changes in the vascular density, the tumor perfusion status, the hypoxic fract ion or the 
proliferation status between IL-12 treated and control tumors in a t ime period ranging from 
8 hours to 11 days post treatment were found in this human tumor model. Neither a significant 
difference in the weight nor the percentage of necrosis between the IL-12 treated tumors and 
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figure 3 The mean values (and 2xSEM) of perfusion fraction (A), vessel density (B), hypoxic fraction (C), and proliferation index 
(D) for IL-12-treated mice ( · ) and control mice ( D ) for each of the four points in time. 
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the control tumors were detected at any t ime point. 
As expected a highly signif icant negative correlation between the vascular density and the 
hypoxic fraction was found. This correlation was stronger in the control tumors than in the 
IL-12 treated tumors. 
A number of reasons for the lack of effect of the mlL-12 on the vasculature, perfusion, hypoxia 
and proliferation in this tumor mouse model can be suggested. 
First, the inhib i t ion of angiogenesis by IL-12 is, largely, an immunological process, that is 
originated by induction of IFN-yand increased expression of IP-10 and M i g ' . Therefore one might 
argue that the absence of a change in the micro-environment is caused by choosing BALB/c nu/nu 
mice, lacking Τ cell functions and displaying enhanced NK act iv i ty 3 1 , in our experiments. 
However, Strasly et a l . 3 2 showed in BALB/c nu/nu mice, clear inhib i t ion of angiogenesis after 
mlL-12 treatment, although impaired w i t h 50% compared to normal mice. Also others 1 1 · 3 3 have 
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Pearson's correlation analysis disclosed a highly significant negative correlation between the vascular density and hypoxic 
fraction (r=-0.71, p<0.001) for the whole group of 50 mice. In the IL-12 treated ( · ; ) and control mice ( • ; ) 
these values are r=-0.55, p<0.005 and r =-0.85, p<0.001, respectively. 
Hypoxic fraction (%) 
Vessel density (number/mm2) 
described inhib i t ion of angiogenesis in BALB/c nu/nu mice in experiments w i t h IL-12. 
Secondly, we used a relatively short t ime schedule of IL-12 treatment by sacrificing the mice after 
maximally 11 days, i.e., 8 days after the last in ject ion. This short t ime schedule was chosen to 
prevent the development of substantial necrosis in the tumor, which would complicate analysis 
of tissue sections due to an increase in artefacts resulting from non-specific staining. Indeed, the 
necrotic fraction was low in most tumors. However, Ogawa et al. found a clear inhibi t ion of 
angiogenesis even w i th a short t ime schedule for injection (3 days) and w i th a short follow-up 
period (5 to 15 days)34. 
Third, the size of the tumor may be a factor in the absence of effect. We started the rhlL-12 
treatment when the tumor was relatively large (6-8 mm in diameter). However, i t is unlikely that 
the size of the tumor is the reason for the absence of an effect on tumor vasculature. Cavallo et 
al .2 0 started treatment when the tumors were 2.5 mm in diameter, and Ogawa" when the tumor 
was 7 mm in diameter, both showing inhib i t ion of angiogenesis. 
Fourth, the micro-environmental characteristics of the tumor, are important for the ant i -
angiogenesis effects of mrlL-12 in the tumor. Inhibi t ion of angiogenesis by IL-12 was shown 
to exist in many tumor models, but not all. Factors indicated as crit ical for the inhib i t ion of 
angiogenesis by IL-12 in tumors are the peritumoral stromal reaction34·35 and the lymphocyte-
endothelial cell cross-talk32. Therefore, we investigated the ICAM-1 expression in the tumor 
model used. A fast and high induction of ICAM-1 was detected in the IL-12 treated tumors, 
which decreased after 5 to 8 days after the last IL-12 in ject ion. However, in the control tumors, 
which received an intratumoral injection of PBA also a mild induct ion was seen, although i t 
was clearly lower and later than in the IL-12 treated tumors. Thus, a reason for not detecting 
differences between the IL-12 treated and control tumors might be that after intratumoral 
injection of PBA an upregulation of ICAM-1 is seen, also. However, if this would be a main 
factor, one would expect to see time-related differences in any of the studied parameters in 
both groups. 
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The last reason for the lack of effect in our model, can be the maturation of the tumor 
vasculature. The level of vessel maturat ion is strongly correlated w i t h the response to IL-12 
treatment: matured pericyte-positive vessels were less sensitive3 6. In our model we implanted 
viable 1 mm 3 tumor pieces. In studies of IL-12 studying the effect of anti-angiogenesis single 
cell suspension tumor cells were injected s.c.1 5 ·1 7 ·"·3 5 ·3 7. Analysis of tumor at a smaller size may 
imply that a large proportion of vessels are immature relative to larger tumors, such as we used 
in our tumor model. 
In conclusion, in the patients treated in the phase I study w i t h rhlL-12 i.t. the observation in 
change of the colour of the tumor was very clear. However, in the described implanted xenograft 
tumor mice model, which was chosen because this mimics much more the human situation than 
a model which injects single cell suspension tumor cells, we could not detect changes in vascular 
density, tumor perfusion status, hypoxic fraction or proliferation status, although an upregulation 
of ICAM-1 was seen. Both in the human and mice study we treated large tumors w i t h probably a 
lot of mature vessels. The main difference between our human and mice study in Balb/c nu/nu 
mice is the presence of a complete immune system. Thus, we suggest that the main reason why 
the observation made in humans could not be confirmed in this mice study is the combination of 
a lack of possessing an intact immune system in the Balb/c nu/nu mice and a relatively large 
tumor w i t h probably a lot of mature vessels. 
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The objective of this phase I I study was to evaluate the pharmacodynamic and immune effects of 
intratumorally administered recombinant human interleukin-12 (rhlL-12) on regional lymph 
nodes, primary tumor, and peripheral blood. Ten previously untreated patients with head and 
neck squamous cell carcinoma (HNSCC) were injected in the primary tumor 2 to 3 times, once per 
week, at two dose levels of 100 ng/kg or 300 ng/kg, before surgery. We compared these patients 
with 20 control (non-IL-12-treated) patients. 
Toxicity was high, with unexpected dose-limiting toxicities (DLTs) at the 300 ng/kg dose level. 
Dose-dependent plasma interferon-yand IL-10 increments were detected. These cytokine levels 
were higher after the first injection than after the subsequent injections. A rapid, transient 
reduction in lymphocytes, monocytes, and all lymphocyte subsets, especially NK cells, was 
observed, due to a redistribution to the lymph nodes. In the enlarged lymph nodes of the IL-12-
treated patients, a higher percentage of NK cells and a lower percentage of Τ helper cells were 
found compared with control patients. The same pattern was detected in the infiltrate in the 
primary tumor. 
Real-time semi-quantitative PCR analysis of peripheral blood mononuclear cells (PBMCs) in the 
peripheral blood showed a transient decrease of T-bet mRNA. Interestingly, the PBMCs in the 
lymph nodes showed a 128-fold (mean) increase of IFN-γ mRNA. A switch from the Th2 to a Thl 
profile in the lymph nodes compared with the peripheral blood occurred in the IL-12-treated 
patients. 
In conclusion, in previously untreated HNSCC patients, rhlL-12 intratumorally showed DLTs at 
the dose level of 300 ng/kg and resulted in measurable immunological responses locoregionally at 
both dose levels. 
INTRODUCTION 
Head and neck squamous cell carcinoma (HNSCC) provides an excellent model to study the effects 
of locoregional immunotherapy such as cytokines. HNSCC is characterized by the occurrence of 
regional lymph node metastases. Therefore, a resection of the primary tumor, along with a 
regional lymph node dissection, is part of the standard treatment in limited disease. Furthermore, 
HNSCC is an immunogenic tumor, as demonstrated by a variable amount of infiltrating 
lymphocytes and other immune cells susceptible for activation by immunomodulatory cytokines1. 
Several kinds of immune dysfunction, starting at the site of the tumor and eventually 
generalized, have been reported2·3. Locoregional immunotherapy given preoperatively allows study 
of the effects on the primary tumor and the lymph nodes in addition to the peripheral blood. 
Tumors in the oral cavity or oropharynx carcinoma permit local injection of cytokines. 
interleukin-12 (IL-12) is a heterodimeric cytokine that consists of two disulfide-linked subunits, 
i.e., IL-12p40 and IL-12p354. IL-12 has a wide range of biological activity4·5. It stimulates the 
proliferation and activation of cytotoxic Τ lymphocytes (Tc) and natural killer (NK) cells and 
induces the production of a number of other cytokines, especially IFN-γ, but also TNF-a and 
CM-CSF6·. IL-12 is the key cytokine in the induction of Τ helper 1 (Thl) responses and thereby 
of cellular immunity'. Furthermore, IL-12 inhibits angiogenesis10·11. In experimental murine tumor 
model IL-12 has antineoplastic activity1 2·1 3. Several phase I14-19 and phase I I studies in various 
cancer types20-22 have been performed with either intravenous (i.v.) or subcutaneous (s.c.) 
administration of recombinant human IL-12 (rhlL-12). Toxicity was strongly schedule 
dependent20·23. Some clinical responses were observed. However, IFN-γ production induced in vivo 
by rhlL-12 was attenuated rapidly with consecutive cycles, suggesting down-regulation of the 
biological response to rhlL-12 during therapy14-16. 
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Recently, we performed a phase l b study w i t h rhlL-12 administered mtratumorally (ι t .) in patients 
w i t h recurrent or metastatic HNSCC at 100 ng/kg or 300 ng/kg once per week 2 4 . RhlL-12 was 
administered i.t rather than systemically because of the expected higher locoregional 
concentration in the primary tumor and the draining lymph nodes, which may enhance efficacy 
w i t h less systemic tox ic i ty RhlL-12 ι t . at these dose levels and schedule was well tolerated and 
resulted in measurable immunological responses m peripheral blood Significant reductions in 
absolute numbers of peripheral blood lymphocytes m all subsets, especially NK cells and Tc cells, 
were detected. Most interesting was the significant decrease of 80% in T-bet mRNA, a Τ helper 1 
transcription factor, 12 hours after rhlL-12 inject ion, w i t h normalization after 48 to 72 hours. 
Also, the T-bet/c-Maf (a Τ helper 2 (Th2) transcription factor) rat io, an indicator for t h e T h l / T h 2 
balance, decreased. 
The primary objective of this phase I I study was to evaluate the pharmacodynamic (PD) and 
immune effects of i.t. injected rhlL-12, administered before surgery, at t w o previously studied 
dose levels, on the regional lymph nodes, the primary tumor, and the peripheral blood, in 
previously untreated HNSCC patients We were interested m the distr ibut ion of the different 
lymphocyte subsets locoregionally compared w i t h the peripheral blood and in the expression 
levels of IFN-γ, IL-10, and the T-bet/c-Maf ratio locoregionally The secondary objectives were 
the assessment of tox ic i ty and clinical act iv i ty and the pharmacokinetics (PK) of rhlL-12 after 
ι t . administrat ion. 
P A T I E N T S A N D M E T H O D S 
P A T I E N T S E L E C T I O N 
All patients had histological proof of HNSCC, w i t h the primary tumor in the oral cavity or 
oropharynx, staged as T1-4, N0-2, M o , for which surgical resection including a supra-omohyoid or 
radical neck lymph node dissection was planned Patients were previously untreated, 1 e., they did 
not have prior surgery, radiotherapy, or any systemic therapy. The tumor had to be accessible for 
local injection w i t h a diameter not exceeding 5 cm. Further el igibi l i ty criteria included age 
between 18 and 75 years, WHO performance score 0-2, life expectancy >3 months, adequate renal 
funct ion (serum creatinine < 1 5 times normal), adequate hepatic funct ion (serum bil irubin < 1 5 
times normal, ALT and AST < 2 times normal), normal serum calcium ( < 1 1 mg/dl), serum 
hemoglobin > 9 g/dl , granulocytes >1500/μΙ and platelets > 1 0 0 , 0 0 0 / p l Systemic corticosteroids 
were not allowed. Patients w i t h major concurrent disease were excluded, as were patients known 
t o be positive for HIV or hepatit is Β surface antigen 
To allow comparison of the immunological parameters of the rhlL-12-treated HNSCC patients, 
we collected also blood samples, lymph nodes, and primary tumor resection material from 
20 control patients, these patients were eligible for the study, but preferred not to receive 
the rhlL-12 injections. 
The local regulatory committee approved the study. All patients gave w r i t t e n informed consent 
S T U D Y D E S I G N A N D T R E A T M E N T S C H E D U L E 
In this single-center study, open-label, nonrandomized phase I I study rhlL-12 was supplied by 
Wyeth (Cambridge, MA, USA) and was administered at two dose levels of 100 ng/kg and 300 ng/kg, 
by single or mult iple i.t. injections m the primary tumor only Five patients per dose level were 
planned Patients were treated once weekly in the normal w a i t i n g procedure before surgery, w i t h 
a min imum of t w o and a maximum of four doses Surgery was never postponed because of 
participation in this study The last planned injection was administered 24 hours before surgery 
This was based on the results of the prior phase l b study 2 4 , m which the most pronounced 
immunological effects were seen after 12 to 24 hours The f irst injection was given as inpatient 
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treatment; others were on an outpatient basis, with an observation period of 1 hour after each 
injection. The mean volume of the injected rhlL-12 was 0.51 ml (range 0.37-1.1 ml), related to 
the dose level and the weight of the patient. 
Toxicity was assessed using the National Cancer Institute Common Toxicity Criteria Version 2. 
Dose-limiting toxicities (DLTs) were defined as drug-related grade 3 or 4 toxicity, with the 
exception of lymphopenia. 
Before the start of the study, all patients underwent a complete medical history, physical 
examination, electrocardiography, hematology and blood chemistry tests, dipstick urinalysis, 
test for occult blood in stool, and chest X-ray. Patients were monitored by physical examinations, 
complete blood counts, and serum chemistry tests before each weekly injection. The duration 
between the first injection and the surgery (8-15 days) was too short to use computed 
tomography scans for clinical response evaluation. In two IL-12-treated patients, an ultrasonic 
examination to measure the lymph nodes was performed. 
PHARMACOKINETIC AND PHARMACODYNAMIC SAMPLING AND PARAMETERS 
Venous blood samples were collected after the first injection and just before the last injection. 
Whole blood samples anticoagulated in EDTA and citrate were obtained for determination 
of total and differential leukocyte counts and the separation of peripheral blood mononuclear 
cells (PBMCs) by Percoli density centrifugation. Immunophenotypic analysis and semi-quantitative 
PCR were performed before rhlL-12 injection, after 8 and 24 hours in both weeks, and after 
72 hours in the first week. Plasma samples were obtained for determination of serum cytokine 
levels before rhlL-12 injection, after 0.5, 1, 2, 4, 8, and 24 hours in both weeks, and after 
72 hours in the first week. Twenty-four hours before surgery, venous blood samples were 
collected anticoagulated in EDTA and citrate from the control patients for the same 
determinations. 
Immediately after the resection of the primary tumor and the lymph nodes, the resected material 
was put on ice. The lymph node specimen was freshly cut out by the pathologist (PdW).The neck 
was divided in six lymph node regions (i-vi), from which all lymph nodes were collected. Each 
lymph node was fixated in unifix for routine histology and, depending on the size of the lymph 
node, parts were taken for flow cytometry or RT-PCR. If the primary tumor was sufficiently large, 
samples were taken for flow cytometry. Before performing flow cytometry or RT-PCR, a single-cell 
suspension was made of the lymph nodes and primary tumor by using an open filter chamber 
(NPBI).The lymph nodes regions were designated as draining or nondrammg based on the 
expected anatomic draining pathway. 
Plasma IL-12p70 and IL-12p40 were measured in an enzyme-linked immunosorbent assay (ELISA) 
as previously described25. To measure IFN-yand IL-10, commercial ELISA kits were used (Sanquin 
Reagents, Amsterdam, the Netherlands). They were standardized with the standards of the 
National Institute for Biological Standards and Control. 
The total number of leukocytes and differential leukocyte counts were determined on the Advia 
120 (Bayer). Whole blood samples (100 pi) and the single-cell suspension of the lymph nodes 
and primary tumor were incubated with directly staining monoclonal antibodies (mAb).The 
following mAbs (and clones) used were: CD2 (MT910; DAKO), CD3 (UCHT1; DAKO), CD4 (MT310; 
DAKO), CD8 (DK25; DAKO), CD19 (HD37; DAKO), CD28 (CD28.1; DAKO), CD45-FITC (PN IM0782; 
Coulter), CD45/CD14 (T29/33,TUK4; DAKO), CD45 (IQP-124C; IQ Products), CD45RA (Leu™-18; 
Becton-Dickinson), CD45R0 (F0800; DAKO), CD62L (FMC46; DAKO), and CD56 (NCAM16.2; 
Becton Dickinson). After incubation of the PBMCs in the peripheral blood sample, the 
erythrocytes were lysed using erylysis (NH4CI).To determine the percentage of death cells in 
the cell suspension of the lymph nodes or primary tumor, 7-AAD (IQ-products) was used. The 
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expression of the markers on the PBMCs was analyzed by f low cytometry using a FACScan of 
Becton Dickinson (Mountain View, CA). 
In six selected IL-12-treated patients, all of whom received >1 in ject ion, and six control patients, 
comparable w i t h regard to all patient characteristics, total RNA of PBMCs was extracted using 
Trizol Reagent (Life Technologies, Inc.) Reverse transcript ion was performed using 5 μg total 
RNA, random hexamers, and Mo-MLV reverse transcriptase (Life Technologies, Ine ) Pre-developed 
assay reagents (PDARs) (PE Biosystems) were used for determinat ion of IFN-γ, IL-10, IL-12p35 
andlL-12p40 A PDAR (PE Biosystems) was used for determinat ion of a housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).Taqman probes for T-bet, c-Maf, and 
phorphobilmogen deaminase (PBCD), a housekeeping gene, were synthesized by PE Biosystems 
(Branchburg, New Jersey). The sequence of the primers and probes of T-bet, c-Maf, and PBGD 
used m this study have been described previously2 4 Real-time sequence quantitat ive analysis was 
performed as described previously2 6 To compare the amount of mRNA of cytokines and 
transcription factors in the peripheral blood and the lymph nodes of the IL-12-treated and the 
control patients, the quant i ty was normalized t o CAPDH and calculated relative to the mean of 
the control group In the IL-12-treated patients, the PD effect of rhlL-12 in the peripheral blood 
on the amount of mRNA of cytokines or transcription factors in t ime was determined by 
normalizing to CAPDH and calculating relative to the amount of target present before the start 
of rhlL-12 administrat ion. A cycle t ime (CT) of less than 35 cycles was established as meaningful. 
Total IgC was measured on the Beekman Coulter (Mi jdrecht, the Netherlands) Image Nefelometer 
using Beekman Coulter reagents Calibration was on the international standard CRM470 IgC 
subclasses were measured on a BNII Nefelometer Dade Behring, Brussels, Belgium) using the 
reagents of The Binding Site (Birmingham, England). Calibration was performed on a CLB 
(Amsterdam, The Netherlands) standard H1234 
S T A T I S T I C S 
The cl imcopathologic characteristics of the IL-12-treated and control patients were analyzed by 
the use of a contingency table, statistical significance was evaluated using the Fisher exact test. 
Overall survival (OS) and disease-free survival (DFS) were calculated from the date of surgery and 
estimated using the Kaplan-Meier m e t h o d 2 7 The DFS was defined as the length of t ime after 
surgery that a patient experienced a complete remission The comparison of survival parameters 
in IL-12-treated versus control patients was performed using the log-rank t e s t 2 ' . Nonparametric 
tests according to Mann-Whitney and Wilcoxon signed-rank tests were performed to compare 
independent and related samples. Linear regression analyses were performed to compare the 
monocytes, lymphocytes, and lymphocyte subsets m t ime after IL-12 injection and t o compare 
the f irst versus the second or th i rd in ject ion. 
For correlation analysis between variables, Spearman's correlation coefficient was calculated 
For all tests, p<0.05 was considered to be statistically signif icant All statistical analysis were 
two-tai led. Statistical analysis was performed w i t h SPSS 11.0 for Windows 
R E S U L T S 
P A T I E N T C H A R A C T E R I S T I C S 
A total of 10 patients were entered m the study: four men and six women, w i t h a median age 
of 55 years (range, 46-69) (table i ) . T h e median WHO performance score was 1 (range, 0-1). 
Tumor sites were the oral cavity (n=8) and oropharynx (n=2) The Τ and Ν tumor stages are 
summarized in table 1. Radical modified neck dissections or supraomohyoidal neck dissections 
were performed m eight and t w o patients, respectively The characteristics of the IL-12-treated 
patients were comparable w i t h the 20 control patients (table 1) 
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Surgery of the neck 
RND 
SOHD 
Abbreviations: RND= radical neck lymph node dissection; SOHD= supra-omohyoid lymph node dissection 
T R E A T M E N T S C H E D U L E , T O X I C I T Y , C L I N I C A L RESPONSE A N D S U R V I V A L 
As planned the f irst five patients received t w o to three injections w i t h 100 ng/kg of rhlL-12 i.t.. 
In one patient the injected rhlL-12 flew out of the tumor immediately, and therefore this patient 
was omit ted from the PK analysis. One patient developed a grade 3 increase of transaminases 
after the t h i r d injection (table 2). Besides fever and transient lymphopenia, nausea grade 2, 
v o m i t i n g grade 2, and myalgia grade 2 were seen. The next four patients received 300 ng/kg. 
Two of the four patients received only 1 injection due to grade 3 fatigue and grade 3 liver 
toxicity, respectively. In one of the four remaining patients, the dose for the second injection 
was decreased t o 100 ng/kg due to grade 2 liver toxicity. The one patient who received three full 
doses of 300 ng/kg developed grade 3 metabolic acidosis after surgery, possibly related to rhlL-12 
inject ion, and had a prolonged stay at the intensive care uni t for 24 hours. Thus, grade 3 tox ic i ty 
at the 300 ng/kg dose level was seen in three out of four patients and therefore this dose level 
showed DLT. Consequently, in the t e n t h patient the dose level was decreased to 100 ng/kg. He 
received three injections w i t h o u t serious toxicity. 
We did not observe measurable changes in the primary tumor or the lymph nodes in the neck by 
physical examination during the short treatment period. However, in t w o tested IL-12-treated 
patients, we measured a signif icant increase in the diameter of the lymph nodes in the neck 
by ultrasonic examination after 24 hours compared w i t h pretreatment measurements (data not 















































table 2 Toxicity of the IL-12-treated patients (n=10). The numbers of patients with grade 3 and 2 toxicities are shown. 
100 ng/kg (n=6) 300 ng/kg (n=4) 
Grade 3 Grade 2 Grade 3 Grade 2 
Elevation AST/ALT 1 
Fatigue 






Abbreviations: AST= aspartate aminotransferase; ALT= amino alanine transferase 
' possibly related 
pathologic TNM stage were not different between the IL-12-treated and control patients. Seven 
of 10 IL-12-treated patients and 16 of 20 control patients received radiotherapy after surgery 
according t o the standard protocol. 
The median OS has not yet been reached in the IL-12-treated group, and is 2.3 years in the 
control group (p=0.09).The median DFS has not been reached in the IL-12-treated group unti l 
now, and is 2.9 years in the control group (p=0.14).The median follow-up of the IL-12-treated 
patients is 2.9 years (1.7-4.8 years) and of the control patients 3.5 years (1.7-5.0 years). In the 
IL-12-treated group t w o of 10 patients developed a local recurrence and three a second primary 
tumor. In the control group, nine out of 20 patients developed a local recurrence, t w o generated 
distant metastases, and four a second primary tumor. 
R H I L - 1 2 P H A R M A C O K I N E T I C S 
Results of the pharmacokinetic studies are shown in table 3. PK analysis was performed in five 
out of six patients at the 100 ng/kg dose level, both after the f irst injection and the last (second 
or third) in ject ion. The A U C 0 j 4 hours of IL-12p70 was decreased after the second or th i rd injection 
compared w i t h the AUC after the f irst injection (p<0.05). At the 300 ng/kg dose level in three 
of four patients, PK analysis was performed only after the f irst injection these patients received 
either only one injection (n=2) or had a dose reduction to 100 ng/kg ( n = l ) in the subsequent 
in ject ion. In one of the four patients a complete PK analysis was not possible, because of a 
reluctant at t i tude to all the blood collections. 
In all patients, IL-12 was detected in plasma 30 minutes after rhlL-12 in ject ion. 
P H A R M A C O D Y N A M I C S 
Effects on plasma cytokine levels 
The effect of rhlL-12 on the plasma levels of IFN-γ (figure iA) and IL-10 was analyzed (figure iB). 
An increase of IFN-γ was seen after 4 hours w i t h peak concentration occurring at 24 hours. After 
72 hours the level of IFN-γ was nearly normalized. After the f irst injection at the 100 ng/kg dose 
level, the mean maximal concentration was 143 pg/ml (range, 65 to 323 pg/ml) and was 
increased at the 300 ng/kg dose level to 435 pg/ml (range, 369 to 506 pg/ml; p<0.05). At the 
100 ng/kg dose level, the mean maximal concentration of IFN-γ was higher after the first 
injection than after the subsequent injections (p<0.05). 










o-» (pg χ h/ml) 
0-34 hours \ p £ X h/ml 
table 3 Pharmacokinetic data: mean (± SD) pharmacokinetic parameters on dose levels 100 ng/kg and 300 ng/kg after the first 
injection (week 1) and the last injection (week 2 or 3; only on the 100 ng/kg dose level), 24 hours before surgery. 
100 ng/kg 100 ng/kg 300 ng/kg 
Week 1 (n=5) Week 2/3 (n=5) Week 1 (n=3) 
600 (668.8) 350 (294.8) 813.7 (306.8) 
6.5 (3.4) 4.9 (3.2) 6.7 (2.3) 
7.8 (3.5) 9.8 (8.3) 10.1 (2.3) 
9523 (6383.8) 15870 (4800.5) 
7402.2 (6105.8)a 4169.2 (2366.5)a 12309.3 (4236.3) 
' difference between AUC (0-24 hours) in week 1 and week 2 or 3 at 100 ng/kg (p<0.05) 
f irst detected after 4 to 8 hours and reached its maximum after 24 hours. After 72 hours the IL-10 
level was normalized. In week 1 at the 100 ng/kg dose level, the mean maximal concentration 
was 27 pg/ml (range, 22 to 33 pg/ml) and at the 300 ng/kg dose level 71 pg/ml (range, 32 to 
107 pg/ml; p=0.07). At the 100 ng/kg dose level the mean maximal concentration of IL-10 was 
higher after the f irst injection than after the subsequent injections (p<0.05). 
Effects on the lymph nodes in the lymph node dissection specimen 
In the lymph node dissection specimen, the mean diameters of the lymph nodes were 7.9 mm 
(range 7 t o 8.7 mm) in the IL-12-treated group and 6.1 mm (range 4.6 to 8.5 mm) in the control 
group (p<0.001). Eventual differences in the number of lymph nodes were only analyzed in patients 
who underwent a radical lymph node neck dissection. The mean number of the lymph nodes was 42 
(range 31-50) in the IL-12 group (n=7) versus 28 (range 15-42) in the control group (n=14) ( p = 0 . 0 0 l ) . 
Effects on leukocyte subsets 
In the peripheral blood of all 10 patients after the f irst rhlL-12 injection a rapid and signif icant 
absolute decrease of lymphocytes, monocytes, CD2+CD3+ cells (T cells), CD3+CD4+ cells (Th cells), 
CD3+CD8+ cells (Tc cells), CD3-CD16+CD56+ cells (NK cells), CD19+CD45+ cells (B cells), 
CD45RA+CD4+ cells, CD45R0+CD4+ cells, CD45RA+CD8+ cells and CD45RO+CD8+ cells was 
detected (table 4 ) . The observed decreases were maximal after 24 hours and were also detected 
to the same extent after the second or th i rd inject ion. An exception were the monocytes, which 
did not show a decrease after repeated injections. No differences in the absolute amounts of 
lymphocytes, monocytes, and subsets of lymphocytes were found between the start of treatment 
or before the second or th i rd in ject ion. After 24 hours, hardly any NK cells were detected. The 
Th/Tc ratio increased signif icantly in the f irst 24 hours (4 t o 10; p<0.005), indicating that the 
CD3+CD8+ cells decreased faster than the CD3+CD4+ cells. Seventy-two hours after the rhlL-12 
inject ion, all subclasses were rising, but were not fully normalized. However, the T-cell/B-cell ratio 
was increased compared w i t h the pretreatment values (p<0.05), because of a stable number of 
Β cells and an increasing number of Τ cells between 24 and 72 hours after the rhlL-12 in ject ion. 
After 8 hours the percentage of the CD8+ cells that were CD28+ (63% to 80%;p<0.02) or CD62L+ 
(54% to 73%;p<0.02) increased significantly. The expression of these activation markers on the 
CD4+ cells remained stable. 
The lymph nodes of nine of 10 évaluable IL-12-treated patients were compared w i th 15 control 
patients. A signif icantly higher percentage of NK cells (1.6% versus 0.7%; p<0.001), and a lower 
percentage of Τ cells (56% versus 64%; p<0.05) and Th cells (46% versus 55%; p<0.05) were 
found in the enlarged lymph nodes of the IL-12-treated patients (table 5). The percentage of 
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figure ι The IFN-γ (A) and IL-10 (B) production after treatment with rhlL-12 (100 ng/kg week 1 = • ; 100 ng/kg week 2 
or 3 = • ; 300 ng/kg week 1 = • ) . The IFN-γ induction (both the Cma,and the AUC) are higher in the 300 ng/kg 
treated patients compared with the 100 ng/kg treated patients (p<0.05). Both the IFN-γ and IL-10 production 













time in hours after IL-12 it 
Β cells ( 4 1 % versus 34%) was not significantly higher and the percentage of Tc cells (8.7% versus 
8.2%) did not differ between the IL-12-treated and control patients. The increase in NK cells in 
the lymph nodes f its well w i t h the observed decrease in NK cells in the blood. The Th/Tc ratio in 
the lymph nodes was lower in the IL-12-treated versus control patients (6.1 versus 7.6; n.s.J.This 
corresponds well w i t h the observation in the blood of an increase in this ratio after rhlL-12. There 
were no differences between the 2 dose levels of rhlL-12. A direct comparison of the absolute 
numbers of leukocyte subclasses in the lymph nodes between the IL-12-treated and control 
patients was not possible, because only parts of the lymph nodes were available for analysis. 
Analysis of draining versus non-draining lymph nodes and metastases-containing lymph nodes 
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table 4 Absolute numbers of lymphocytes, monocytes and lymphocyte subsets and the T/B cell ratio in the peripheral blood 






































































































t = 0 a n d t = 7 2 
<0.05 
in IL-12 treated and control patients demonstrated essentially the same effects on redistr ibut ion 
of lymphocyte subsets. In three IL-12-treated and seven control patients, we were able t o isolate 
the inf i l t rat ing immune cells from the primary tumor (table 5). Although the number was small, 
a trend toward a higher percentage of NK cells and Β cells and a lower percentage of Τ cells was 
seen in the IL-12-treated patients, as in the lymph nodes. 
Because of the increase of Β cells in the lymph nodes, the total IgC and the IgC subclasses were 
determined in plasma in three patients before treatment and after 14 (n=2) or 7 (n = l ) days of 
t reatment. No IgC subclass sh i f t ing was found (data not shown). 
Collectively, these data demonstrate t h a t a strong decrease in absolute numbers of lymphocytes, 
monocytes and all subsets of lymphocytes, especially NK cells, occurred in the peripheral blood 
after rhlL-12 in ject ion. This decrease was maximal at 24 hours and reached approximate 
normalization after 72 hours. In the IL-12-treated patients, the larger lymph nodes contained a 
higher percentage of NK cells and surprisingly, a lower percentage of Τ cells (especially Th cells, 
w i t h a stable percentage of Tc cells) and a non-significant higher percentage of Β cells. 
Ejects on mMiA of cytokines and transcription /actors 
A semi-quantitative PCR was performed in five IL-12-treated patients t o determine the effects 
of rhlL-12 on the expression of IFN-γ, IL-10, IL-12p35, IL-12p40, T-bet, and c-Maf at d i f ferent 
t ime points after rhlL-12 in ject ion. In the peripheral blood the mRNA encoding IFN-γ showed no 
differences in t ime before and 8, 24 or 72 hours after rhlL-12 in ject ion. The expression of IL-10 
showed a mean maximal increase of 2.2 t imes after 24 hours relative to the pre-treatment sample 
in week 1 and no differences in weeks 2 or 3 (data not shown). The mRNA expression of IL-10p35 
showed a mean maximal increase of 2.9 after 8 hours, both in week 1 and week 2 or 3. After 24 
hours in both weeks an increase of 2.1 was stil l detected, which returned to baseline values after 
72 hours (figure 2). T-bet expression decreased in all five patients. During the f irst week 8 hours 
and 24 hours after in ject ion, respectively, of the init ial amount of mRNA of T-bet was present. 
The T-bet mRNA levels returned to normal after 48 or 72 hours (figure 2). In week 2 or 3 the 
decrease was less impressive: after 24 hours, 47% relative to the pretreatment sample was 
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table 5 Lymphocyte subsets in the lymph nodes and primary tumors of the IL-12-treated and control patients (mean (SD)). 
Τ cells (CD2+CD3+) (%) 
Th cells (CD3+CD4+) (%) 
Tc cells (CD3+CD8+) (%) 
NK cells (CD3-CD16+CD56+) (%) 
Β cells (CD19+CD45+) (%) 
Tcell/B cell ratio (CD2+CD3+/CD19+CD45+) 
CD28+Th cells (CD28+CD4+/CD4+) (%) 
CD28+TC cells (CD28+CD8+/CD8+) (%) 
CD62L+Th cells (CD62L +CD4+/CD4+) (%) 
CD62L+TC cells (CD62L +CD8+/CD8+) (%) 
CD62L+B cells (CD62L +CD19+/CD19+) (%) 
CD45RA+CD4+/CD45RO+CD4+ 
CD45RACD8+/CD45RO+CD8+ 
Living cells (%) 
Lymph nodes 
IL-12-treated 
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present. The mRNA encoding c-Maf showed no differences in t i m e . The T-bet/c-Maf ratio 
decreased in t ime t o 0.3 and 0.29 after 8 and 24 hours, respectively (figure 2). The expression 
of IL-12p40 was too low for reliable measurements. 
Strikingly, a 128 times higher IFN-γ mRNA expression was found in the lymph nodes of the 
IL-12-treated patients compared w i t h control patients (mean 139 in IL-12-treated patients and 
1.O8 in control patients; p<0.005) (figure 3). T-bet expression was 1.7 times (non significant) 
higher in the IL-12-treated patients compared w i t h control patients. The t w o IL-12-treated 
patients w i t h the largest tumor load (patients 2 and 8) had the lowest T-bet and IFN-γ expression 
of the group of six investigated patients. The T-bet/c-Maf ratio was not significantly higher in 
the IL-12-treated patients. The t w o patients (patients 2 and 4) w i t h no "upregulat ion'Of the 
T-bet/c-Maf ratio were the same patients who developed a local recurrence of their disease after 
6 months and died because of the recurrence (figure 3). Of the other four IL-12-treated patients 
w i t h an upregulated T-bet/c-Maf rat io, none had a local recurrence or metastases. No correlation 
was found between the expression of T-bet and IFN-γ in the IL-12-treated or control patients. 
No differences were found in IL-10, IL-12p35 or IL-12p40 expression. 
The expression levels of the cytokines and transcription factors were compared between the 
lymph nodes and the peripheral blood in both the control patients, collected the day before 
surgery, and in the IL-12-treated patients, collected one hour before surgery. These expression 
levels were compared because of the observed lymphocyte redistr ibution after rhlL-12 inject ion. 
The analysis revealed that in control patients, IFN-γ and T-bet expression was higher in the 
peripheral blood and IL-10 and c-Maf expression was higher in the lymph nodes (figure 4) . 
Strikingly, the expression profile was completely reversed in the IL-12-treated patients: IFN-γ and 
T-bet expression was higher in the lymph nodes and IL-10 expression was higher in the peripheral 
blood. The c-Maf expression was somewhat higher in the lymph nodes, but much less than in the 
control patients. The T-bet/c-Maf ratio ( T h l / T h 2 balance) was approximately the same in the 
blood as in the lymph nodes in the control patients, but was higher in the lymph nodes compared 
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Figure 2 The mRNA expression encoding IL-12p35, T-bet and the T-bet/c-Maf ratio in PBMCs in peripheral blood after the first 
IL-12 injection in 6 patients. 
IL-12p35 
relative to t=0 
T-bet 
relative to t=0 
24 48 72 
time in hours after IL-12 i.t. 
48 72 
time in hours after IL-12 i.t. 
relative to t=0 
T-bet/c-Maf 
48 72 
time in hours after IL-12 i.t. 
w i t h blood in the IL-12-treated patients. These observations are a strong indication of the 
existence of a locoregional Th2 profile in control patients tha t switches toward a locoregional 
T h l profile after rhlL-12 in ject ion. 
DISCUSSION 
We studied various immunological effects of the i.t. administrat ion of rhlL-12 in previously 
untreated HNSCC patients before surgery. The same dose and schedule was used as in our 
previous study, i.e., 100 ng/kg or 300 ng /kg i.t., given once weekly, in which pre-treated HNSCC 
patients w i th a local recurrence or metastases after prior surgery and radiotherapy were treated 24. 
To our surprise remarkable toxic i ty was observed in the present study, i.e., at the 100 ng /kg dose 
level grade 3 liver tox ic i ty and at the 300 ng/kg dose level grade 3 liver toxici ty, grade 3 fatigue 
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figure 3 The mRNA expression encoding IFN-γ and T-bet and the T-bet/c-Maf ratio in PBMCs in lymph nodes m 6 IL-12-treated 
( • , 2-10) and 6 control ( D , cl-c6) patients. The IFN-γ mRNA expression was significant higher m the IL-12-treated 
patients (p<0.002). The T-bet expression was comparable except in one patient. The T-bet/c-Maf ratio was higher m 
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patients 
and grade 3 metabolic acidosis. The 300 ng/kg had DLT. This toxic i ty was absent in the previous 
study of pretreated patients. The difference might be a reflection of the compromised immune 
status in the recurrent patients who had been pretreated w i t h surgery and radiotherapy. 
Indications for this are the pretreatment number of lymphocytes (1767/pl versus 833/μΙ, 
respectively), and the higher and dose-dependent IFN-γ production in this study compared w i t h 
the earlier study. Another difference was the injection site: the primary tumor versus lymph node 
metastases or local recurrence. Triggering might be more eff icient w i t h an intact locoregional 
lymph node system. 
Instead of a lower toxic i ty after i.t. administration compared w i t h i.v. or s.c. administration, 
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figure 4 The expression levels of IFN-γ, IL-10, T-bet and c-Maf in PBMCs of 6 IL-12-treated (•) and 6 control ( D ) patients. 
The expression was calculated comparing the levels in peripheral blood with lymph nodes. The bars are showing the 
site, e.g., the peripheral blood or the lymph nodes, where the highest expression is present. 






DLT was observed after i.t. injection at the 300 ng/kg once-weekly dose level, compared w i t h 
a maximal tolerated dose of 500 ng/kg i.v. twice weekly 1 ' and more than 2100 ng/kg s.c. once 
weekly 2 ' . The liver tox ic i ty in our present study was extremely high: three of 10 patients had 
grade 2 ( n = l ) or 3 (n=2) liver toxicity. Besides the different routes of administrat ion, these 
studies differ in patient characteristics. Probably part of the observed toxici ty in this study 
reflects highly eff icient immune tr iggering via the primary tumor and in the regional lymph 
nodes after the relatively high concentration of rhlL-12 locally. 
In this study we compared 10 IL-12-treated patients w i t h 20 control patients, who were eligible 
but preferred not t o receive rhlL-12 injections. The patient characteristics and the duration of the 
follow-up of these control patients are similar t o those of the IL-12-treated patients. We realize 
that this is not identical to a randomized approach, but such an approach was not considered 
feasible in this sett ing. 
After the l imited number of 2 or 3 injections, we were not able to detect any clinical act iv i ty 
in the tumor. However, in t w o tested patients an enlargement of the lymph nodes was seen 24 
hours after the f irst in ject ion. To test if the IL-12-treated patients were doing equally well as 
control patients, overall and disease-free survival were analyzed. The IL-12-treated patients have 
a trend toward better overall survival, but i t had not reached significance at the most recent 
follow-up. 
We are the f irst to demonstrate that the observed IL-12 induced lymphopenia in humans is due 
to a redistr ibution of peripheral blood lymphocytes to extravascular sites, e.g., lymph nodes. In 
the neck dissection specimen of the IL-12-treated patients, larger and a higher number of lymph 
nodes were found. This lymphadenopathy is in agreement w i t h the observation that normal mice 
receiving IL-12 develop a marked splenomegaly3 0 and that in a murine tumor model, i.t. injection 
of IL-12 plasmid DNA resulted in lymphadenopathy and splenomegaly". In the lymph nodes of 
the IL-12-treated patients a higher percentage of NK cells and a lower percentage of Τ cells and 
Th cells were measured. Surprisingly, the percentage of Β cells was slightly higher (n.s.); Tc cells 
were the same. The same trends were seen in the primary tumors. The percentages in the lymph 
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nodes and primary tumor correspond with the observation of the extreme decrease of NK cells, 
the late recurrence of Β cells m the peripheral blood, and the moderate decline of Th cells after 
rhlL-12 injection However, Tc cells decreased in the peripheral blood, but no increase was 
detected m 
the lymph nodes. Our results of the differential redistributions of the lymphocyte subsets are in 
agreement with those of Cately et al., who observed, after administration of IL-12 to normal 
mice, an increase in the numbers of NK cells and Β cells m the spleen and NK cells and Tc cells 
in the liver, whereas the number of Th cells m these sites remained essentially unchanged Our 
observation m the human lymph nodes is exactly the same as this observation in the spleen of 
mice. It is imaginable that the disappearing Tc cells in the peripheral blood m our study 
accumulate in the liver together with NK cells, as seen m the mouse model. 
The measured redistribution of activated immune cells from the peripheral blood to the lymph 
nodes (and primary tumor), clearly show that monitoring the immune effects solely m the 
peripheral blood, after IL-12 or other immune therapy, can be misleading. 
Remarkably, in the peripheral blood, lymph nodes, and the primary tumor, a higher percentage 
of the CD3+CD8+ cells were positive for CD28 and CD62L. This observation cannot be simply 
explained by the hypothesis that the CD28-CD8+ and CD62L-CD8+ extravasate preferentially, 
leaving the CD28+ and CD62L+ "behind". The CD28+CD8+and CD62L+CD8+ are also present 
in a higher percentage in the lymph nodes. Because of the higher percentage at both locations 
(blood and lymph nodes), it appears that a true upregulation of CD28 and CD62L on CD8+ cells 
occurs. 
CD28 upregulation on CD8+ cells after IL-12 administration is not previously described CD28 
plays an important role in the initiation and expansion of the T-cell response. It has been 
described that CD28 expression is lost m a subset of CD8+ cells, which correlates with the 
inability to produce IL-12 and proliferate after activation by antigen presenting cells. These 
functions could be restored by reexpressmg CD28 in vitro32 Moreover, CD28+CD8+ cells produce 
more IFN-γ after IL-12 stimulation than CD28-CD8+ cells in vitro33 Thus, these data suggest that 
after IL-12 treatment CD8+ cells are activated in vivo 
CD62L (L-selectm) is a lymphocyte homing receptor and plays a key role in the migration of naive 
Τ cells through the lymph nodes CD62L expression on Thl cells can be maintained by IL-12 and 
thereby facilitate the traffic of Thl cells" Moreover, it was shown that CD8+ cells expanded in 
vitro m the presence of exogenous IL-12 acquired CD62L35. So, this study confirms the in vitro 
observations, that the CD62L is upregulated on CD8+ cells after IL-12 treatment. 
The PK data of the injected rhlL-12 were comparable with the PK data of the earlier rhlL-12 ι t . 
study The mam difference is that in this study the AUCc24 hours after the second or third injection 
decreased compared with the first injection. This is in accordance with observations after s.c 
and ι v. administration18 ".The produced IFN-γ was clearly higher and the produced IL-10 was 
slightly higher in this study compared with the earlier i.t. study. Both IFN-γ and the IL-10 
production decreased after the repeated injection compared with the first injection The 
diminished production of IL-10 after repeated injections is in agreement with an earlier 
observation after s c. administration36 and in disagreement with another s c. study37 The IL-10 
production observed after rhlL-10 administration has been suggested to be responsible for the 
down-regulation of clinical and immunological effects However, our data show that despite the 
IL-10 production in the blood, a potent Thl environment is present locoregionally in the lymph 
nodes m IL-12-treated patients. Moreover, recent data imply that IL-10 has a distinct role in the 
different phases of the immune response. Besides its potent capacity to down-regulate immunity 
during the effector phase, IL-10 might actually enhance immunity (e.g., IL-10 is known to 
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enhance NK cell function) during the onset of an immune response38. Therefore, it is doubtful 
that the observed IL-10 production after IL-12 administration can simply be regarded as a 
negative side effect. 
In contrast to the peripheral blood, in which no differences in IFN-γ expression were seen, we 
detected a 128-fold higher IFN-γ expression in the lymph nodes of the IL-12-treated patients than 
in control patients. Plasma IFN-γ protein was clearly produced after rhlL-12 injection, starting 
after 4 hours and maximal after 24 hours. IFN-γ mRNA levels were low in the PBMCs isolated 
8 hours after IL-12 injection. Possibly 8 hours after treatment is too late to detect the peak of 
IFN-γ mRNA. In the earlier i.t. study we detected a slight increase in expression after 4 hours. In 
addition, our data are also in line with the finding that the IFN^producing cells (i.e., NK cells, 
Tc cells, Thl cells) might extravasate and are no longer present in the circulation. Although 
slightly higher IL-10 and IL-12p35 levels were found in the blood after 24 and 8 hours, 
respectively, no differences of these cytokines were seen in the lymph nodes. 
The impressive decline in mRNAT-bet expression in the peripheral blood occurred to the same 
extent as in the former study. T-bet expression in the lymph nodes was higher in one IL-12-
treated patient and approximately the same in the others. The resection of the primary tumor 
and the lymph nodes was performed 24 hours after the last injection. Probably this was too 
late to measure a higher increase of T-bet in the lymph nodes. However, the T-bet/c-Maf ratio 
(Thl/Th2 ratio) decreased in the peripheral blood in all IL-12-treated patients and increased in 
four of six IL-12-treated patients. Remarkably, the two patients who did not show an increase 
in this ratio both had local recurrence of their disease after 6 months; the other four patients 
were disease free. Possibly the ability to up-regulate the T-bet/c-Maf ratio is a prognostic or 
predictive favorable sign. The observation that the IL-12-treated patients with the largest 
tumors had the lowest T-bet and IFN-γ expression in their lymph nodes supports this hypothesis. 
The observation that the PBMCs isolated from the lymph nodes of the control patients exhibited 
a Th2 profile compared with the PBMCs of the peripheral blood is also interesting. In contrast, 
in the IL-12-treated patients a clear Thl profile in the lymph nodes was observed compared 
with the peripheral blood. The Th2 profile is probably an indication of locoregional 
immunosuppression, which switched to a Thl profile after rhlL-12 treatment. Such a switch 
has been shown in mice in vivo with infectious diseases treated with IL-123', but was not 
earlier shown in humans. 
In summary our data demonstrate that in previously untreated HNSCC patients, the i.t. 
administration of rhlL-12 is more toxic at doses of 100 ng/kg and 300 ng/kg than in pretreated 
HNSCC patients. Its main biological effects locoregionally are a redistribution of lymphocytes 
from the peripheral blood to the enlarged lymph nodes in the neck, a significant higher 
percentage of NK cells and a lower percentage of Th cells in the lymph nodes and the primary 
tumor, and a huge increase in mRNA-encoding IFN-γ in the lymph nodes. A switch from the 
Th2 profile, present in control patients, to a Thl profile in the lymph nodes after rhlL-12 
administration, occurred. The IL-12-treated patients, who showed no increase in the T-bet/c-Maf 
ratio in the lymph nodes, had the worst prognosis. 
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A B S T R A C T 
The objective of this study was to evaluate the histologic and immunohistopathological effects 
of mtratumoral ly administered recombinant human interleukin-12 (rhlL-12) on the immune cells 
m the primary tumors and regional lymph nodes. Ten previously untreated patients w i t h head and 
neck squamous cell carcinoma (HNSCC) were injected in the primary tumor 2 to 3 t imes, once 
weekly, at t w o dose levels of 100 ng/kg or 300 ng/kg, before surgery. These patients were 
compared w i t h 20 non-IL-12-treated control HNSCC patients. 
In the primary tumor, the number of CD56+ Natural Killer (NK) cells was increased in IL-12-
treated patients compared w i t h control patients. In some IL-12-treated patients, an impressive 
pentumoral invasion of CD20+ Β cells was not iced, but overall the pentumoral invasion of Β cells 
was not higher after IL-12 treatment No differences were seen in the numbers or d istr ibut ion of 
CD8+ or CD4+ Τ lymphocytes. Interestingly, major differences were apparent in the architecture 
of the enlarged lymph nodes of IL-12-treated patients; m particular, the distr ibut ion of Β cells 
differed and fewer primary and secondary follicles w i t h smaller germinal centers were observed. 
In addi t ion, a decrease of DC-LAMP+ cells in the paracortex was noted, resulting m a reduction 
f paracortical hyperplasia. In the lymph nodes, especially the CD56+ NK cells, but also the CD8+ 
and CD4+ Τ lymphocytes, produced a high amount of IFN-γ 
In conclusion, after i.t. IL-12 treatment m HNSCC patients, the largest effect was seen on the NK 
cells, w i t h a higher number in the primary tumor and a high IFN-γ mRNA expression in the lymph 
nodes Significant effects were noted on Β cells, w i t h altered lymph node architecture in every 
IL-12-treated patient and excessive pentumoral in f i l t rat ion in some patients. 
I N T R O D U C T I O N 
Head and neck squamous cell carcinoma (HNSCC) provides an excellent model to study the 
effects of locoregional immunotherapy w i t h cytokines. HNSCC is characterized by the occurrence 
of regional lymph node metastases Therefore, resection of the primary tumor, along w i t h a 
regional lymph node dissection, is part of the standard treatment in patients w i t h l imited 
disease. HNSCC is an immunogenic tumor, as demonstrated by a variable amount of in f i l t ra t ing 
lymphocytes and other immune cells. In principle, these in f i l t ra t ing leukocytes are susceptible 
to activat ion by immunomodulatory cytokines 1 . However, several types of immune dysfunct ion, 
start ing at the site of the tumor and eventually generalized, have been r e p o r t e d 2 3 . Locoregional 
immunotherapy given preoperatively allows for study of the effects of the treatment on the 
primary tumor, the lymph nodes, and peripheral blood. Tumors m the oral cavity or oropharynx 
carcinoma permit local injection of cytokines. 
lnterleukin-12 (IL-12) is a heterodimeric cytokine t h a t consists of t w o disulfide-lmked subumts, 
1 e , IL-12p40 and IL-12p35 4 IL-12 has a wide range of biological activit ies 4 · 5 , and has effect on 
both the innate and adaptive immune system. IL-12 stimulates the proliferation and activat ion 
of cytotoxic Τ lymphocytes (Tc) and natural killer (NK) cells and induces the production of 
cytokines, especially interferon-γ ( ΐΡΝ-γΚ'. IL-12 is the key cytokine in the induction of Τ helper 1 
( T h l ) responses and thereby of cellular immunity» In addit ion to a crucial role in in i t ia t ing cell-
mediated immune responses, IL-12 also has an effect on humoral immuni ty IL-12 stimulates 
Β cell g r o w t h by inducing IFN-γ production in Β cells in v i tro 1 0 , causes immunoglobulin (Ig) 
isotype selection 1 1 and triggers a cascade of molecular events m human Β cells similar t o T h l 
c o m m i t m e n t 1 2 . Furthermore, IL-12 inhibits angiogenesis 1 3 1 4 . IL-12 has antineoplastic act iv i ty m 
experimental murine tumor m o d e l s 1 5 1 6 . Several Phase I 1 7 2 2 and Phase I I studies in various cancer 
t y p e s 2 3 2 6 have been performed w i t h either intravenous (i.V.), subcutaneous (s.c ), or mtratumoral 
(1 t ) administrat ion of recombinant human IL-12 (rhlL-12). However, only a l imited number of 
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clinical responses were observed, probably because of opposing immune mechanisms 
We have performed a phase I I study of the administrat ion of rhlL-12 (recombinant human IL-12) 
to HNSCC patients before surgery to evaluate the immunologic effects on the primary tumor 
and regional lymph nodes2 6 Toxicity was higher than expected at the dose levels used Dose-
dependent plasma interferon-yand IL-10 increments were detected In peripheral blood a rapid, 
transient reduction m lymphocytes, especially NK cells, was observed The redistribution of 
lymphocytes t o lymphoid organs led to enlarged lymph nodes Real-time quantitat ive polymerase 
chain reaction (PCR) analysis of blood mononuclear cells m the lymph nodes showed a 128-fold 
increase of IFN-γ mRNA A switch from the Th2 t o a T h l profile m the lymph nodes compared 
w i t h the peripheral blood occurred in the IL-12-treated patients 
The objective of this paper was to unravel the cascade of effects of IL-12 on the cells of the 
immune system m the primary tumor and the locoregional lymph nodes We report on the 
histologic and immunohistochemical f indings in the primary tumor and lymph nodes of the 
IL-12-treated patients compared w i t h control patients 
P A T I E N T S A N D M E T H O D S 
P A T I E N T S E L E C T I O N 
All patients had histologic proof of HNSCC, w i t h the primary tumor in the oral cavity or 
oropharynx, staged as T1-4, N0-2, Mo, for which surgical resection including a supra-omohyoid 
or radical neck lymph node dissection was planned Patients were previously untreated, 1 e , they 
did not have prior surgery, radiotherapy, or any systemic therapy The tumor, w i t h a diameter not 
exceeding 5 cm, had to be accessible for local injection Further el igibi l i ty criteria included age 
between 18 and 75 years, WHO performance score 0-2, life expectancy >3 months, adequate renal 
funct ion (serum creatinine < 1 5 times normal), adequate hepatic funct ion (serum bil irubin < 1 5 
times normal, ALT and AST < 2 times normal), normal serum calcium ( < 1 1 mg/dl), serum 
hemoglobin > 9 g/dl , granulocytes > 1 5 0 0 / p i and platelets >100,000/μΙ Systemic corticosteroids 
were not allowed Patients w i t h major concurrent disease were excluded, as were patients known 
t o be positive for HIV or hepatitis Β surface antigen 
To allow comparison of the histologic and immunohistochemical parameters of the 10 rhlL-12-
treated HNSCC patients, we collected also primary tumor resection material and lymph nodes 
from 20 control patients, these patients were eligible for the study, but preferred not to receive 
the rhlL-12 injections 
The local regulatory committee approved the study All patients gave w r i t t e n informed consent 
S T U D Y D E S I G N A N D T R E A T M E N T S C H E D U L E 
In this single-center, open-label, nonrandomized, phase I I study, rhlL-12 was supplied by Wyeth 
(Cambridge, MA, USA) and was administered at t w o dose levels of 100 ng/kg and 300 ng/kg, 
by single or multiple 1 t injections m the primary tumor only Five patients per dose level were 
planned Patients were treated once weekly m the normal w a i t i n g period before surgery, w i t h 
a min imum of t w o and a maximum of four doses Surgery was never postponed because of 
part icipation in this study The last planned injection was administered 24 hours before surgery 
This was based on the results of the prior phase l b study 2 4 , m which the most pronounced 
immunologic effects in peripheral blood were seen after 12 to 24 hours The f irst injection 
was given as inpatient treatment, others were on an outpat ient basis, w i t h an observation 
period of 1 hour after each injection The mean volume of the injected rhlL-12 was 0 51 ml 
(range 0 37-1 1 ml), related to the dose level and the weight of the patient 
Instead of five planned patients per dose level, six patients received 100 ng/kg and four patients 
300 ng/kg, because of toxic i ty Two patients at the 300 ng/kg level received only 1 in ject ion. 
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8 and 15 days before surgery, respectively. One patient received 300 ng/kg as first administration 
and 100 ng/kg as second administration26 Because no immunologic differences were seen 
between the 100 and 300 ng/kg dose level, we have not separated the 2 dose levels in this 
pathological study. 
HANDLING OF THE RESECTED MATERIAL AND TISSUE PREPARATION 
Immediately after resection of the primary tumor and the lymph nodes, the material was put 
on ice. The lymph node specimen was cut out freshly by the pathologist (PdW).The neck was 
divided into 6 lymph node regions (l-Vl), from which all lymph nodes were collected Dependent 
on the size of the lymph node, part of the lymph node was directly snap frozen. If the primary 
tumor was sufficiently large, a sample was taken for direct snap freezing. Thereafter the primary 
tumor was fixated m 4% (v/v) phosphate buffered formalin and cut out on the following day, 
or after decalcification. The lymph nodes were fixated in unifix, dehydrated and embedded m 
paraffin Tissue sections of 4 pm were cut, mounted onto glass slides pretreated with 2% 
3-aminopropyltriethoxysilane (Sigma), and dried overnight. Serial sections were stained 
with haematoxylm and eosin (H&E) or processed for immunohistochemistry. 
SCORING OF H&E SECTIONS AND CATEGORIES 
Routinely H&E-stamed histopathological sections were used to determine the differentiation 
(WHO and Broders), growth pattern and inflammatory reaction of the primary tumor. 
Routinely H8iE-stained histopathological sections of the lymph nodes were scored as follows. 
(1) primary follicles (PF) and (11) secondary follicles (SF) 0 no follicles, 1· very few follicles, 
2. few follicles, 3: many follicles, 4: filled with follicles, ( in) paracortical hyperplasia: 0: absent, 
1: small area, 2 large areas, (iv) sinus histiocytosis. 0. absent, 1 very small and few areas, 
2 small and multiple areas, 3 "bands" that occupy less than 40% of the lymph node, 
4: "bands" that occupy 40% or more of the lymph node. 
IMMUNOHISTOCHEMICAL STAINING 
All primary tumors were immunohistochemically stained with the antibodies listed below. One lymph 
node was stained from every IL-12-treated patient and from 10 control patients. The 10 control 
patients were selected based on patient and tumor characteristics and were comparable with the 
10 IL-12-treated patients The lymph nodes of both groups were selected based on histologic 
features and size. The average size, number of primary and secondary follicles, and degree of para-
cortical hyperplasia and smushistiocytosis were identical m H&E-stamed specimens and immuno-
histochemical-stamed specimens m each group. All chosen lymph nodes were without metastasis. 
Tissue sections were incubated by the following primary antibodies anti-CD3 (Clone SP7, 1:100, 
Lab Vision-Neomarkers, Immunologic, Duiven, the Netherlands), anti-CD4 (Clone 1F6, 1.80, 
Lab Vision-Neomarkers, Immunologic, Duiven, the Netherlands), anti-CD8 (Clone C8/144B, 1 80, 
Dakocytomation, Heverlee, Belgium), anti-CD20 (Clone L26, 1:500, Dakocytomation, Heverlee, 
Belgium), anti-CD21 (Clone 1F8, 1.200, Dakocytomation, Heverlee, Belgium), anti-CD56 (Clone 
123C3, 1.10, Monosan/Sanbio, Uden, the Netherlands), anti-CD57 (Clone NCi, 1:5, Immunotech/ 
Coulter, Mijdrecht, the Netherlands), anti-CD68 (Clone Kpi, 1:2000, Dakocytomation, Heverlee, 
Belgium), anti-CD79a (Clone JCB117, 1:500, Dakocytomation, Heverlee, Belgium), BerMacDRC 
(Clone BerMac, 1.20, Dakocytomation, Heverlee, Belgium), DC-SICN/anti-CD209 (20 pg/ml, 
AZN-D1)", DC-LAMP/ anti-CD208 (Clone 104 C4, 1:10, Immunotech/Coulter, Mijdrecht, the 
Netherlands), Langerm/anti-CD207 (Clone DCCM4, 1·40, Immunotech, Marseille, France), 
anti-CDllc (Clone SHCL-3, 1:5, BD Pharmmgen, San Diego, California, US), ICAM-2/anti-CD102 
(CBR-IC2/2)2e, Neutrophil elastase (1 100, Dakocytomation, Heverlee, Belgium), AA-1 (Clone AA1, 
1 400, Dakocytomation, Heverlee, Belgium), EC-2 (1:20, Monosan/Sanbio, Uden, the 
Netherlands), and MIB (Clone Mib-1, 1:200, Dakocytomation, Heverlee, Belgium) 
1 0 5 
In brief, sections were deparaffinized in xylene and rehydrated. Endogenous peroxidase 
was blocked with 0.3% hydrogen peroxide in methanol for 20 minutes. Antigen retrieval was 
performed using 0.1 M citrate buffer pH6.0 (anti-CD3, anti-CD8, anti-CD20, anti-CD56, anti-
CD57, anti-CD79a, anti-CD207, and MIB), microwave cooking in 0.1 M EDTA pH /8.0 (anti-CD4, 
anti-CD209, anti-CDllc, and anti-CD102), and fresh pronase 0.1%/PBS (anti-CD21, BerMacDRC, 
anti-CD208, neutrophil elastase, AA-1, and EC-2), respectively. Subsequently, sections were 
preincubated with 1% bovine serum albumin. After overnight incubation with the primary 
antibody, the secondary biotin-conjugated antibody and a tertiary complex of streptavidin-
avidin-biotin conjugated to 3-amino-9-ethyl-carbazole were applied. Finally, the sections were 
counterstained with Mayer's haematoxylin. Incubation with phosphate-buffered saline instead 
of the primary antibody served as a negative control. 
SEMIQUANTITATIVE SCORING OF IMMUNOHISTOCHEMICAL STAINING OF THE PRIMARY TUMORS 
The scoring of the markers was performed within the tumor (intratumoral infiltrating cells, 
present in the stroma of the tumor), as well as separately along the invasive border of the tumor 
in the surrounding tissue (peritumoral infiltrating cells). If equal expression was observed both 
intratumorally and peritumorally, or if cryosections were scored, only "overall" was scored. After 
analysis of the distribution of the numbers of positive cells the infiltrate was scored 
semiquantitatively, using 3 to 5 categories: none/ few, moderate, many/ extensive. 
QUANTITATIVE ANALYSIS OF IMMUNOHISTOCHEMICAL STAINING OF THE LYMPH NODES 
Quantification of the immunohistochemical staining product was performed in stored images 
of completely scanned tissue sections. Images were acquired with an AxioCam MRc (Carl Zeiss, 
Germany) connected to an AxioPlan 2 Imaging microscope (Carl Zeiss, Germany). The microscope 
was equipped with a computer-controlled scanning stage (8 specimen stage, Marzhauser GmbH, 
Wetzlar, Germany, controlled by a Ludi MAC5000 controller, Ludi Electronic Products Ltd., 
Hawthorne, NY). Images were acquired using a lOx objective (Plan Apochromat, NA=0.32; 
specimen level pixel size 1.06 χ 1.06 pm2). Images were corrected for unequal illumination using 
a stored shading reference image. Each microscopic field was individually autofocused before 
acquisition. All image acquisition and processing was performed using custom written macros 
in KS400 image analysis software (version 1, Carl Zeiss, Germany). 
For each specimen the region of interest was interactively defined using a live image display. 
Images of consecutive individual microscopic fields were acquired and stitched together into large 
24-bit RGB TIFF images. Automatic detection of the region occupied by tissue was performed in 
each stored composite image, based on automatic detection of the background peak in the 
histogram of the red camera channel. In a few cases with artefacts in the background, the 
automatically detected threshold was not adequate and therefore was interactively determined. 
Also, in a number of cases parts of the background were interactively labelled to be excluded from 
analysis, to remove small artefacts that were incorrectly thresholded as tissue. 
To recognize positively stained regions, the ratio between the red and green pixel intensity was 
thresholded. The fast red staining product absorbs light in the green part of the spectrum while 
mostly transmitting red light. All other components present in the specimens either absorb red 
light or transmit approximately equal amounts of light in the red and green parts of the 
spectrum. Therefore, the ratio between the red and green pixel intensity is maximum for the red 
dye, with low values for all other tissue components. For each specimen, the threshold was 
interactively set. Finally, the area of the tissue and the area occupied by positive immunostaining 
were calculated. The system is calibrated so that all parameters are expressed in pm.The 
automated procedure was used to quantify tissue sections with mAb anti-CD3, anti-CD4, anti-
CD20, anti-CD79a, anti-CD68, anti-DC-SIGN, anti-CDllc, and anti-ICAM-2. For those cases the 
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threshold for recognition of positive staining was manually set by t w o independent observers 
individually (CvH/JvdL), to study the observer reproducibi l i ty For the other markers, the positive 
area was not considered appropriate scoring In these cases, the number of positive cells was 
counted interactively using the ks400 image analysis system described above Positive cells were 
manually marked on the image screen by mouse clicks The computer administered the number of 
positive cells Also, the area of the region of interest of the lymph node was determined by 
interactive drawing on the computer screen 
S O R T I N G O F L Y M P H N O D E S U S P E N S I O N S 
Lymph node suspensions were obtained as described previously 2 6 and stored m liquid nitrogen 
unt i l further analysis Separate populations of CD4-, CDS-, and CD56-positve cells were obtained 
via fluorescence-activated f low cytometry To this extend, lymph node suspensions were thawed 
and washed w i t h Dulbecco's modif ied Eagle's Medium containing 10% foetal calf serum and 
phosphate buffered saline (PBS) containing 0 5% (w/v) bovine serum albumine (BSA), 
respectively Suspensions were divided m t w o portions and either incubated w i t h fluoresceme-iso-
thio-cyanate (FITC)-conjugated anti-CD4 (clone 13B8 2, Immunotech, Marseille, France) and 
phycoerythrm (PE)-conjugated anti-CD8-FITC (clone B9 11 Immunotech, Marseille, France) and 
anti-CD56-PE (clone NCAM16 2BD, Biosciences, San Jose, California, USA) for 10 minutes at 
room temperature After incubation, cells were washed w i t h PBS/0 5% BSA and sorted on a 
Epics Ultra HyperSorter f lowcytometer (Beekman Coulter, Miami, USA) Cells (3 000-100 000) 
were captured in cold PBS/0 5% BSA After sort ing, cells were pelleted (300C, 5 minutes, 4°C) 
and stored at -80oC unt i l further analysis 
A N A L Y S I S O F IFN-γ E X P R E S S I O N 
RNA from the sorted cell populations was isolated using the RNeasy Kit (QIACEN Sciences, 
Maryland, USA) according to manufacturer's instructions and residual DNA was digested After 
digest ion, RNA cleanup was performed using the RNeasy kit according to the manufacturer's 
instructions RNA isolated from 3000 cells was reversed transcribed w i t h SuperScript π 
(Invitrogen) according to the manufacturer's instructions in a tota l volume of 20 μΙ PCR was 
performed on 1 μΙ cDNA w i t h ThermoPerfect (Integro) according t o standard procedures using a 
primer pair for IFN-γ (5'TCACCACACCCAAAACA and 5'CTCTTCCACTCTCAAACACC, 1,25 mM MgCI2, 
Tm 60oC) or for the low copy peptidylpropyl isomerase, a housekeeping gene product (PPIA, 
S'ACCTCCCAAACACACCACAA and 5'CTCTTCCCACTCCACATCAA, 2 5 mM MgCI2, Tm 630C) that 
served as control for equal input 
S T A T I S T I C S 
The clmicopathologic characteristics of the IL-12-treated and control patients were analyzed by 
the use of a contingency table, statistical significance was evaluated using the Fisher exact test 
Nonparametric tests according to the Mann-Whitney U test and Wilcoxon signed-rank test were 
performed t o compare t w o independent and t w o dependent samples, respectively Differences in 
proportions were evaluated by means of the chi-square test or Fisher exact test For correlation 
analysis between variables, Spearman's correlation coefficient was calculated For all tests, p<0 05 
was considered t o be statistically signif icant All statistical analysis was performed w i t h t w o -
tailed tests using SPSS 11 ο for Windows 
R E S U L T S 
P A T I E N T C H A R A C T E R I S T I C S A N D H I S T O L O G I C FEATURES OF T H E P R I M A R Y T U M O R S 
Ten patients, four men and six women, w i t h a median age of 55 years (range, 46-69) were 
enrolled in the study (table 1) The median WHO performance score was 1 (range, 0-1) Tumor 
sites were the oral cavity (n=8) and oropharynx (n=2) The Τ and Ν tumor stages are summarized 
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cable ι Patient characteristics: no significant differences between the IL-12-treated and control patients were noted. 
IL-12-treated (n=10) control (n=20) 
Sex Male 4 16 
Female 6 4 
Age Median 55.4 57.8 
Range 46.1-69.1 36.7-69.2 
WHO performance 1 (0-1) 1 (0-1) 
Primary tumor site 
Oral cavity 8 14 
Oropharynx 2 6 
Tumor stage 
Tl 3 3 
T2 5 10 
T3 1 6 
T4 1 1 
Lymph node stage 
NO 4 6 
Nl 3 5 
N2a 1 2 
N2b 2 7 
Surgery of the neck 
RND 7 14 
SOHD 3 6 
Abbreviations: RND= radical neck lymph node dissection; SOHD= supra-omohyoid lymph node dissection 
in table i . Radical modified neck dissections and supraomohyoidal neck dissections were 
performed in eight and t w o patients, respectively. The characteristics of the IL-12-treated patients 
were comparable w i t h the 20 control patients (table i ) . 
In one IL-12-treated patient, the primary tumor could not be examined because no tumor 
was present in the resected area. The biopsy taken t o prove the diagnosis showed squamous cell 
carcinoma; most likely, this was an excision biopsy. The lymph nodes of this patient were scored. 
No obvious differences were seen in the di f ferent iat ion and g r o w t h pattern of the primary 
tumors, or inf i l t rat ion of cells of the immune system in the primary tumors of the IL-12-
treated (n=9) versus the control patients (n=20) detected on H&.E-stained tissue sections 
(table 2). 
I M M U N O H I S T O C H E M I C A L D I F F E R E N C E S I N T H E T U M O R - I N F I L T R A T I N G I M M U N E CELLS 
An increase in the CD56+ NK cells was seen in the tumor in the IL-12-treated patients ( p < 0 . 0 l ) 
(table 3 and figure i ) . However, no difference was seen in the CD57+ (NK and subset of Τ cells) 
cells. Peritumoral CD20+ Β cell in f i l t rat ion was very extensive in some IL-12-treated patients. 
However, the increase in peritumoral Β cells was not signif icantly different between the IL-12-
treated and control patients (p=0.06) (table 3 and figure 1). The same trend was seen for the 
peritumoral CD79a+ cells (B cells and plasma cells). Intratumorally no differences were seen in 
CD20+ and CD79a+ cells. The inf i l t rat ion of CD3+ (T cells), CD4+ (T helper cells) and CD8+ 
(T cytotoxic cells) was similar in both groups. 
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table 2 Characteristics of the primary tumor on haematoxylin and eosin sections. The grade of differentiation, growth pattern 
and the inflammatory reaction was not different between the IL-12-treated and control patients. 
Histologic feature IL-12-treated (n=9) Control (n=20) 
Differentiation (WHO) 
Poor 6 11 
Moderately 2 7 
Well 1 2 
Broders grade 
Poor 5 8 
Moderately 2 8 
Well 2 4 
Growth pattern 
Invasive 5 13 
Mixed 1 5 
Pushing 3 2 
Inflammatory reaction 
Low 2 3 
Intermediate 4 8 
High 3 9 
A remarkable f ind ing was the altered distr ibut ion of the CD68+ (macrophages) cells in IL-12-
treated patients. In all IL-12-treated patients the majori ty of the CD68+ cells were located 
peritumorally (p<0.05) (table 3), whereas in controls the CD68+ cells were more equally spread. 
No differences between the total numbers of intra- and peritumoral CD68+ cells were seen. 
Next we analysed the presence of in f i l t ra t ing dendrit ic cells (DCs), using novel DC markers. In 
both groups the DC-SICN+ cells were located in the stroma very near to the tumor nests, and the 
DC-LAMP+ cells were located deeper in the stroma, w i th more distance to the tumor cell nests 
(data not shown). No differences were detected in the numbers of DRC+ (follicular dendrit ic 
cells), DC-SICN+, DC-LAMP+, Langerin+, and C D l l c + cells. Also ICAM-2, one of the ligands of 
DC-SIGN, was not di f ferent between the groups. 
A somewhat lower number of eosinophils was observed in the IL-12-treated patients, but this 
difference was not statistically signif icant in the entire group of patients (p=0.06) (table 3). 
No differences were detected in the number of mast cells. Whereas most intratumoral immune 
cells were located in the stroma between the tumor nests, neutrophils were located in the 
stroma, and also w i t h i n the tumor cell nests. Although the numbers of peritumoral and 
intratumoral (in the stroma) neutrophils were not dif ferent between the two groups, a 
trend to a lower number of neutrophils in the tumor nests was observed in the IL-12-treated 
group (figure 1). 
H I S T O L O G I C C H A N C E S I N T H E L Y M P H N O D E S 
In the lymph node dissection specimen, the mean diameters of the resected lymph nodes were 
7.9 mm (range 7 to 8.7 mm) in the IL-12-treated group and 6.1 mm (range 4.6 to 8.5 mm) in the 
control group (p<0.001). In patients who underwent a radical lymph node neck dissection, the 
mean number of the lymph nodes was 42 (range 31-50) in the IL-12 group (n=7) versus 28 
(range 15-42) in the control group (n=14) (p<0.005) (figure 2). 
In to ta l , 336 lymph nodes in 10 IL-12-treated and 469 lymph nodes in 20 control patients were 
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table 3 Immunohistochemical scoring (mean) of the primary tumor in IL-12-treated (n=9) and control patients (n=20). Some 
markers were scored intratumorally and peritumorally, others only overall. More CD56+ NK cells were seen in the primary 
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collected and scored per patient for the presence of primary and secondary follicles, paracortical 
hyperplasia, and sinus histiocytosis. The number of secondary follicles, primary follicles, and the 
presence of paracortical hyperplasia was strongly decreased in the IL-12-treated patients compared 
w i t h the control patients (p<0.005, p<0.005, and p<0.05, respectively) (figure 3). As a 
consequence, the lymph nodes had a much more monotonous appearance in IL-12-treated 
patients (figure 4 ) . In the IL-12-treated patients, the secondary follicles contained smaller 
germinal centers. Furthermore, the outl ine of the primary and secondary follicles w i t h i n the 
lymph node was less sharp, and appeared less separated from the paracortex. The degree of 
sinus histiocytosis was similar in both groups. 
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figure 1 Immunohistochemical staining of the primary tumors with CD56, CD20, and neutrophil elastase of IL-12-treated 
(left panel) and control (right panel) patients. IL-12 induced an increase of CD56+ cells. In some IL-12-treated 
patients impressive peritumoral CD20+ infiltration was seen. Fewer neutrophils (not significant) in the tumor 
nests were detected in IL-12-treated patients compared with control patients. 
IL-12-treated Control 
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figur. The mean maximal diameter (mm) of lymph nodes is larger and the mean number of lymph nodes is higher in 
rhlL-12-treated (n=10) patients compared with control (n=20) patients (p<0.001 and p<0.005, respectively). 
The error bars indicate the standard error of the mean (SEM). 
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I M M U N O H I S T O C H E M I C A L D I F F E R E N C E S A N D M R N A IFN-γ E X P R E S S I O N I N T H E L Y M P H N O D E S 
To investigate the presence and distr ibut ion of leucocytes w i t h i n the lymph nodes quantitat ive 
analysis after their immunohistochemical detection was performed. 
The CD20+ Β cells showed a different distr ibut ion in IL-12-treated patients. The Β cells were not 
only located in the follicles, but were also situated outside the follicles (figure 5). However, the 
percentage area of CD20+ cells was not different between the lymph nodes of the IL-12-treated 
and control patients. The immunohistochemical analysis did not reveal a major difference in the 
number of CD56+ NK cells ( 1 0 6 / m m 2 versus 7 8 / m m 2 ) . The number and distr ibut ion of CD3+, 
CD4+, CD8+, and CD57+ (outside the germinal centers) cells were not different between the 
IL-12-treated and control patients. RT-PCR of isolated cell suspensions of the lymph nodes 
showed that the CD56+ cells were the key IFN-γ producing cells in the IL-12-treated patients. 
Also, the IFN-γ mRNA expression in CD8+ and CD4+ cells increased compared w i t h control 
patients (figure 6). Thus, although the number of CD56+, CD8+ and CD4+ cells did not increase, 
IL-12 treatment resulted in their act ivat ion. 
Because dendrit ic cells and macrophages are the mam producers of IL-12, we also investigated the 
effects of the administered IL-12 on these cell populations. IL-12 induced an impressive decrease 
in the number of DC-LAMP+ cells (mature DCs) in the paracortex (p<0.005) (table 4 and figure 5). 
The localisation of DC-LAMP+ cells corresponded w i t h the paracortical hyperplasia seen w i t h H&E 
staining. Thus, the decrease of DC-LAMP+ cells correlated w i t h the reduction of paracortical 
hyperplasia in IL-12-treated patients. Although the number of DC-LAMP+ cells was diminished, 
no differences were seen in the other DC or macrophage markers (DC-SICN (immature DCs), 
C D l l c (DCs), Langerm (Langerhans'cells), CD21 (follicular DCs), and CD68 (macrophages)). In 
both IL-12-treated and control patients, DC-SICN was expressed mainly in sinus histiocytosis 
and to a lesser degree in the paracortex. The stromal expression of ICAM-2, especially in sinus 
histiocytosis, was lower in the IL-12-treated patients (p<0.001) (table 4 and figure 5), but the 
expression on the endothelium l ining the vessel walls was similar. 
More neutrophils, especially around regions of sinus histiocytosis, and fewer mast cells were 
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Figure 3 The mean scoring of lymph nodes w i t h pr imary fol l icles, secondary fol l icles, paracortical hyperplasia and sinus 
hist iocytosis of 10 IL-12-treated ( • ; w i t h 336 lymph nodes) and 20 control ( D ; w i t h 469 lymph nodes) pat ients 
In IL-12-treated pat ients, the lymph nodes showed fewer secondary follicles (p<0 005), fewer pr imary foll icles ( p < 0 . 0 0 5 ) , 
and less paracortical hyperplasia (p<0 05) than in contro l pat ients. No s igni f icant differences were detected in the 
a m o u n t of sinus h ist iocytosis. The error bars indicate the SEM 
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present in the IL-12-treated pat ients ( p < 0 . 0 1 and < 0 . 0 0 5 , respectively) ( table 4 and f igure 5 ) . 
The number of eosinophils was not d i f fe rent be tween the groups. However, in the IL-12- t reated 
pat ients a negat ive correlat ion be tween the number of neutrophi ls and eosinophils was not iced 
( r = - . 8 2 , p < 0 . 0 0 5 ) . 
D I S C U S S I O N 
The main purpose of this histopathological and immunohisto logic study was to evaluate the 
effects of IL-12 t r e a t m e n t on the i m m u n e cells in the pr imary t u m o r and lymph nodes in pat ients 
w i t h HNSCC. In th e pr imary tumor , the number of CD56+ NK cells was increased in IL-12- t reated 
" 3 
figure 4 Haematoxylin & eosin-stained lymph nodes showing secondary follicles ( " ^ 1 and paracortical hyperplasia ( , = ! > ) . 
The lymph nodes of the IL-12-treated patients (left panel) contain fewer and smaller secondary follicles and less presence 
of paracortical hyperplasia. This lymph node of the IL-12-treated patient shows no paracortical hyperplasia. 
IL-12-treated Control 
cytometry data 2 6 , which showed a signif icant increase of CD3-CD16+CD56+ NK cells (1.6% versus 
0.7%; p<0.001) after IL-12 treatment, w i t h immunohistochemical analysis we did detect the 
same trend in the increased number of CD56+ NK cells, but i t was not significantly different. 
This discrepancy could possibly be explained by the use of mult iple markers to identify the NK 
cell by f low cytometry, and the very low number of NK cells in a lymph node. The CD56+ NK cells 
in the IL-12-treated lymph nodes produced considerable amounts of IFN-γ. The higher number of 
intratumoral NK cells and the high IFN-γ production by NK cells in the lymph nodes, implies a 
prominent role of the NK cell in ant i tumor immuni ty after i.t. IL-12 treatment in HNSCC 
patients. The number of peritumoral CD20+ Β cells was extremely high in some patients, but the 
difference between the groups was not signif icant. Remarkably, no differences were seen in CD8+ 
or CD4+ Τ cells. This is in contrast w i t h other studies of rhlL-12 treatment in humans, in which 
histopathological examination was performed. In melanoma and cutaneous T-cell lymphoma 
patients, an increase in CD8+ cells was detected in the neoplastic lesions after s.c. IL-12 
treatment; however, no B-cell markers were used in either s tudy 2 9 · 3 0 . In a Phase I study w i t h s.c. 
IL-12 and rituximab in B-cell non-Hodgkin lymphoma, T-cell and B-cell markers were studied in 
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table 4 Immunohistochemical scoring (mean) of lymph nodes in IL-12 treated (n=10) and control patients (n=10). 
Part of the markers are scored by semiautomatic counting (number/mm2); others by automatic recognition of the 
positive stained area (percentage of positive area/total square of the lymph node). The number of DC-LAMP+ cells and 
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sections of biopsies and a sl ight increase in T-cell (and not B-cell) inf i l t rat ion was not iced 3 1 . 
Unfortunately, these biopsies did not allow proper examination of the localization of the Β cells 
intratumorally or peritumorally. Our results in part agree w i t h mice studies in which effector cells 
required for IL-12 induced ant i tumor effect include NK, NKT, CD8+, and/or CD4+ cells. In these 
mouse models, however, the contr ibut ion of the different effector cells to the ant i tumor effects 
are mouse model and IL-12 treatment schedule dependent" . The role of the Β cell in the 
ant i tumor effect of IL-12 has not yet been described. A l imited number of studies report on the 
role of the Β cell in immunosurveillance of cancer. Both in mice and in human breast cancer there 
are indications of involvement of B-cell responses against tumors 3 3 · 3 4 . 
The increased size of lymph nodes resulted in a higher number of lymph nodes found in the neck 
dissection specimens in the IL-12-treated patients. This agrees w i t h studies in mice 3 5 - 3 6 . The 
change in architecture of the lymph nodes after IL-12 treatment was remarkable. Fewer secondary 
and primary follicles were seen, although the lymph nodes were larger and the number of CD20+ 
cells was certainly not decreased. The germinal centers in the secondary follicles were smaller and 
CD20+ cells had a di f ferent d is t r ibut ion. To our knowledge, this is the f irst report describing a 
change in the architecture of the lymph nodes after IL-12 treatment. The organisation of the 
lymph node and the germinal center formation is a complex process, that includes B-cell 
proliferation and d i f ferent ia t ion, a follicular dendrit ic cell (FDC) network, antigen-specific 
Τ helper cells, and t ingible body macrophages. A wide variety of cytokines and chemokines 
influence the germinal center cell v iabi l i ty, prol i ferat ion, and d i f ferent iat ion, including 
immunoglobulin class switching and terminal d i f f e r e n t i a t i o n 3 7 . Notably, IL-12 i.t. in patients 
" 5 
figure 5 Immunohistochemical staining of the lymph nodes with CD20, DC-LAMP, ICAM-2, neutrophil elastase, and mast cell 
tryptase of IL-12-treated (left panel) and control (right panel) patients. In the IL-12-treated patients, a different 
distribution of CD20+ cells, fewer DC-LAMP+ cells, less expression of stromal ICAM-2+ cells, more neutrophils around 
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figure 6 IFN-γ mRNA expression in mononuclear cells in lymph nodes of IL-12-treated and control patients. (A) IFN-γ and PPIA 
expression analysis via RT-PCR of CD4+, CD8+, and CD56+ cells from a control (c) and an IL-12-treated (t) patient. (B) 
Semi-quantitative analysis of IFN-γ mRNA expression by mononuclear cells in a lymph node region. After IL-12 treatment 
higher IFN-γ expression was found in CD56+ cells in all patients, and also in CD8+ and CD4+ cells in most patients. The 























Abbreviations: n.a. -not available 
w i t h HNSCC has effects on the Β cell, both in the lymph nodes and peritumorally. The cause of 
the change in the architecture in the lymph nodes is currently unknown. Further studies are 
required t o determine the causes of the change in architecture. 
The change in lymph node architecture in the IL-12-treated patients is partly caused by less 
paracortical hyperplasia and correlates w i t h lower numbers of DC-LAMP+ cells in the paracortex 
compared w i t h the control patients. DC-LAMP (DC lysosyme-associated membrane glycoprotein) 
is a lysosomal glycoprotein protein expressed by interdig i tat ing DCs in human 3 8 . DC-LAMP is 
localized in the MHC class I I molecules-containing compartments and has been reported to be 
predominantly expressed by mature DCs. The f inding that large amounts of DC-LAMP+ cells are 
present in the control patients and decreases in IL-12-treated patients is counter intu i t ive as one 
would rather expect enhanced DC maturation upon immune act ivat ion. However, recently i t was 
" 7 
shown that semi-mature DCs can induce tolerance 3 9 · 4 0 . The phenotypic characterization of these 
toleriz ing DCs is not yet fully known. Therefore, it is t e m p t i n g to speculate that the high number 
of DC-LAMP+ cells in the immunosuppressed control HNSCC patients is a manifestation of 
tolerance rather than immunity, which is reversed upon IL-12 treatment. 
The number of neutrophils in the lymph nodes increased after IL-12 treatment. In the primary 
tumor, however, the neutrophils are slightly diminished by number in the tumor nests and 
remained the same peritumorally and intrastromally. There are conf l ict ing data in animal and 
human studies about the role of neutrophils in cancer4 1. Their presence may be detrimental by 
favouring malignant g r o w t h and progression. Nevertheless, recent studies have suggested that 
they are active in immunosurveillance against several tumors 4 1 . 
The number of mast cells in the lymph nodes of IL-12-treated patients decreased, but no 
differences were detected in the primary tumor. In oral squamous cell carcinoma, the number of 
mast cells is correlated w i t h the number of microvessels and w i t h a bad prognosis4 2. The number 
of eosinophils was slightly lower in the primary tumor of the IL-12-treated patients. This agrees 
w i t h studies in mice treated w i t h IL-124 3. Because both mast cells and eosinophils are seen 
as cells involved in the Τ helper 2 pathway, these findings were as expected considering the 
Τ helper 1 act iv i ty of IL-1244. 
Altogether, in the histopathological and immunohistologic analysis of the primary tumors and 
lymph nodes of i.t. administered rhlL-12 in patients w i t h HNSCC, the most striking effect was 
seen on the number and IFN-γ production by NK cells, in the primary tumor and the lymph 
nodes, respectively. In addit ion a change in the architecture of the lymph nodes was detected 
because of a dist inct d istr ibut ion of the Β cells, the smaller germinal centers, and the smaller 
number of DC-LAMP+ cells. The peritumoral B-cell inf i l t rat ion was very high in some IL-12-treated 
patients. Further investigations are required to examine the events that occur in the lymph nodes 
after IL-12 treatment, in particular the effects on the Β cell. 
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The objectives of this study were to investigate the effects of mtratumorally (ι t ) administered 
recombinant human interleukin-12 (rhlL-12) on the distribution and function of Β cells in the 
primary tumors, lymph nodes and peripheral blood of HNSCC patients The initial characterization 
of the patients participating in this phase lb and phase I I study have been previously reported 
After IL-12 treatment less secondary follicles with a broader outer region of the mantle zones 
were seen m the enlarged lymph nodes compared with control HNSCC patients The size of the 
germinal center (CC) was diminished, partly due to a decrease in the number of CD57+ CC cells 
These changes did not correlate with signs of apoptosis or CXCR5 expression by Β cells In three 
of four IL-12 treated patients IFN-γ production by Β cells was detected, which was not found m 
4 control patients Eight weeks after treatment an IgC subclass switch was seen in the plasma 
with more IgCl, less lgC2 and more lgC4, indicating a switch to Τ helper 1 phenotype 
Pentumoral Β cell infiltration was a positive prognostic sign for overall survival in the 29 
investigated HNSCC patients, irrespectively of IL-12 treatment However, after IL 12 treatment 
a high number of pentumoral Β cells was detected in most patients, but this was not significant 
different m comparison to control patients 
In conclusion, after ι t IL-12 treatment in HNSCC significant effects on the Β cell and the Β cell 
compartment were seen Β cell activation existed of an IgC subclass switch to a Thl profile m the 
peripheral blood, and IFN-γ mRNA expression, a broader outer region of the mantle zones and an 
increase of mterfollicular B-blasts in the lymph nodes Pentumoral Β cell infiltration correlated 
with a better overall survival We will discuss the observed changes m the Β cell and the germinal 
center 
INTRODUCTION 
lnterleukin-12 (IL-12) is a heterodimenc cytokine that consists of two disulfide-lmked subumts, 
ι e , IL-12p40 and IL-12P351 IL-12 has a wide range of biological activities12, and has effects on 
both the innate and adaptive immune system It stimulates the proliferation and activation of 
cytotoxic Τ lymphocytes (Tc) and natural killer (NK) cells and induces the production of 
cytokines, especially IFN-y3S IL-12 is the key cytokine in the induction of Τ helper 1 (Thl) 
responses and thereby of cellular immunity Furthermore, it inhibits angiogenesis' Because of 
these abilities, IL-12 was used m pre-clmical models of anti-tumor immunotherapy IL-12 induced 
regression of established primary tumors, inhibited the formation of tumor metastases, and 
prolonged the survival of tumor-bearing mice7 1 0 Several phase I 1 1 1 6 and phase I I studies m 
various cancer types17 2 0 have been performed, but only a limited number of clinical responses 
were observed In most clinical studies the immunological effects of IL-12 were studied in 
peripheral blood However, after IL-12 administration a transient lymphopenia with a 
redistribution of activated immune cells from the peripheral blood to the lymph nodes (and 
primary tumor) occurred21 Thus, monitoring of the immune effects of IL-12 therapy solely m 
the peripheral blood can be misleading 
In the recent past we have performed two clinical studies in which we administered rhlL-12 
mtratumorally (ι t ) in head and neck squamous cell carcinoma (HNSCC) patients HNSCC is 
an immunogenic tumor and provides an excellent model to study the effects of locoregional 
immunotherapy RhlL-12 was administered ι t rather than systemically because of the expected 
higher locoregional concentration m the primary tumor and the draining lymph nodes, which 
may enhance efficacy with less systemic toxicity First, we performed a phase lb study in 
pre-treated HNSCC patients with the objective to determine toxicity and to investigate the 
pharmacokinetic and pharmacodynamic effects m peripheral blood after IL-12 administration16 
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Thereafter, we performed a phase I I study in non-pre-treated HNSCC patients, in which IL-12 was 
administered before surgery to evaluate the immunological effects in locoregional lymph nodes, 
primary tumor and peripheral blood2 0 2 1 The largest effect was seen on NK cells, with a higher 
number in the primary tumor and a high IFN-γ mRNA expression in the lymph nodes An excessive 
pentumoral CD20+ Β cell infiltration in some patients was observed No differences between 
IL-12-treated and control patients were seen in the numbers or distribution of CD8+ or CD4+ 
Τ lymphocytes, but induction of IFN-γ mRNA expression was seen m these Τ cells Interestingly, 
major differences were apparent m the architecture of the enlarged lymph nodes of IL-12 treated 
patients Besides fewer primary and secondary follicles with smaller germinal centers (CCs), also 
a redistribution of Β cells was observed m lymph nodes of IL-12-treated patients In addition, a 
decrease of DC-LAMP+ cells (dendritic cells) in the paracortex was noticed resulting in a reduction 
of paracortical hyperplasia 
In lymph nodes primary follicles contain mostly mature, naive Β lymphocytes After antigenic 
stimulation germinal centers (CC) develop, these follicles are called secondary follicles In the 
CC Β cell proliferation, selection of Β cells producing high-affinity antibodies, and generation of 
memory Β cells occur Other cells in the CC are follicular dendritic cells (FDCs), CD57+ Th cells and 
CD68+ tmgible body macrophages The CCs are sites of tremendous apoptosis, because Β cells 
that do not express high affinity receptors for antigen will not survive The anatomic segregation 
of the Τ and Β cells in the lymph node is dependent on chemokmes and cytokines Naive Τ cells 
and dendritic cells (DCs) express a chemokme receptor CCR7 and are attracted to the Τ cell zones, 
where CCL19 and CCL21 are produced, which attract the CCR7+ cells Naive Β cells and CD57+ 
Th cells express another chemokme receptor, CXCR5, that recognizes CXCL13 produced only m 
the follicles22 CXCR4 is involved in the homing of antibody secreting cells23 
In pre-clmical models IL-12 is shown to have an effect on humoral immunity IL-12 stimulates 
Β cell growth by inducing IFN-γ production in Β cells in vitro24, causes Ig isotype selection25 and 
triggers a cascade of molecular events in human Β cells similar to Thl commitment26 The effects 
of IL-12 on Β cells m cancer patients have hardly been studied The objectives of this study were 
to study the effects of IL-12 on the presence and distribution of cells m the follicles, apoptosis, 
chemokme receptor expressions on Β and Τ cells, and Β cell functions in patients with HNSCC 
PATIENTS A N D M E T H O D S 
PATIENT SELECTION AND TREATMENT SCHEDULE PHASE I B AND PHASE I I STUDY 
In the phase Ib study all patients (n=6) had histological proof of recurrent HNSCC with either 
local recurrence or subcutaneous or lymph node metastases, not amenable for curative surgery 
or radiotherapy16 In the phase I I study all patients (n=10) had histological proof of HNSCC, with 
the primary tumor m the oral cavity or oropharynx, staged as T1-4, N0-2, Mo, for which surgical 
resection including a supra-omohyoid or radical neck lymph node dissection was planned Patients 
were previously untreated, 1 e , they did not have prior surgery, radiotherapy, or any systemic 
therapy20 In both studies the tumor, with a diameter not exceeding 5 cm, had to be accessible 
for local injection The other eligibility criteria have been described before1 6 2 0 
Both studies were single center, open-label, non-randomized studies RhlL-12 was supplied by 
Wyeth (Cambridge, MA, USA) and administered by 1 t injection RhlL-12 was weekly administered 
at two dose levels of 100 ng/kg and 300 ng/kg body weight, by single or multiple 1 t injections 
In the phase Ib study patients were treated for a period of minimal 8 and maximal 24 weeks In 
the phase I I study patients were treated in the normal waiting procedure prior to surgery and 
received 2 or 3 injections, of which the last was administered 24 hours before surgery 
To allow comparison of the immunological parameters of the rhlL-12-treated HNSCC patients m 
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the phase I I study, blood samples, lymph nodes, and primary tumor resection material from 20 
control patients were also collected; these patients were eligible for the study, but preferred not 
to receive the rhlL-12 injections. 
All patients have given wr i t ten informed consent The local regulatory committee approved the 
studies. 
H A N D L I N G OF T H E RESECTED M A T E R I A L A N D T I S S U E PREPARATION 
Material of the primary tumor and the lymph nodes of patients m the phase I I study was put on 
ice immediately after resection. The pathologist cut out the lymph node specimen freshly. The 
neck was divided into 6 lymph node regions (l-VI), from which all lymph nodes were collected 
Dependenmg on the size of the lymph node parts were taken for direct snap freezing or single-
cell suspension preparation, m order to perform f low cytometry or RT-PCR If the primary tumor 
was sufficiently large, samples were taken for f low cytometry and a sample was snap frozen. Then 
the primary tumor was fixated m 4% (v/v) phosphate buffered formalin and cut the day after, or 
after decalcif ication. The remaining part of the lymph nodes were fixated in unif ix, dehydrated 
and embedded m paraff in. Tissue sections of 4 pm were cut, mounted onto glass slides pre-
treated w i th 2% 3-aminopropyltriethoxysilane (Sigma) and dried overnight Serial sections were 
stained w i t h haematoxylin and eosm (H&.E) or processed for immunohistochemistry. 
I M M U N O H I S T O C H E M I C A L S T A I N I N G A N D S C O R I N G 
One lymph node of 10 IL-12-treated and 10 control patients was subjected to 
immunohistochemical analysis. Selection of the control patients was based on patient and tumor 
characteristics and was comparable w i th the 10 IL-12 treated patients. The lymph nodes of both 
groups were selected based on histological features and size The average size, number of primary 
and secondary follicles, the degree of paracortical hyperplasia and smushistiocytosis were 
identical m H&.E stained specimens and immunohistochemical stained specimens in each group 
All chosen lymph nodes were w i thou t metastases. 
Tissue sections were incubated w i t h the fol lowing primary antibodies anti-CD4 (Clone 1F6, 1.80, 
Lab Vision-Neomarkers, Immunologic, Duiven, the Netherlands), anti-CD20 (Clone L26, 1:500, 
Dakocytomation, Heverlee, Belgium), anti-CD21 (Clone 1F8, 1.200, Dakocytomation, Heverlee, 
Belgium), anti-CD57 (Clone NCI , 1:5, Immunotech/Coulter, Mijdrecht, the Netherlands), anti-CD68 
(Clone Kpi , 1 2000, Dakocytomation, Heverlee, Belgium), MIB (Clone M ib -1 , 1 200, Dakocyto-
mat ion, Heverlee, Belgium), and caspase-3 (Clone 19, BD Pharmmgen, Erembodegem, Belgium) 
In brief, sections were deparaffmized in xylene, and rehydrated Endogenous peroxidase was 
blocked w i th 0.3% hydrogen peroxide in methanol for 20 minutes Antigen retrieval was 
performed using 0.1 M citrate buffer pH 6.0 (anti-CD20, anti-CD57, and MIB), microwave cooking 
m 0.1 M EDTA pH 8.0 (anti-CD4), or fresh pronase 0.1%/PBS (anti-CD21, caspase-3), respectively 
Subsequently, sections were premcubated w i t h 1% bovine serum albumin in PBS After overnight 
incubation w i th the primary antibody, the secondary biotm-conjugated antibody and a tert iary 
complex of streptavidin-avidin-biotm conjugated to 3-amino-9-ethyl-carbazole were applied 
Finally, the sections were counterstamed w i t h Mayer's haematoxylin. Incubation w i th phosphate-
buffered saline instead of the primary antibody served as a negative control . 
The numbers of CD4+ CC cells and CD68+ CC cells were scored semi-quantitatively, using 3 to 
5 categories none/ few, moderate, many/ extensive. 
Q U A N T I T A T I V E A N A L Y S I S OF I M M U N O H I S T O C H E M I C A L S T A I N I N G OF T H E L Y M P H N O D E S 
To determine the number of CD57+ GC cells, CD21+ cells, MIB+ CC cells and to determine the 
size of the CCs a quant i tat ive analysis was performed All image acquisition and processing was 
performed using custom wr i t ten macros m KS400 image analysis software (version 3.0, Carl 
Zeiss, Germany). The method of analysis has been described before21. 
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T O T A L ICG A N D ICG SUBCLASSES M E A S U R E M E N T 
In the phase l b study venous blood was collected in week 1, before the f irst inject ion, and in 
week 8, before the eighth in ject ion. Whole blood samples anticoagulated w i t h citrate were 
obtained for determination of total IgC and IgC subclasses. Total IgC was measured on the 
Beekman Coulter (Mi jdrecht, the Netherlands) Image Nefelometer using Beekman Coulter 
reagents. Calibration was on the international standard CRM470. IgC subclasses were measured 
on a BNII Nefelometer (Dade Behring, Brussels, Belgium) using the reagents of The Binding Site 
(Birmingham, England). Calibration was performed on a CLB (Amsterdam, The Netherlands) 
standard H1234. 
Q U A N T I T A T I V E R E A L - T I M E PCR O F IFN-γ M R N A E X P R E S S I O N 
CD4+, CD8+, CD19+ and CD56+ cells were FACS-sorted from lymph node suspensions and the 
fraction of each cell type in the total suspension (f,) was analysed. Subsequently, RNA was 
isolated from 2000-5000 cells, reverse transcribed and subjected to quant i tat ive real-time PCR 
analysis (TaqMan, Applied Biosystems) as has been reported previously2 0. To quantify IFN-γ and 
PBCD-R2 copy number in a given sample, Cj values of t w o independent experiments were 
extrapolated in standard curves generated by serial d i lut ion of plasmid containing amplicons of 
IFN-γ and PBCD-R2, respectively. Subsequently, the ΙΡΝ-γ/ΡΒϋ0-Ρ2 ratio (r) in CD4+, CD8+, 
CD19+ and CD56+ cells in a locoregional lymph node of control (n=4) and IL-12-treated (n=4) 
patients was determined and mult ipl ied by the fraction o f t h a t population in the lymph node 
from which they were isolated (rf,).The relative contr ibut ion of a cell type to the total IFN-γ 
expression in a lymph node is expressed the percentage rf, / îrf,. 
RNA I S O L A T I O N , cDNA REACTION A N D Q U A N T I T A T I V E PCR FOR D E T E R M I N A T I O N OF BCL-2 F A M I L Y 
MEMBERS 
RNA was isolated using RNAzol Β (Campro Scientific, Veenendaal, The Netherlands). Reverse 
transcription was performed w i t h 1 pg RNA in a total mixture of 20 pi f i rst strand RT buffer 
w i t h 10 mM di th iothre i to l (DTT), 625 μΜ dNTPs, 2.5 ng/pl oligo dT (all from Life Technologies, 
Caithersburg, MD, USA), 0.1 pg/pl random hexamers (Amersham Pharmacia, Piscataway, NJ, 
USA), 20 U RNAsin (Promega, Madison, W l , USA) and 200 U M-MLV reverse transcriptase 
(Life Technologies, Caithersburg, MD, USA). This reaction mixture was incubated at 20I>C for 
10 min, at 42°C for 45 min and at 950C for 10 min. Subsequently, 80 pi of Η,Ο was added and 
samples were stored at -80oC. 
Quantitative PCR was performed w i t h the ABI/PRISM 7700 Sequence Detection System (Applied 
Biosystems, Foster City, CA, USA). Primer and probe sequences are given in table 1. PCR 
conditions were as follows: 10 min at 950C followed by 45 cycles of 15 s at 950C and 1 min at 
60oC, w i t h data collection in the last 30 s. All PCRs, except those for the reference gene PBCD, 
were performed in SYBR Green PCR buffer w i t h 125 pM dNTP mix, 1.25 U AmpliTaq Cold and 
5 mM MgCI; (Applied Biosystems, Foster City, CA, USA). The PCR for PBCD was performed in 
TaqMan Universal PCR MasterMix w i t h 200 nM Vic-labeled (6-carboxy-rhodamine) PBCD probe 
(Applied Biosystems). Primer concentrations for the PCRs were 300 n M . All PCRs were performed 
in a total volume of 50 p i . PCR products were checked by gel-electrophoresis. 
W E S T E R N B L O T A N A L Y S I S O F B C L - 2 
Cell pellets were resuspended in lysis buffer, containing 142.5 mM KCl, 5 mM MgCb, 10 mM 
Hepes pH=7.3, 1 mM EGTA, 1% Triton X-100, 0.5% Nonidet-P40 and freshly added protease 
inhibitors (0.3 pM aprot in in, 0.3 pM pepstatin A, 10 pM leupeptin and 0.2 mM phenylmethyl-
sulphonyl f luoride and kept on ice for 45 min. Proteins were separated by gel-electrophoresis on 
14% tr is-glycine gels and transferred to polyvinylidene dif luoride membranes. Bcl-2 was stained 
using an anti-human Bcl-2 monoclonal antibody (clone 124, Dako Diagnostics, UK). 
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table ι Primer and probe sequences of Bcl-2 and family members used for quantitative PCR. 
PBCD forward primer 
PBCD reverse primer 
PBCD probe 
Bcl-2 forward primer 
Bcl-2 reverse primer 
Bax forward primer 
Bax reverse primer 
Bcl-xL forward primer 
Bcl-xL reverse primer 
Bak forward primer 
Bak reverse primer 
Bid forward primer 
Bid reverse primer 
5'-CCCAATCCCCCTCCAA-3' 
5'-CCGTACCCACCCCAATCAC-3' 









V - C L I K J L I L U J I C J A I C I C I I I L - Ì ' 
b-ICCCillCACILCAICCCAIII-J' 
I M M U N O P H E N O T Y P I N C W I T H FLOW C Y T O M E T R Y 
The fol lowing moAb were used for immunofluorescence analysis: Cy5-conjugated anti-CD3 
(UCHT1), anti-CD4 (13B8.2), anti-CD8 ( B 9 . l l ) , anti-CD19 (J4.119) (Beekman Coulter, Mijdrecht, 
The Netherlands), FITC-conjugated anti-CD57 (Leuy) (BD Biosciences, Erembodegem, Belgium), 
and PE-conjugated anti-CXCR5 (51505), anti-CXCR4 (12C5), CCR7 (150503) (R&D systems, 
Abingdon, UK). Cells were incubated w i th the appropriate concentration of moAb in PBS 
supplemented w i t h 20% pooled human serum and 0 . 1 % NaN3 (40C, 30 min) . Cells were washed in 
PBS supplemented w i t h 1% BSA and analyzed on an Epics XL f lowcytometer (Beekman Coulter, 
Fullerton, CA). 
STATISTICS 
Nonparametric Mann-Whitney-U tests were performed to compare two independent samples. 
Spearman's correlation coefficient was calculated for correlation analysis. Paired student t test 
was used for calculating differences in the IgC subclasses between week 1 and 8 in each patient. 
The paired student Τ test was suitable, because the values were normally divided and the standard 
deviation was not di f ferent. Overall survival (OS) was calculated from the date of surgery and 
estimated using the Kaplan-Meier m e t h o d 2 7 . The comparison of survival parameters was 
performed using the log-rank test 2 8 . For all tests, p<0.05 was considered to be statistically 
significant. All statistical analysis was performed w i t h two-tailed tests using SPSS n . o for Windows. 
R E S U L T S 
C H A N C E D A R C H I T E C T U R E O F L Y M P H N O D E S AFTER IL-12 T R E A T M E N T 
As described before, histopathological analysis of lymph nodes derived from IL-12-treated and 
control patients revealed apparent architectural differences. Although lymph nodes of IL-12 
treated patients were enlarged, fewer primary and secondary follicles w i t h smaller CCs were 
observed w i t h o u t signif icantly affecting the number of Β cells present2 1. Routinely H8tE-stained 
histopathological sections showed a broader outer region of the mantle zone of secondary follicles 
in the IL-12-treated lymph nodes compared to the control lymph nodes (figure i ) . Furthermore, a 
high number of CD20+ centroblasts, i.e., interfoll icular B-blasts, was located outside the GCs in 
IL-12-treated patients figure 2. Occasionally, CD20+ Β cells were detected in the sinus around the 
lymph node (figure 2). 
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figure ι Differences in the germinal centers of IL-12-treated (left panel) and control patients (right panel). Hematoxylin & 
eosin stained (H&E) tissue sections show the broader outer region of the mantle zone in IL-12-treated patients. Staining 
with CD21 show the less grouped CD21+ cells in germinal centers in IL-12-treated patients. Staining with CD57 show 







figure 2 Lymph nodes of IL-12 treated patients: CD20 staining show interfollicular B-blasts that are lying between follicles 
( ^ ^ H A ) and a vessel full of Β cells (B). FDCs are stained with CD21 and show the bizarre germinal centers with the 
localization of FDCs outside the germinal center (C and D). 
Abbreviations: FDC-follicular dendritic cell 
The IL-12 treated lymph nodes sometimes showed bizarre CCs w i t h the follicular dendrit ic cells 
(FDCs) located outside instead of inside the CC (figure 2). Because i t was not possible to count 
the CD21+ cells due to the shape and the staining pattern of the FDCs, we determined the 
surface area of the CD21+ regions in the CCs in the lymph nodes, which was not di f ferent 
between the IL-12-treated and control patients (table 2). However in some patients the FDCs 
were less densely positioned inside the CC (figure 2). 
The number of CD57+ CC cells was assessed quantitatively. The median number of CD57+ cells in 
the CC was strongly decreased in IL-12-treated patients compared to control patients (10.3 versus 
31.4, respectively (p<0.05) (table 2 and figure 1)), while the number of CD57+ cells outside the 
CC was not di f ferent (as described before 2 1 ). A semi-quantitative scoring of CD4+ cells in the CCs, 
partly the same cells as the CD57-I- GC cells, showed a trend t o fewer CD4+ CC cells (mean scoring 
of 1.4 and 2.2 in IL-12 treated and control patients, respectively). The number of CD68+ t ingible 
body macrophages was not d i f ferent. Also, the number of MIB+ cells, a proliferation marker, was 
not different outside the GC between IL-12 treated and control patients (data not shown). The 
number of MIB+ cells in CCs was such high that it was impossible to count these proliferating cells. 
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table 2 Quantitative analysis of CD57+ and CD21+ cells in germinal centers (CCs) in lymph nodes of IL-12-treated and control 
patients. The size of the CCs and the CD57+ cells per CC were decreased after IL-12 treatment. No significant differences 
were detected in the surface area of the CD21+ cells. 
Total size of lymph node (mm3) 
Mean number of GCs 
Sum of surface areas of CCs (mm1) 
Surface areas of CCs/total size of LN 0.39 1.38 <0.05 
Mean size of CC (mmJ) 0.011 0.032 <0.05 
Median size of CC (mms) 0.010 0.022 <0.05 
Total number CD57+ cells in CCs 
Mean number of CD57+ cell per CC 
Median number of CD57+cell per CC 10.3 31.4 <0.05 
Sum of surface areas of CD21+ regions (mm3) 
Surface area of CD21+ regions/total size of LN 
Mean size of CD21+ area (mm3) 
Median size of CD21+ area (mm3) 





























In conclusion, the changed architecture of the secondary follicles in the lymph nodes of 
IL-12-treated patients is mainly caused by changes in Β cell formation and fewer CD57+ CC cells. 
NO SIGNS OF ALTERED APOPTOSIS OR C H E M O K I N E RECEPTOR EXPRESSION IN LYMPH NODE DERIVED 
Β AND Τ CELLS 
To investigate whether apoptosis played a role in the changed architecture after IL-12 treatment, 
mRNA expression of Bcl-2 and other members of the Bcl-2 family in mononuclear cells isolated 
from the lymph nodes were determined. No differences were found in Bcl-2 or Bcl-xl, known as 
anti-apoptotic molecules, and Bax, Bak, or Bid known as pro-apoptotic members between five 
IL-12 treated and five control patients (data not shown). Moreover, the protein expression of 
Bcl-2 in purified lymph node derived Τ and Β cells was not different between both groups and 
thus confirmed the RNA expression data (data not shown). Furthermore, active caspase-3 on 
immunohistochemical sections of lymph nodes was not different between IL-12 treated and 
control patients (data not shown). 
As the expression of CXCR5 and CXCR4 on Τ and Β cells is important for the distr ibut ion and 
traff ic of these cells t o and w i t h i n the lymph nodes, we also determined their expression in 
three IL-12-treated and three control patients. No apparent differences were seen in the mean 
expression of CXCR4 on Β (51.9% vs 58.8%), Th (21.8% vs 14.9%), and Tc (5.2% vs 7.0%) cells, 
and CXCR5 on Β (68.7% vs 67.9%), Th ( 8 . 1 % vs 5.2%), and Tc cells (3.6% vs 5.0%) in IL-12-treated 
versus control patients, respectively. 
Altogether, these results do not support a role for apoptosis or altered chemokine receptor 
expression in the observed lymph node architecture after IL-12 treatment. 
Β CELL ACTIVATION WITH IFN-γ MRNA EXPRESSION AND IcC SUBCLASS SWITCH 
The altered distr ibut ion of Β cells in the lymph nodes of IL-12-treated patients suggested activation 
of these cells in response t o IL-12. Therefore, the IFN-γ mRNA expression in purified lymph node 
derived Β cells and the amount of the different IgC subclasses in plasma were determined. 
Previously, we showed that the IFN-γ mRNA expression in the mononuclear cells of the lymph 
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figure 3 IgC subclass switching in five IL-12 treated patients. The subclasses (IgCl, lgC2, lgC3 and lgC4) were divided by 
the total IgC before start of IL-12 (i.e., wk i) and before the 8th injection (i.e., wk 8). The IgCl/lgC and lgC4/lgC 
increased in time (p<0.05), whereas lgC2/lgC decreased in time (p<0.05).The lgCl/lgC2 ratio increased in time 
(p<0.005). 
change (%) from 
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nodes was more than 100 times higher in IL-12-treated patients than in control pat ients 2 0 . To 
investigate whether Β cells started t o produce IFN-γ after IL-12 treatment quant i tat ive real-time 
PCR analysis of IFN-γ expression on FACS-sorted cell populations of locoregional lymph node 
suspensions was performed. In the IL-12 treated patients the relative contr ibut ion to IFN-γ 
expression of lymphoid subsets revealed an increase in the relative contr ibut ion of CD19+ and 
CD56+ cells after i.t. IL-12 in ject ion. The highest expression was seen in the CD56+ NK cells, 
whereas the largest relative change in CD19+ Β cells was seen (figure 4) . Whereas the Β cells of 
all four control patients did not express IFN-γ mRNA, in three out four IL-12 treated patients 
IFN-γ expression was readily detected in their Β cells. 
Next IgC subclasses were analyzed in the plasma of five patients treated in the phase l b study, 
because in this study the patients were treated for a longer period than in the phase I I study. 
In all these patients an increase in the IgCl (Thelper l ) / t o t a l IgC ratio (p<0.05), a decrease of 
the lgC2 (Thelper 2)/total IgC ratio (p<0.05), and thus, a decrease in the lgCl/lgC2 ratio (p<0.005) 
was seen in week 8 (after 7 injections) relative to before IL-12 treatment (figure 3). Also, the lgC4/ 
total IgC ratio increased in t ime (p<0.05).The relative change in the lgC4/lgC ratio was larger 
than in the IgCl/tota l IgC ratio and lgC2/total IgC ratio. The absolute plasma levels of IgCl (mean 
5.6 g/l) and lgC2 (mean 2.5 g/l) were higher than of lgC4 (mean 0.2 g/ l ) ; the levels of the IgC 
subclasses were all w i t h i n the normal l imits. No changes were detected in the lgC3/total IgC ratio. 
Thus, IFN-γ mRNA expression in Β cells and a clear IgC subclass switch w i t h increased production 
of IgCl and lgC4 and decreased production of lgC2 was detected in IL-12-treated patients. 
P E R I T U M O R A L Β C E L L I N F I L T R A T I O N A N D C L I N I C A L O U T C O M E 
As described before, we found a very high expression of peritumoral CD20+ Β cells in a part of 
the IL-12 treated patients in the phase I I study. Eight of the nine IL-12-treated patients and 12 
of the 20 control patients had a high expression (scoring of 2,3 or 4) of peritumoral Β cells. Both 
IL-12 treated and control HNSCC patients w i t h a high expression of CD20+ Β cells had a better 
prognosis w i t h a longer overall survival than the patients w i t h a low expression of CD20+ Β cells 
(scoring of 0 or 1) (p<0.0 l ) ( f igure 5 ) 2 1 . 
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figure 4 The relative contributions of lymphoid cells to IFN-γ expression in locoregional lymph nodes of HNSCC patients. The 
quantitative real-time PCR analysis of IFN-γ expression on FACS-sorted cell populations of locoregional lymph node 
suspensions of IL-12-treated (•) and control ( D ) HNSCC patients. After intratumoral IL-12 injection an increase in the 
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The peritumoral Β cell inf i l t rat ion was negatively correlated w i t h the median size of the CCs in 
the lymph nodes (r=-0.905;p=0.001). 
D I S C U S S I O N 
Patients w i t h HNSCC treated w i t h i.t. rhlL-12 exhibit major changes in the architecture of their 
tumor draining lymph nodes, i.e., fewer and smaller CCs as described before 2 1 . We now 
demonstrate that in IL-12-treated patients compared to control patients the outer zone of the 
mantle zone of the SFs was broader, as a result of an increased number of mantle zone Β cells. 
Inside the CC, the number of CD57+ CC cells was decreased. Moreover, we described IFN-γ mRNA 
expression by purif ied lymph node derived Β cells, an IgC subclass switch in plasma, and an 
increase in interfoll icular Β blasts after IL-12 treatment. Peritumoral Β cell inf i l t rat ion correlated 
w i t h overall survival in HNSCC patients. 
Activation of Β cells was revealed by ident i fy ing IFN-γ mRNA expression in Β cells in the lymph 
node and an IgC subclass switch in plasma. This is the f irst clinical study in which Β cell 
activation after IL-12 treatment is demonstrated. Three of four IL-12-treated patients showed a 
clear IFN-γ mRNA expression in the Β cell. In vitro it was shown that Β cells could produce IFN-γ 
after IL-12 administrat ion 2 4 . In all five IL-12-treated patients analyzed a switch to more IgCl and 
less lgC2 was established, and thus, all patients showed an increase in the lgCl/ lgC2 ratio, i.e., 
indicative for an increase in t h e T h l / T h 2 profi le. Furthermore, an increase in lgC4 was detected. 
Our data are in accordance w i t h mice data in which after IL-12 treatment an enhanced lgC2a 
(analogous w i t h human IgCl) and decreased IgCl (considered as Thelper 2 IgC in mice) synthesis 
was seen2 9. The meaning of the switch to more lgC4 production is more controversial, because is 
it not clear whether it should be regarded as a T h l or Th2 immunoglobul in. Both IL-12 and IL-10 
can increase the production of lgC4 in vitro 3 0 ' 3 1 .The t ime required for the Β cell to switch to the 
demonstrated IgCl and lgC4 production is uncertain. Before, we have measured these subclasses 
in peripheral blood of patients in the phase I I study and have found no significant differences 
after 2 weeks. Apart from the synthesis rate of IgCs, the half-life of the IgC is also important, 
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figure 5 The overall survival of 29 HNSCC patients. The survival of patients with a high (—) pericumoral Β cell expression (n=20) 
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which is 23 days for I g C l , lgC2, and lgC4 and 8 days for lgC3 3 2 . Therefore, i t is possible that the 
switch in the peripheral blood could not be detected after 2 weeks, but was evident after 8 weeks. 
Because IL-12 in vitro has been shown to affect the expression of several Bcl-2 family members and 
decreases activation-induced cell death in human naïve Th cells33, and IL-10 has been shown to 
prevent spontaneous death of CC Β cells by induction of the Bcl-2 prote in 3 4 , we investigated the 
Bcl-2 family both at the RNA and the protein level. No changes were detected in Τ or Β cells 
between the IL-12- treated and control patients. Furthermore, the expression of caspase-3 was 
not d i f ferent, precluding that another pathway of apoptosis, i.e., FasL mediated, played an 
important role in the observed changed architecture. Also, the expression of CXCR5 and CXCR4 on 
B, Th and Tc cells was not different between the IL-12-treated and control patients. However, we 
tested this in only three IL-12-treated and three control patients. 
With immunohistochemical analysis we revealed more Β cells in the outer (l ighter) region of the 
mantle zone of SFs in the IL-12-treated compared t o the control lymph nodes. Due to the reduced 
size of the CC, we suppose that the number of GC Β cells were decreased. The Β cells in the outer 
region of the mantle zone of lymph nodes have probable the same funct ion as the Β cells in the 
marginal zone of follicles of the spleen. The marginal zone Β cells had been shown to be more 
potent in activat ing Τ cells than follicular Β cells3 5. Furthermore, an increase in interfoll icular 
B-blasts was detected after IL-12 treatment. This is also seen in several viral infections and is 
another indication of Β cell act ivat ion. Thus, both the increase in the number of Β cells in the 
outer region of the mantle zone and the increase in the number of interfoll icular Β blasts are 
signs of activation of Β cells by IL-12. 
Previously, in a number of patients a very high number of peritumoral Β cells after IL-12 
treatment in the primary tumor was described, whi le no difference in the intratumoral Β cell 
number was detected. Now we showed a better overall survival in HNSCC patients which have 
a high peritumoral Β cell in f i l t ra t ion, independent whether they were treated w i t h IL-12 or not. 
However, after IL-12 treatment more patients had a higher peritumoral Β cell number than 
control patients, although this was not signif icant. Due to the l imited number of IL-12-treated 
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patients separation in high and low peritumoral Β cell expression within the IL-12-treated and 
control patients was not possible Remarkably, a negative correlation was observed between the 
peritumoral Β cell infiltration and the size of the CCs. The Β cell is much less investigated than 
the Τ cell and the NK cell m immunity m cancer A limited number of studies report on the role 
of the Β cell in immunosurveillance of cancer. Both m mice and m human breast cancer there are 
indications of involvement of Β cell responses against tumors36·37. 
The form and size of the CC had also changed by the decrease in the number of CD57+ CC cells. 
The number of CD57+ cells outside the CCs did not differ between the IL-12 treated and control 
patients. CD57 m the lymph node is expressed on NK cells, mainly lying outside the follicles, and 
on CD4+Th cells, partially lying in the CC Approximately half of the CD4+ cells in the CC express 
CD57 The CD57+CD4+ CC cells express high levels of CXCRS". We also found a slight decrease m 
the CD4+ CC cells However, the scoring of CD4+ CC cells was less accurate than the counting of 
CD57+CC cells, because this marker was stained on freezing sections of small parts of the lymph 
nodes In vitro data have shown that CCs provide an appropriate microenvironment forTh2 
polarization via IL-4 production by follicular Β cells3» and IL-10 production by CD57+ Th cells« 
Additionally, the CD57+ CC Τ cells have been shown to be anergic Τ cells38 and might be 
analogous to the murine CCR5+ CCT cells, which is a subset of regulatory Τ cells41. Thus, after IL-12 
treatment we observed a decrease in number of CD57+ CC cells, which may be regulatory Τ cells. 
Previously, we showed a decrease of the DC-LAMP+ cells in the paracortex m IL-12-treated 
patients compared with control patients Interestingly, in the IL-12 treated lymph nodes 
correlation was seen between the DC-LAMP+ cells and the median number of CD57+ CC cells per 
CC (r=0 5; p<0 05). Furthermore, the number of DC-LAMP+ cells was related to the percentage 
of lymph nodes with a high number of secondary follicles (i.e., grade 3 (many follicles) or 4 (filled 
with follicles))21 (r=0 6;p<0 01). CD57+CD4+ cells enter the lymph node in the cortex and after 
contact with DCs in the paracortex, the CD57+CD4+ cells that upregulate the expression of CXCR5 
will be attracted to the CC. Whether the DC-LAMP+ cells are involved in upregulation of CXCR on 
Th cells is unknown Possibly, both the high number of DC-LAMP+ cells and the high number of 
CCs in the control HNSCC patients may be manifestations of tolerance, which could be reversed 
after IL-12 treatment 
In conclusion, after IL-12 treatment in HNSCC tremendous effects on Β cells were observed. We 
detected activation of Β cells measured by an IgC subclass switch and IFN-γ production. A broader 
outer region of the mantle zone and the mterfollicular B-blasts were also indicators of Β cell 
activation The activation of the Β cell caused the changed architecture, certainly partially. The 
CD57+ CC cells decreased, as did the DC-LAMP+ cells m the paracortex The peritumoral Β cell 
infiltration was a prognostic positive sign m HNSCC patients. We suppose that in the lymph 
nodes of HNSCC patients CCs with follicular Β cells and CD57+ CC cells reflect a state of 
tolerance We propose that the Β cells in the outer region of the mantle zone, ι e , the activated 
Β cells, leave the lymph node and induce a peritumoral Β cell infiltration and hereby induce tumor 
immunity, which leads to a better survival. The negative correlation between the number of 
peritumoral Β cells and the size of the CCs m the lymph nodes supports this hypothesis IL-12 
seems to play a role in break down tolerance induced by DC-LAMP+ DCs and by CD57+ CC cells, 
which are probably regulatory Τ cells. If IL-12 is indeed able to break tolerance, IL-12 may be 
developed further as adjuvant in tumor vaccination m future Until now the role of Β cells has 
not been studied under circumstances where IL-12 was used as adjuvant42 Such studies are 
required for the development of rational IL-12 treatment The role of the "underestimated" Β cell 
m tumor immunity in HNSCC or other cancers also needs further investigation 
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Head and neck squamous cell carcinoma (HNSCC) is characterized by an active, but often fai l ing 
interaction w i t h the immune system. Various tumor related factors may play a role in the down 
regulation of the immune system. The locoregional application of interleukin-2 (IL-2) induced 
partial restoration of immune competence at the site of the tumor, but did not result in 
meaningful clinical results. One of the explanations could be a predominant Τ helper 2 (Th2) 
response fol lowing IL-2 treatment, as reflected by the commonly observed eosinophil ia1. 
Cytokines produced byTh2 cells have a negative influence on the Τ helper 1 ( T h l ) response, the 
latter being regarded as crucial for a strong cellular immune response. IL-12 possesses several 
biological activit ies that contr ibute t o ki l l ing of cancer cells, i.e., activation and proliferation of 
cytotoxic Τ cells (Tc) and natural killer (NK) cells, induction of T h l responses and thereby cellular 
immunity, production of IFN-yand inhib i t ion of angiogenesis. Therefore IL-12 is of great interest 
to explore in this context. 
We performed t w o clinical studies w i t h intratumoral ( i . t . ) rhIL-12 administrat ion in head and 
neck squamous cell carcinoma (HNSCC) patients, a phase l b and a phase I I study. The most 
important differences between the t w o studies were ( i) the patients, i.e., recurrent versus 
previously untreated HNSCC patients, (11) the site of the in ject ion, i.e., in a lymph node 
metastases or a local recurrence versus the primary tumor, ( i n ) the median number of injections, 
i.e., 9 (range, 3-24) versus 2 (range, 1-3), respectively. All recurrent patients have undergone a 
lymph node neck dissection, and/or radiotherapy on the neck. In this way the locoregional 
immune is likely t o be damaged. 
In both studies rhIL-12 was administered at t w o dose levels of 100 ng/kg and 300 ng/kg body 
weight. For the toxicity, the pharmacokinetic and part of the pharmacodynamic analysis we 
looked at differences between both dose levels. For other pharmacodynamic parameters, such 
as the immunohistopathological analysis or RT-PCR data, we did not analyse each dose level 
separately, due t o the l imited number of treated patients. In the phase l b study six patients were 
treated and in the phase I I study 10 patients, who were compared w i t h 20 control patients. The 
collected materials were unique because human material obtained after locoregional 
immunotherapy is rarely available and permitted detailed analysis partly compensated for the 
sample size under study. 
In the phase I I study the patients received the last injection 24 hours before the start of surgery. 
The study of the effects of IL-12 in the primary tumor and lymph nodes was performed at that 
moment. Therefore, the effects occurring at earlier or later t ime points remain unknown. Twenty-
four hours was chosen, because in the peripheral blood the maximal effects of IL-12 were seen 
after 12 to 24 hours. Furthermore, less than 24 hours between the last injection and the surgery 
was not feasible, because of the high fever patients could develop after 8 to 12 hours. 
In this chapter we wi l l discuss the performed studies in view of the four questions mentioned in 
the introduction of this thesis. Finally, concluding remarks and future perspectives wil l be discussed. 
1 W H A T I S T H E T O X I C I T Y O F R H I L - 1 2 A F T E R I N T R A T U M O R A L A D M I N I S T R A T I O N A N D H O W D O E S T H I S 
R E L A T E T O T H E T O X I C I T Y O B S E R V E D A F T E R S Y S T E M I C A D M I N I S T R A T I O N ? 
The toxic i ty in the phase l b study, in which recurrent HNSCC patients were treated, was low; 
however, in the phase I I study, in which non-pre-treated HNSCC patients were treated, toxic i ty 
was much higher than expected. To our surprise the weekly dose of 300 ng/kg IL-12 i.t. showed 
dose-limiting tox ic i ty (DLT) in the phase I I study, although this dose was well tolerated in the 
phase l b study. The most likely cause for the discrepancy between the low toxic i ty in the 
recurrent HNSCC patients and high toxic i ty in the non-pre-treated patients is the less 
compromised immune status in the non-pre-treated patients. Indications for this are the higher 
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pre-treatment number of lymphocytes, and the higher and dose-dependent IFN-γ production in 
the phase I I study compared w i t h the phase l b study An additional cause could be the injection 
site· the primary tumor versus lymph node metastases or local recurrence. Triggering might be 
more eff icient in the presence of an intact locoregional lymph node system. 
Remarkable was the difference in DLT m the phase I I study w i t h i.t administrat ion, i.e., weekly 
300 ng/kg, and the maximal tolerated dose m studies w i t h subcutaneous (s c.) or intravenous 
(i.v ) administration of IL-12, i.e , weekly more than 2100 ng/kg or three times a week 500 ng/kg, 
respectively. Probably by administrat ion of IL-12 m the primary tumor near the locoregional 
lymph nodes, highly eff icient immune tr iggering occurred. This can explain the high liver toxici ty 
seen m the phase I I study, probably caused by NK cells producing high levels of IFN-γ. 
2 HOW IS THE PHARMACOKINETICS OF IL-12 AFTER INTRATUMORAL ADMINISTRATION COMPARED TO 
SYSTEMIC ADMINISTRATION? 
In all patients, both m the phase l b and phase I I study, IL-12 was already detectable in plasma 
30 minutes after i.t administrat ion This is in accordance w i t h the observation of Mattijssen et 
al w i t h PEC-IL-22 Probably the measured IL-12 in plasma was mainly rhlL-12, but the induction 
of IL-12 mediated through IFN-γ cannot be excluded. When we compare our PK data w i t h i.v.3 
or s.c 4 6 administrat ion of rhlL-12, the AUC and Cma« is higher after i.v. and lower after s.c 
administrat ion, respectively, compared w i t h i.t administrat ion. 
The PK data m both studies were comparable, except for the difference in AUC in the first week 
and the fol lowing weeks of administrat ion In the phase l b study an unexpected increment in 
AUC from week 1 to week 6 m three of four patients was observed, however, in the phase I I 
study the AUC 0 2 4 hours after the second or th i rd injection decreased compared w i t h the first 
in ject ion, which in accordance w i t h observations after s.c and i.v. administrat ion 5 7 .This 
difference is d i f f icu l t t o explain Perhaps the perfusion of recurrent HNSCC lesions is different 
than that of a primary tumor 
3 W H A T A R E T H E P H A R M A C O D Y N A M I C E F F E C T S O F IL-12 I N T H E P E R I P H E R A L B L O O D , 
T H E L O C O R E G I O N A L L Y M P H N O D E S A N D T H E P R I M A R Y T U M O R S ? 
3.1 DECREASE OF T H E L Y M P H O C Y T E S I N T H E P E R I P H E R A L B L O O D A N D E N L A R G E M E N T OF 
L O C O R E G I O N A L L Y M P H N O D E S 
One of the pharmacodynamic effects of rhlL-12 administrat ion seen in the t w o HNSCC studies 
was the rapid decrease m number of lymphocytes and monocytes m the peripheral blood. The 
most prominent decline was seen m the NK cells and Tc cells, but also a decrease m Th cells 
and Β cells occurred. The maximal decrease was seen after 12 to 24 hours These observations 
were comparable w i t h the decreases described m studies w i t h systemic treatment 4 After 72 
hours an almost full normalisation of all the subsets was seen, however, the normalisation of 
the Β cell level in the circulation took a longer period, as reflected by the increase m T/B cell 
ratio after 72 hours 
We found evidence that the observed IL-12 induced lymphopenia m humans was due to a 
redistr ibution of peripheral blood lymphocytes to extravascular sites, e g lymph nodes In the 
phase I I study, in which we examined the locoregional lymph nodes and the primary tumor, we 
found m the IL-12-treated patients compared w i t h control patients larger, and as consequence 
more detectable lymph nodes Flow cytometric analysis of the lymph nodes of the IL-12-treated 
patients showed a higher percentage of CD3-CD16+CD56+ NK cells Surprisingly a lower 
percentage of CD2+CD3+ Τ cells, w i t h a lower percentage of CD3+CD4+ Th cells and an unchanged 
percentage of CD3+CD8+ Tc cells, and a slightly higher percentage of CD19+CD45+ Β cells were 
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measured The same trends were seen in the primary tumors. With immunohistochemical 
examination we found an increase m CD56+ NK cell infiltration in the primary tumor and a trend 
to an increase m peritumoral CD20+ Β cell infiltration, with no changes in the number of CD3+ 
Τ cell, CD4+ cells (Th cells or macrophages) and CD8+ Tc cells. In the lymph nodes no significant 
changes in number of CD56+ NK cells, CD20+ Β cells, or CD3+ Τ cells were detected, but, the 
trend was the same as with flow cytometric analysis. This partial discrepancy could possibly be 
explained by the use of multiple markers to identify the lymphocyte subsets by flow cytometry 
The percentages of the lymphocyte subsets in the lymph nodes and primary tumor correspond 
with the observation m the peripheral blood of the extreme decrease of NK cells, the late 
recurrence of Β cells, and the moderate decline of Th cells after rhlL-12 injection However, 
Tc cells decreased in the peripheral blood, but no increase was detected in the lymph nodes Our 
results of the differential redistributions of the lymphocyte subsets are in agreement with studies 
in mice, after administration of IL-12 to normal mice, an increase in the numbers of NK cells and 
Β cells in the spleen and NK cells and Tc cells m the liver was observed, whereas the number of 
Th cells m these sites remained essentially unchanged8 Our observation in the human lymph 
nodes is exactly the same as this observation in the spleen of mice. It is imaginable that the 
disappearing Tc cells in the peripheral blood in our study accumulate in the liver together with 
NK cells, as seen in the mouse model. 
The measured redistribution of activated immune cells from the peripheral blood to the lymph 
nodes (and primary tumor), clearly show that monitoring the immune effects solely in the 
peripheral blood, after IL-12 or other immune therapy, can be misleading. 
3.2 IFN-γ PRODUCTION, ESPECIALLY IN THE LYMPH NODES 
In both studies after rhlL-12 administration an increase of the plasma levels of IFN-γ was seen in 
the peripheral blood, which was lower after repeated injections The IFN-γ mRNA expression in 
the peripheral blood showed only a slight increase m the phase lb and no differences m the phase I I 
study In the lymph nodes, however, we detected a 128-fold higher IFN-γ mRNA expression m the 
IL-12-treated patients than in control patients Altogether, these results suggest that the lympho­
cytes, which start to produce IFN-γ, leave the circulation. In addition resident leucocytes already 
present in the lymph node will upregulate IFN-γ RNA m response to the IL-12 administration. 
Further analysis demonstrated that the NK cells produced the highest amount of IFN-γ mRNA 
The IFN-γ mRNA expression was also higher m the Th, Tc and surprisingly the Β cells (see 3 6) 
Besides induction of IFN-γ, we found also IL-10 production, which was lower after repeated 
injections. Others have suggested that the IL-10 production observed after systemic rhlL-12 
administration accounts for the down-regulation of clinical and immunological effects 
However, our data show that despite the IL-10 production in the peripheral blood, a potent 
Thl environment is present locoregionally in the lymph nodes m IL-12-treated patients (see 3.3) 
Moreover, recent data imply that IL-10 has a distinct role m the different phases of the immune 
response. Besides its potent capacity to down-regulate immunity during the effector phase, IL-10 
might actually enhance immunity (eg., IL-10 is known to enhance NK cell function) during the 
onset of an immune response' Therefore, it is doubtful that the observed IL-10 production after 
IL-12 administration can simply be regarded as a negative side effect. 
3.3 OTHER SIGNS O F T H I RESPONSE 
3.3.1 T-bet and c-A1a/ 
Two transcriptionfactors that are critically involved m determining the Thl and Th2 response are 
T-bet and c-Maf, respectively. Unexpectedly, in peripheral blood a distinct decrease of 70 to 80% 
m the mRNA level of T-bet was detected after rhlL-12 i.t. administration m all patients in both 
studies The T-bet mRNA levels returned to normal after 48 or 72 hours An explanation for this 
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apparent contradiction could be the time frame m which the measurements were performed We 
could have missed a possible peak in T-bet gene expression, occurring prior to our first sampling 
time. The maximal increase of IFN-γ mRNA was detected after 4 hours and of plasma IFN-γ after 
12 hours Thus, an upregulation of T-bet could have occurred prior to our 4-hour sampling time. 
This is supported by data in a murine model, in which a rapid induction of T-bet expression was 
seen10. A second hypothesis is that the T-bet positive (Thl) cells become adherent to the blood 
vessel wall and preferentially leave the circulation. It has been previously reported that in the 
process of inflammation the recruitment of Thl and Th2 cells into peripheral tissues is different 
In the lymph nodes T-bet expression was higher in one IL-12-treated patient and approximately 
the same in the others versus control patients. The resection of the primary tumor and the 
lymph nodes was performed 24 hours after the last injection. Probably this was too late to 
measure a higher increase of T-bet m the lymph nodes. However, the T-bet/c-Maf ratio (Thl/ 
Th2 ratio) decreased m the peripheral blood in all IL-12-treated patients and increased m four 
of six IL-12-treated patients m the lymph nodes. Remarkably, the two patients who did not 
show an increase in this ratio m the lymph node both had local recurrence of their disease 
after 6 months, the other four patients were disease free. The ability to up-regulate the 
T-bet/c-Maf ratio might be a prognostic or predictive favorable sign The observation that 
the IL-12-treated patients with the largest tumors had the lowest T-bet and IFN-g expression 
m their lymph nodes supports this hypothesis. The measurement of CATA-3 as Th2 
transcriptionfactor might be a valuable addition 
The mononuclear cells isolated from the lymph nodes of the control patients exhibited a 
Th2 profile, with high expression of IL-10 and c-Maf, compared with the peripheral blood 
mononuclear cells (PBMCs) of the peripheral blood. In contrast, in the IL-12-treated patients 
a clear Thl profile, with high expression of IFN-γ and T-bet, m the lymph nodes was seen when 
compared with the peripheral blood. The Th2 profile is probably an indication of locoregional 
immunosuppression, which switched to a Thl profile after rhlL-12 treatment Such a switch 
has been shown in mice in vivo with infectious diseases treated with IL-123e, but was not 
earlier shown m humans. 
3.3.2 IgC subclass switch to Thl antibody production 
To investigate whether an IgC subclass switch m the Β cell occurred after IL-12 treatment, we 
measured the IgC subclasses and total IgC m the peripheral blood in patients in the phase lb study 
with a relative long period of follow up. Indeed, we found m all 5 patients a switch to more IgCl 
and less lgC2, and thus, all patients showed an increase in the lgCl/lgC2 ratio, i.e , indicative for 
an increased Thl/Th2 antibody ratio Besides this, we found an increase m lgC4. Whether the 
increase m the lgCl/lgC2 ratio is biological meaningful remains to be determined However, the 
switch is an indication of Β cell activation towards a Thl profile Our data are in accordance with 
mice data in which after IL-12 treatment an enhanced lgC2a (analogous with human IgCl) and 
decreased IgCl (considered as Thelper 2 IgC in mice) synthesis was seen11 The switch to more 
lgC4 production is more controversial. It is not clear whether lgC4 should be regarded as a Thl or 
Th2 immunoglobulin, as both IL-12 as IL-10 can stimulate the production of lgC4 m vitro1 2 1 3 
The time it takes for the Β cell to switch to IgCl and lgC4 production is uncertain. We have 
measured these subclasses also m plasma of patients treated m the phase I I study and found no 
significant differences between day 1 and day 8 or 15. Next to the rate of the synthesis of the 
changed IgCs, also the half-life of the IgC is important The half-life of IgCs is 8 (lgC3) to 23 days 
(IgCl, lgC2 and lgC4)14 Considering the limited switch and this relative long half-life time, it is 
imaginable that the switch m the peripheral blood could not be detected after 2 weeks, but was 
clear after 8 weeks 
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3.3.3 Less Τ helper 2 cells 
The number of mast cells in the lymph nodes of IL-12-treated patients decreased, but no 
differences were detected in the primary tumor. The number of eosinophils was slightly lower in 
the primary tumor of the IL-12-treated patients. This is in agreement with studies in mice treated 
with IL-12IS. Because both mast cells and eosinophils are seen as cells involved in theTh2 
pathway, these findings were as expected. 
3.4 WHICH CELLS ARE IMPORTANT FOR ANTI-TUMOR IMMUNITY? 
In the primary tumor, the number of CD56+ Natural Killer (NK) cells was increased in IL-12-
treated patients compared with control patients with immunohistochemical examination. In 
some IL-12-treated patients, an impressive peritumoral invasion of CD20+ Β cells was noticed, 
but overall the peritumoral invasion of Β cells was not higher after IL-12 treatment. No 
differences were seen in the numbers or distribution of CD8+ or CD4+ Τ lymphocytes. 
The CD56+ NK cells in the IL-12-treated lymph nodes produced the highest amount of IFN-γ. Thus, 
the higher number of intratumoral NK cells and the high IFN-γ production by NK cells in the lymph 
nodes, implies a prominent role of the NK cell in anti-tumor immunity after i.t. IL-12 treatment in 
HNSCC patients. The CD20+ Β cell, the CD4+ Τ cell and the CD8+ Τ cell produced also considerable 
amounts of IFN-γ. Compared with the control patients the increase of IFN-γ production was the 
highest in the Β cell, with a mean of 18% in IL-12-treated versus 1% in control patients. However, 
not every IL-12-treated patient showed IFN-γ mRNA expression in the Β cell in the lymph node. 
It is interesting to test whether a specific Τ cell response was induced, or specific antibodies were 
produced. 
A remarkable finding was the altered distribution of the CD68+ (macrophages) cells in the 
primary tumors of IL-12-treated patients. In all IL-12-treated patients the majority of the CD68+ 
cells were located peritumorally, whereas in controls the CD68+ cells were more equally spread. 
No differences between the total numbers of intra- and peritumoral CD68+ cells were seen. 
The number of neutrophils in the lymph nodes increased after IL-12 treatment. In the primary 
tumor, however, the neutrophils are slightly diminished by number in the tumor nests and 
remained the same peritumorally and intrastromally. There are conflicting data in animal and 
human studies about the role of neutrophils m cancer16. Their presence may be detrimental by 
favouring malignant growth and progression. Nevertheless, recent studies have suggested that 
they are active in immunosurveillance against several tumors16. 
The number of IL-12-treated patients was limited. Thus, only impressive differences between 
IL-12-treated and control patients were statistically significant different. 
3.5 ACTIVATION OF THE Β CELL AND ALTERATIONS IN ARCHITECTURE OF LYMPH NODES 
Patients with HNSCC treated with i.t. rhlL-12 exhibit major changes in the architecture of their 
tumor draining lymph nodes. Fewer and smaller CCs were seen, although the lymph nodes were 
larger and the number of CD20+ cells was certainly not decreased. The outer region of the mantle 
zone of the SFs was broader, as a result of an increased number of mantle zone Β cells. Inside the 
CC, the number of CD57+ CC cells was decreased. Moreover, we described IFN-γ mRNA expression 
by purified lymph node derived Β cells, an IgC subclass switch in plasma, with an increase m 
the lgCl/lgC2 ratio, indicative for an increase in theThl/Th2 profile, and an increase in 
interfollicular Β blasts after IL-12 treatment. Peritumoral Β cell infiltration correlated with 
overall survival in HNSCC patients. 
Apoptosis or the expression of CXCR5 and CXCR4 on B, Th and Tc cells did not play a role in the 
observed changed architecture. 
The form and size of the CC had also changed by the decrease in the number of CD57+ CC cells, 
in vitro data have shown that CCs provide an appropriate microenvironment for Th2 polarization 
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via IL-4 production by follicular Β cells1 7 and IL-10 production by CD57+Th c e l l s " Additionally, 
the CD57+ CC Τ cells have been shown to be anergic Τ cells1 9 and might be analogous to the 
murine CCR5+ CC Τ cells, which is a subset of a r e g u l a t o r y ! cells2 0 Thus, after IL-12 treatment 
we observed a decrease in number of CD57+ CC cells, which may be r e g u l a t o r y ! cells 
Furthermore, the change in lymph node architecture was partly caused by less paracortical 
hyperplasia, which correlated w i t h a lower number of DC-LAMP+ cells m the paracortex m IL-12-
treated patients compared w i t h control patients Interestingly, in the IL-12 treated lymph nodes a 
correlation was seen between the DC-LAMP+ cells and the median number of CD57+ CC cells per 
CC Furthermore, the number of DC-LAMP+ cells was related to the percentage of lymph nodes 
w i t h a high number of secondary follicles CD57+CD4+ cells enter the lymph node m the cortex 
and after contact w i t h DCs m the paracortex, the CD57+CD4+ cells that upregulate the expression 
of CXCR5 wi l l be attracted to the CC Whether the DC-LAMP+ cells are involved m upregulation of 
CXCR5 on Th cells is unknown Possibly, both the high number of DC-LAMP+ cells and the high 
number of CCs m the control HNSCC patients may be manifestations of tolerance, which could be 
reversed after IL-12 treatment 
If IL-12 is indeed able to break tolerance, IL-12 may be further developed as adjuvant m tumor 
vaccination in future Unti l now the role of Β cells has not been studied under circumstances 
where IL-12 was used as adjuvant 2 1 Such studies are required for the development of rational 
IL-12 treatment The role of the "underestimated" Β cell in tumor i m m u n i t y m HNSCC or other 
cancers also needs further investigation 
3.6 EFFECTS O N T H E VESSELS 
One of the ant i tumor actions of IL-12 is inhibi t ion of angiogenesis In the phase l b study init ial ly 
we observed in 4 of 5 évaluable patients, a reddening of the tumor After 3 to 5 weeks the tumor 
developed a more pale appearance, suggesting a vascular effect Therefore, an analysis of the 
microenvironmental effects of mouse rlL-12 ι t in a human head and neck squamous cell 
carcinoma xenograft tumor line m Balb/c nu/nu mice over t ime was performed Our hypothesis 
that IL-12 f irst induces an increase in perfusion, al lowing the accumulation of immune cells 
(eg , NK cells) in the tumor, followed by an inhib i t ion of angiogenesis or changes m existing 
vessels, which eventually leads to tumor shrinkage, could not be confirmed Although a fast and 
high induction of ICAM-1 was detected m the IL-12 treated tumors, no signif icant changes m the 
vascular density, the tumor perfusion status, the hypoxic fract ion or the proliferation status 
between IL-12-treated and control tumors m a t ime period ranging from 8 hours to 11 days post 
t reatment were found in this xenograft model Both m the human and mice study we treated 
large tumors w i t h probably a lot of mature vessels The mam difference between our human 
model and the Balb/c nu/nu mice is the presence of a complete immune system Others showed 
that inhib i t ion of angiogenesis also occurred m Balb/c nu/nu mice, although impaired w i t h 50% 
Even though, we suggest that the mam reason why the observation made m humans could not 
be confirmed m this mice study is the combination of a lack of possessing an intact immune 
system in the Balb/c nu/nu mice and a relatively large tumor w i t h probably a lot of mature 
vessels, which are known t o be less sensitive t o the effects of IL-12 than immature vessels22 
It wi l l be interesting m the resected material of the patients treated m the phase I I study to 
determine immunohistochemical vessel markers, such as CD34 and CD105 
4 C A N W E D E T E C T A N Y C L I N I C A L A C T I V I T Y ? 
In the phase l b study we saw some clinical act iv i ty m the l imited number of six HNSCC patients 
In 2 patients a long-lasting stable disease (SD) was observed, w i t h a reduction m tumor size of 
40% m one of these patients 
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In the phase I I study after a limited number of one to three injections, we were not able to 
detect any clinical activity in the tumor To test if the IL-12-treated patients were doing equally 
well as control patients, overall and disease-free survival were analyzed The IL-12-treated patients 
have a trend toward better overall survival, but it had not reached significance at the most 
recent follow-up The survival data must be carefully analyzed, because the number of the IL-12 
treated patients and the control patients was limited, and furthermore, the tumor stage of the 
patients in the two groups were slightly (non significant) different, with a higher Ν stage for 
the control patients 
CONCLUSION A N D FUTURE PERSPECTIVES 
IL-12 is a cytokine with effects on both the innate and adaptive immunity In our studies indeed 
we observed effects on the cells of the innate, ι e , NK cells, macrophages and neutrophils, and 
the adaptive immune system, ι e , Β cells and Τ cells High locoregionally mRNA expression of 
IFN-γ was detected IFN-γ is a cytokine with effects on the cells of both the innate and adaptive 
immune system Because of the disappointing results in phase I and I I studies with systemic 
administration of IL-12 (see introduction), the worldwide initial enthusiasm for the use of rhlL-12 
m trials is hampered However, IL-12 is a potent immune modulator of which it is still unknown, 
what the optimal schedule and route of administration are 
Based on the results of our and other studies, we consider the following research questions 
relevant for the near future 
- The performed phase I I study was not randomized and not developed for determination 
of survival However, the observation that the IL-12-treated patients seem to have a better 
prognosis than the control group raises the question whether IL-12 1 t must be investigated 
in a randomized phase I I I study prior to surgery m HNSCC patients However, before starting 
such a study, more patients should be treated at the 100 ng/kg dose-level, to determine the 
toxicity and confirm the observed immunohistochemical changes 
- In view of the observed changes in the lymph nodes after one to three injections of IL-12, 
with a Thl profile, the Β cell activation, and the effects on CD57+CC cells and DC-LAMP+ DCs, 
probable players in inducing tolerance, it is reasonable to combine IL-12 with vaccinations, such 
as DC vaccinations Based on our data we believe that only a limited number and a relatively low 
dose of rhlL-12 must be administered m future studies, m which IL-12 is used 
- The used model of HNSCC is very useful for investigation of new immune modulators, 
such as CpC or other activators of the Toll-like receptor 9 (TLR9)23 CpC DNA acting through 
TLR9 is especially active at plasmacytoid DCs, and seems to be particularly important m the 
early triggering of Thl responses, thereby inducing multiple cytokines 
The observed changes m lymph nodes warrants further investigation in patients with 
follicular Β cell lymphoma, m which large germinal centers with many CD57+ cells are present 
Recently, a phase I I study with IL-12 administration m patients with lymphoma showed a 
response rate of 21% in patients with non-Hodgkm's lymphoma24 No histolopathological or 
immunohistologic examination was performed It is essential to investigate this m future 
studies to understand the mechanisms by which IL-12 can act m lymphoma and to predict 
which patients with follicular Β cell lymphoma can profit by treatment with IL-12 
- It is sensible to combine systemic IL-12 with IL-2, to attempt to sustain an upregulation of 
IFN-γ Other suggested combinations are IL-12 with IFN-a, because IFN-a upregulates the IL-12 
receptor, or with IL-18, because this cytokine is synergistic with IL-12 m inducing a Thl response 
To study the role of the Β cell and the germinal centers, especially the CD57+ CC cells, 
in tumor immunity and m tolerance m HNSCC or other cancers is exciting 
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In this thesis primarily the immune effects of intratumoral (i.t.) recombinant human interleukin-12 
(rhlL-12) administration m patients with head and neck squamous cell carcinoma (HNSCC) are 
described. 
The introduction and outline of the thesis in Chopter 1 presents a short overview of the incidence, 
staging, and treatment of head and neck squamous cell carcinoma and the biological and clinical 
activities of systemic interleukin-12 (IL-12). The outline of the studies is given The aims of the 
studies with i.t administration of rhlL-12 in HNSCC patients were (i) to determine the toxicity 
of this route administration (n) to perform pharmacokinetic analysis (m) to study the 
pharmacodynamic effects m the primary tumor, the locoregional lymph nodes and the peripheral 
blood and (iv) to detect possible clinical activity. A brief description of the studies is presented. 
A review of the literature on the clinical studies using locoregional immunotherapy in cancer 
patients is presented in Chopter 2. Mainly phase I and I I studies were performed Clinical 
responses were seen No single locoregional treatment has become a standard therapy Relatively 
few studies were performed to estimate the influence on the local effector mechanisms or 
immune dysfunction. We concluded that in future studies it would be essential to investigate 
changes both m the primary tumor and locoregional lymph nodes after treatment to provide a 
better insight m the immune mechanisms. 
Chapter 3 describes a phase I study of rhlL-12 administered subcutaneously (s.c ) once weekly m 
patients with advanced cancers. Forty patients with malignant melanoma, 14 patients with renal 
cell carcinoma, and six patients with other cancers were enrolled; they received rhlL-12 s.c. at 
once-weekly dosages ranging from 30 to 2100 ng/kg The maximally tolerated dose was not 
reached, not even with the highest dose rhlL-12 used The most commonly reported adverse 
events were fever, asthenia, headache, nausea, and vomiting Two patients had a minor response, 
but no complete or partial responses were seen It was concluded that this dose schedule of rhlL-12 
was safe and relatively well tolerated. 
Based on the results of this phase I study, with s c administration of rhlL-12 once weekly, the 
dose-levels for the i.t. administration m HNSCC patients were chosen For our future studies it 
was essential that immune modulation was observed with minimal risk of toxicity Based on 
these prerequisites the dose of 100 and 300 ng/kg was choosen 
In chapter 4 we present the results of a phase lb study with ι t administration of rhlL-12 in 
patients with HNSCC Six patients were treated weekly at two dose levels of 100 ng/kg or 
300 ng/kg, up to 24 weeks. Toxicity was mild, with prolonged grade 4 lymphopenia observed m 
only one patient. No dose limiting toxicities occurred In all six patients IL-12 was detectable m 
plasma within 30 minutes. Significant reductions m the absolute number of peripheral blood 
lymphocytes and all lymphocyte subsets, especially cytotoxic Τ cells and NK cells, were observed, 
maximal after 12-24 hours. Maximal plasma concentrations of interferon-γ (IFN-γ) and interleukin-10 
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(lL-10) were detected after 12 hours A real-time semi-quantitative polymerase chain reaction 
(PCR) analysis m peripheral blood mononuclear cells (PBMCs) showed a mean increase of mRNA 
encoding IFN-γ of 2 2 times relative to the pre-treatment sample An unexpected, significant 
decrease of 80% in T-bet mRNA, a Τ helper 1 transcription factor, was detected after 12 hours, 
with normalization after 48-72 hours No complete or partial responses were observed In one 
patient a 40% regression of a tumor lesion was noted 
In four out of five évaluable patients treated in the phase lb study the colour of the injected 
tumor lesion changed during the course of treatment Initially, a reddening of the tumor was 
seen After 3 to 5 weeks the tumor developed a more pale appearance, suggesting a vascular 
effect In view of this observation the mice study presented in chapter 5 was performed The 
aim was to investigate the micro-environmental effects of recombinant mouse IL-12 i t in an 
implanted human HNSCC xenograft tumor, with a relatively large diameter, m Balb/c nu/nu mice 
over time The tumors were ι t injected for 3 days with either 200 ng rmlL-12 or PBA Mice were 
sacrificed at 4 different time points, between 8 hours and 8 days after the last injection Despite 
a faster and higher upregulation of anti-mouse ICAM-1, suggesting activation of the endothelium, 
in the IL-12 treated tumors, no significant differences in vascular density, perfusion fraction, 
hypoxic fraction, and proliferation of tumor cells were detected between IL-12 treated tumor and 
control tumors The mam reason why the clinical observation made m humans could not be 
corroborated by this mice study might be found m the combination of a compromised immune 
system m the Balb/c nu/nu mice and the relatively large tumor containing more mature vessels 
The subsequent phase I I study was performed to evaluate the pharmacodynamic and immune 
effects of ι t administered rhlL-12 on regional lymph nodes, primary tumor, and peripheral blood 
Ten previously untreated patients with HNSCC were injected weekly with rhlL-12 m the primary 
tumor prior to definite surgery RhlL-12 was administered two to three times, at the two in 
phase lb tested dose levels For comparison a similar surgical specimen and peripheral blood was 
collected from 20 control (non-IL-12-treated) HNSCC patients 
In chapter 6 we described that in these previously untreated HNSCC patients, the ι t 
administration of rhlL-12 resulted in more toxicity at doses of 100 ng/kg and 300 ng/kg than 
observed in the pre-treated HNSCC patients, treated in the phase lb study The 300 ng/kg dose 
level showed dose-limiting toxicities (DLTs), ι e , grade 3 fatigue, grade 3 liver toxicity and 
grade 3 metabolic acidosis after surgery The mam biological effects locoregionally were (i) a 
redistribution of lymphocytes from the peripheral blood to the enlarged lymph nodes m the neck, 
(n) a significant higher percentage of NK cells and a lower percentage of Τ helper (Th) cells in 
the lymph nodes and the primary tumor, and (in) a strong increase m mRNA-encodmg IFN-γ 
in the lymph nodes Furthermore, a switch from the Th2 profile, present m control patients, to 
a Thl profile m the lymph nodes related to the peripheral blood after rhlL-12 administration, 
was observed The IL-12-treated patients, who showed no increase in the T-bet/c-Maf (a Th2 
transcription factor) ratio in the lymph nodes, had the worst prognosis 
In chapter 7 the histologic and immunohistopathological effects on the immune cells m the 
primary tumors and regional lymph nodes m the phase I I study are described The largest effect 
was seen on the NK cells, with a higher number m the primary tumor and a high IFN-γ mRNA 
expression in the lymph nodes A change m the architecture of the lymph nodes was detected 
because of a distinct distribution of the Β cells, the smaller germinal centers, and the smaller 
number of DC-LAMP+ cells, mature dendritic cells (DCs), m IL-12-treated patients The peritumoral 
B-cell infiltration was very high in some IL-12-treated patients No differences were seen m the 
numbers or distribution of CD8+ or CD4+ Τ lymphocytes However, the CD8+ and CD4+ Τ cells 
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in IL-12-treated patients produced more IFN-γ. Furthermore, the following changes were noticed 
in cells of the innate immune system. The number of neutrophils in the lymph nodes increased 
after IL-12 treatment. In the primary tumor, however, the neutrophils were slightly diminished 
by number in the tumor nests and remained the same peritumorally and intrastromally. In IL-12-
treated patients the majority of the CD68+ cells (macrophages) were located peritumorally 
(p<0.05), whereas in controls the CD68+ cells were more equally spread. In the lymph nodes 
a lower number of mast cells was counted, whereas in the primary tumor a trend to a lower 
number of eosinophils was seen. 
In chapter 8 we investigated the effects of i.t. administered rhlL-12 on the function of the Β cell 
and studied the altered architecture of the lymph nodes in more detail. After IL-12 treatment less 
secondary follicles with a broader outer region of the mantle zones were seen in the enlarged 
lymph nodes compared with control HNSCC patients. The size of the germinal center (CC) was 
diminished, partly due to a decrease in the number of CD57+ CC cells. These changes did not 
correlate with signs of apoptosis or CXCR5 expression by Β cells. In three of four IL-12 treated 
patients IFN-γ production by Β cells was detected, which was not found in four control patients. 
Eight weeks after treatment an IgC subclass switch was seen in the plasma with more IgCl, less 
lgC2 and more lgC4, indicating a switch to Τ helper 1 phenotype. Peritumoral Β cell infiltration 
was a positive prognostic sign for overall survival in the 29 investigated HNSCC patients, 
irrespectively of IL-12 treatment. However, after IL-12 treatment a high number of peritumoral 
Β cells was detected in most patients, but this was not significant different in comparison to 
control patients. IL-12 treatment induced a decrease in the number of DC-LAMP+ cells and the 
CD57+CC cells. We discuss the role of these cells in inducing tolerance in the control HNSCC 
patients and the possible break of this tolerance by IL-12. 
Finally, in chapter 9 a general discussion and future perspectives are given. 
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SAMENVATTING 
In dit proefschrift worden de effecten op het immuunsysteem van intratumorale (i.t.) toediening 
van recombinant humaan interleukin-12 (rhlL-12) aan patiënten met een plaveiselcel carcinoom 
van het hoofdhals gebied (HHPCC) beschreven. 
De inleiding en de opzet van het proefschrift in hoofdstuk 1 geeft een korte samenvatting van 
de incidentie, de stadièring en de behandeling van patiënten met een HHPCC. Daarnaast worden 
de biologische eigenschappen en klinische resultaten van systemisch toegediend interleukine-12 
(IL-12) kort beschreven. De opzet van de verrichtte studies wordt gegeven. Het doel van de 
studies was om na i.t. rhlL-12 toediening aan patiënten met een HHPCC (i) de toxiciteit vast 
te stellen van de intratumorale toediening, (n) de pharmacokinetiek te bepalen (m) de 
pharmacodynamische effecten in de primaire tumor, de loco-regionale lymfklieren en het 
perifere bloed te bestuderen en (iv) eventueel klinische activiteit vast te stellen. 
Een overzicht van de in de literatuur gepubliceerde klinische studies bij patiënten met kanker, 
die behandeld zijn met loco-regionale immunothérapie, is gegeven in hoofdstuk 2. Alleen fase I 
en I I studies waren verricht. Klinische responsen werden gezien. Geen enkele locoregionale 
therapie is een "standaard" behandeling geworden. Relatief weinig onderzoek is verricht naar de 
effecten op de lokale immuniteit of de immuunsuppressie. We concludeerden dat het belangrijk 
zou zijn om in toekomstige studies waarin patiënten met loco-regionale immunothérapie 
behandeld worden, onderzoek te verrichten naar de veranderingen in de primaire tumor en 
locoregionale lymfklieren na behandeling. Alleen dan is het mogelijk om meer inzicht in de 
effecten van de gegeven therapie op het immuunsysteem te krijgen. 
Hoofdstuk 3 beschrijft een fase I studie, waarin patiënten met een vergevorderde vorm van 
kanker wekelijks met recombinant humaan IL-12 (rhlL-12), één maal per week subcutaan (s.c.) 
toegediend, behandeld werden. Veertig patiënten met een melanoom, 14 patiënten met niercel-
kanker en zes patiënten met een andere vorm van kanker werden ingesloten in de studie; zij 
werden wekelijks behandeld met rhlL-12 s.c. met doseringen variërend van 30 tot 2100 ng/kg. 
De maximaal tolereerbare dosis werd niet bereikt, zelfs niet met de hoogst gebruikte dosis 
rhlL-12. De meest frequente bijwerkingen waren koorts, moeheid, hoofdpijn, misselijkheid en 
braken. Twee patiënten hadden een "minor" response, maar geen partiële of complete responsen 
werden gezien. De conclusie van deze fase I studie met s.c. toediening van rhlL-12 was dat het 
veilig was en relatief goed verdragen werd. 
Gebaseerd op de resultaten van deze fase I studie met wekelijkse toediening van rhlL-12 s.c, 
werden de doseringen voor de intratumorale (i.t.) toediening in HHPCC gekozen. Biologische 
activiteit was aanwezig op de gekozen doseringen, te weten 100 en 300 ng/kg. 
In hoofdstuk 4 beschrijven we de resultaten van een fase Ib studie met i.t. toediening van 
rhlL-12 in patiënten met een recidief HHPCC na eerdere chirurgie en/of radiotherapie. Zes 
patiënten werden wekelijks behandeld op twee verschillende doseringen van 100 of 300 ng/kg. 
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Ze werden maximaal 24 weken behandeld. De toxiciteit was mild. Slechts één patiënt had een 
graad 4 toxiciteit, namelijk een langdurende lymfopenie. Geen "dose limiting toxicities" traden 
op. IL-12 was in alle zes patiënten in plasma detecteerbaar 30 minuten na inspuiting. Significante 
dalingen, maximaal na 12 tot 24 uur, in het absolute aantal perifere bloed lymfocyten en alle 
lymfocyten subsets, in het bijzonder cytotoxische Τ cellen en "natural killer" (NK) cellen, werden 
gezien. De hoogste plasma concentraties van interferon-γ (IFN-γ) en interleukine-10 (IL-10) werden 
waargenomen na 12 uur. 
Een "real-time quantitative polymerase chain reaction" (PCR) analyse in de perifere bloed 
mononucléaire cellen liet een mediane stijging van het IFN-γ mRNA van 2.2 keer ten opzichte 
van de uitgangssituatie zien. Een onverwachte, significante daling van 80% van T-bet mRNA, 
een Τ helper 1 transcriptiefactor, werd gezien na 12 uur, met een normalisering na 48 tot 72 uur. 
Complete of partiële responsen werden niet gezien. Eén patiënt had een afname van zijn tumor 
van 40%. 
In vier van de vijf evalueerbare patiënten behandeld in de fase Ib studie veranderde de kleur van 
de geïnjecteerde tumor tijdens de behandeling. Aanvankelijk werd een rode verkleuring van de 
tumor waargenomen. Na drie tot vijf weken werd de tumor bleker, wat kon duiden op een effect 
op de bloedvaten. Vanwege deze waarneming werd de muizenstudie, gepresenteerd in hoofdstuk 5, 
verricht. Het doel was om effecten van i.t. toegediend recombinant muis IL-12 op de micro-
omgeving van een humane plaveiselcelcarcinoom van het hoofd-halsgebied xenograft tumor te 
bestuderen. Het was een onderhuidse tumor met een relatief grote diameter, in BALB/c nu/nu 
muizen. Gedurende 3 dagen werd 200 ng IL-12 of PBA in deze tumoren gespoten. De muizen 
werden op vier verschillende tijdstippen, tussen 8 uur en 8 dagen na de laatste injectie, 
opgeofferd. Ondanks een snellere en hogere expressie van anti-muis ICAM-1, als uiting van een 
activatie van het endotheel, in de IL-12 behandelde muizen, werden geen significante verschillen 
in dichtheid van vaten, doorbloeding, hypoxie of proliferatie van tumor cellen tussen IL-12 
behandelde tumoren en controle tumoren waargenomen. De belangrijkste redenen dat we de 
observatie bij de mens niet konden aantonen in dit muizen model is waarschijnlijk de combinatie 
van een gecompromitteerd immuunsysteem in de Balb/c nu/nu muizen en de relatief grote tumor 
die meer "mature" vaten bevat. 
Een fase I I studie werd verricht om de pharmacodynamische effecten en effecten op het 
immuunsysteem van i.t. toegediend rhlL-12 in de regionale lymfklieren, primaire tumor en het 
perifere bloed te bestuderen. Tien voorheen onbehandelde patiënten met HHPCC werden wekelijks 
geïnjecteerd met rhlL-12 in de primaire tumor, voordat ze geopereerd werden. RhlL-12 werd twee 
tot drie maal toegediend, op twee verschillende doseringen, te weten 100 en 300 ng/kg. We 
vergeleken deze patiënten met 20 controle HHPCC patiënten, die geen IL-12 toegediend kregen. 
In hoofdstuk 6 wordt beschreven dat in deze voorheen onbehandelde HHPCC patiënten de i.t. 
toediening van rhlL-12, op de gebruikte doseringen van 100 en 300 ng/kg, veel meer 
bijwerkingen had dan in de voorbehandeide HHPCC patiënten, die behandeld werden in de fase Ib 
studie. De dosering van 300 ng/kg liet "dose limiting toxicity" zien, ten gevolge van één graad 3 
moeheid, één graad 3 leverfunctiestoornissen en één graad 3 metabole acidose na de operatie. De 
belangrijkste loco-regionale biologische effecten waren (i) een redistributie van lymfocyten van 
het perifere bloed naar de vergrote lymfklieren in de hals, (n) een significant hoger percentage 
NK cellen en een lager percentage Τ helper (Th) cellen in de lymfklieren en de primaire tumor, en 
(in) een grote toename van IFN-γ mRNA in de lymfklieren. Een switch van een Th2 profiel, 
aanwezig bij controle patiënten, naar een Thl profiel in de lymfklieren vergeleken met het bloed 
na IL-12 behandeling, trad op. Opvallend was dat de IL-12 behandelde patiënten, zonder toename 
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in de T-bet/c-Maf (een Τ helper 2 transcriptiefactor) ratio in de lymfklieren de slechtste prognose 
hadden. 
Hoofdstuk 7 beschrijft de histologische en immunohistopathologische effecten op de cellen van 
het immuunsysteem in de primaire tumor en regionale lymfklieren bij patiënten behandeld in de 
fase I I studie. Het grootste effect werd gezien op de NK cellen, met een hoger aantal in de 
primaire tumor en een hoge IFN-ymRNA expressie in de lymfklieren. In de IL-12 behandelde 
patiënten werd een verandering in de architectuur van de lymfklieren gezien door een veranderde 
distributie van Β cellen, minder kiemcentra en minder DC-LAMP+ cellen (uitgerijpte dendritische 
cellen (DCs)). De peritumorale Β cel infiltratie was in sommige behandelde patiënten zeer hoog. 
Veranderingen in aantal of distributie van CD8+ of CD4+ Τ lymfocyten werd niet gezien. Wél 
produceerden de CD8+ en CD4+ Τ cellen in de IL-12 behandelde patiënten meer IFN-γ. Verder 
werden veranderingen gezien in cellen van het aangeboren immuunsysteem bij de IL-12 
behandelde patiënten. Het aantal neutrofielen in de lymfklieren nam toe. In de primaire tumor, 
echter, was het aantal neutrofielen in de tumornesten iets lager, terwijl het aantal peritumoraal 
en intrastromaal gelijk bleven. In IL-12 behandelde patiënten was de meerderheid van de CD68+ 
cellen (macrofagen) peritumoraal gelokaliseerd in tegenstelling tot in de controle patiënten, 
waarbij de CD68+ cellen meer gelijkmatig verdeeld waren. In de lymfklieren werd een kleiner 
aantal mestcellen geteld, terwijl er in de primaire tumor een tendens tot een lager aantal 
eosinofielen werd gezien na IL-12 behandeling. 
In hoofdstuk S hebben we de effecten van i.t. toegediend rhlL-12 op de functie van de Β cel en 
de veranderde architectuur van de lymfklieren in meer detail bestudeerd. Na IL-12 behandeling 
werden bredere buitenste regio's van mantelzones gezien, terwijl er minder secundaire follikels 
waren in de vergrote lymfklieren. De afmeting van het kiemcentrum was afgenomen, deels ten 
gevolge van een afname van het aantal CD57+ CC cellen. De veranderingen werden niet 
veroorzaakt door veranderingen in apoptose of CXCR5 expressie op de Β cel. In drie van de vier 
geanalyseerde IL-12 behandelde patiënten werd IFN-γ mRNA aangetoond in de Β cel, wat niet 
gevonden werd in 4 onderzochte controle patiënten. In het perifere bloed werd na 8 weken een 
IgC subklasse switch gezien met een toename van IgCl, een afname van lgC2 en een toename 
van lgC4. Dit is een uiting van een switch naar meerThl profiel. Peritumorale Β cel infiltratie had 
een gunstig effect op de overleving in de 29 onderzochte HHPCC patiënten, onafhankelijk van IL-
12 behandeling. Meer IL-12 behandelde dan controle patiënten hadden een hoog aantal 
peritumorale Β cellen, maar dit was niet significant verschillend. IL-12 behandeling induceerde 
een afname van het aantal DC-LAMP+ cellen en de CD57+ CC cellen. We bediscussiëren de rol van 
deze cellen in het induceren van tolerantie bij de controle HHPCC patiënt en het mogelijk 
doorbreken van deze tolerantie na IL-12 behandeling. 




STAGING OF HEAD A N D NECK T U M O R S Q U A M O U S CELL C A R C I N O M A 
P R I M A R Y T U M O R (T) C L A S S I F I C A T I O N FOR C A N C E R S O F T H E O R A L C A V I T Y , H Y P O P H A R Y N X , O R O P H A R Y N X 
A N D L A R Y N X 
L I P A N D ORAL C A V I T Y 
Tx Minimum requirements to assess the primary tumor cannot be met 
To No evidence of primary tumor 
Tis Carcinoma in situ 
T i Tumor 2 cm or less in greatest diameter 
T2 Tumor more than 2 cm but not more than 4 cm in greatest dimension 
T3 Tumor more than 4 cm in greatest dimension 
T4 Lip: tumor invades through cortical bone, inferior alveolar nerve, floor of mouth, or skin 
of face (ie, chin or nose) 
T4 Oral cavity: 
T4a tumor invades adjacent structures [e.g., through cortical bone, into deep (extrinsic) muscles 
of tongue (gemoglossus, hypoglossus, and styloglossus), maxillary sinus, skin ef face) 
T4b tumor invades masticar space, pterygoid plates, or skull base and/or encases internal carotid 
artery 
H Y P O P H A R Y N X 
Tx Primary tumor cannot be assessed 
To No evidence of primary tumor 
Tis Carcinoma in situ 
T i Tumor l imited to one subsite of the hypopharynx and 2 cm or less m greatest dimension 
T2 Tumor involves more than one subsite of the hypopharynx or an adjacent site, or measures 
more than 2 cm but not more than 4 cm in greatest diameter w i thout f ixat ion of 
hemilarynx 
T3 Tumor measures more than 4 cm in greatest dimension or w i th f ixation of hemilarynx 
T4a Tumor invades thyroid/cr icoid cartilage, thyroid bone, thyroid gland, esophagus, or central 
compartment soft tissue 
T4b Tumor invades prevertabral fascia, encases carotis artery, or involves mediastinal structures 
O R O P H A R Y N X 
Tx Primary tumor cannot be assessed 
To No evidence of primary tumor 
Tis Carcinoma in situ 
T i Tumor 2 cm or less in greatest dimension 
T2 Tumor more than 2 cm but not more than 4 cm in greatest dimension 
T3 Tumor more than 4 cm in greatest dimension 
T4a Tumor invades the larynx, deep/extrinsic muscle of tongue, medial pterygoid, hard palate, 
or mandible 
T4b Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base, 
or encases the carotid artery 
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LARYNX 
Tx Primary tumor cannot be assessed 
To No evidence of primary tumor 
Tis Carcinoma in situ 
Supraglottis 
Ti Tumor limited to one subsite of supraglottis with normal vocal cord mobility 
T2 Tumor invades mucosa of more than one adjacent subsite of supraglottis or glottis or region 
outside the supraglottis (eg, mucosa of base of tongue, vallecula, medial wall of pyriform 
sinus) without fixation of the larynx 
T3 Tumor limited to larynx with vocal cord fixation and/or invades any of the following: 
Postcricoid area, pre-epiglottic tissues, paraglottic space, and/or minor thyroid cartilage 
erosion (e.g., inner cortex) 
T4a Tumor invades through the thyroid cartilage, and/or invades tissues beyond the larynx 
(e.g., trachea, softtissues of the neck, including deep extrinsic muscles of the tongue, 
strap muscles, thyroid, or esophagus) 
T4b Tumor invades prevertebral space, encases carotid artery, or invades mediastinal 
structures 
Glottis 
Ti Tumor limited to vocal cord(s) (may involve anterior or posterior commissure) with 
normal mobility 
Tia Tumor limited to one vocal Cordially 
Tib Tumor involves both vocal cords 
T2 Tumor extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility 
T3 Tumor limited to the larynx with vocal cord fixation and/or invades paraglottic space, 
and/or minor thyroid cartilage erosion (e.g., inner cortex) 
T4a Tumor invades through the thyroid cartilage, and/or invades tissues beyond the larynx 
(e.g., trachea, soft tissues of the neck, including deep extrinsic muscles of the tongue, 
strap muscles, thyroid, or esophagus) 
T4b Tumor invades prevertebral space, encases carotid artery, or invades mediastinal 
structures 
Subglottis 
Ti Tumor limited to the subglottis 
T2 Tumor extends to vocal cord(s) with normal or impaired mobility 
T3 Tumor limited to larynx with vocal cord fixation 
T4a Tumor invades cridoid or thyroid cartilage and/or invades tissues beyond the larynx 
(e.g., trachea, soft tissue of the neck, including deep extrinsic muscles of the tongue, 
strap muscles, thyroid, or esophagus) 
T4b Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures 
REGIONAL LYMPH NODES IN HEAD AN NECK CANCER OTHER THAN NASOPHARYNGEAL CANCER 
NX Regional lymph nodes cannot be assessed 
No NO regional lymph node metastasis 
Ni Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension 
N2 Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in 
greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest 
dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest 
dimension 
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N2a Metastasis in a single ipsilateral lymph node more than 3 cm but not more than 6 cm in 
greatest dimension 
N2b Metastasis in mult iple ipsilateral lymph nodes, none more than 6 cm in greatest dimension 
N2c Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest 
dimension 
N3 Metastasis in a lymph node more than 6 cm in greatest dimension 
R E F E R E N C E 
1 AJCC Cancer Staging Manual. Sixth Edition ed. Springer-l/erlûg New York, Inc.; 2002. 
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Allereerst wil ik de patiënten bedanken die hebben deelgenomen aan de studies De belasting voor 
de patiënten die m de fase I I studie behandeld zijn was groot Kort na het krijgen van het 
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Een aantal mensen wil ik speciaal bedanken 
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bedanken 
Beste Pieter, ik wil je bedanken, omdat je mij hebt gevraagd dit onderzoek te doen JIJ stond aan 
de basis van dit onderzoek en bewaakte de grote lijnen Daarnaast dank ik je voor je positiviteit 
als ik in een dal zat Ik heb respect voor jouw wijze van werken 
Beste Cosse, ik dank je voor de mogelijkheid die je mij gegeven hebt om m het lab, c q TIL, een 
aantal methoden zelf te leren en uit te voeren Daarnaast dank ik je voor je zeer kritische blik bij 
het schrijven van de papers Naast de TIL, is ook de BIL interessant 
Beste Peter, ik dank je voor het minutieus "uitvlooien" van alle nek dissectie preparaten en de 
statistische onderbouwing van een aantal papers 
Het leren bekijken van histologische en immunohistopathologische preparaten van primaire 
tumoren en lymfeklieren heb ik van Prof dr Han van Krieken geleerd Dank hiervoor en ook voor 
je begeleiding 
De analyses op de KS400 heeft zeer veel bloed, zweet en tranen gekost, zonder jou, Jeroen van 
der Laak, was het met gelukt, bedankt 
Een aantal analisten is betrokken geweest bij verschillende delen van het onderzoek Ik wil 
Maaike Looman, Marijke Zonneveld, Richard Huybens, Ine van Raaij en Nicole Scharenborg 
hiervoor bedanken 
Beste Jolande de Vries, dank voor het delen van ergernis 
Ik bedank de collega's Ingolf Bruaset, Thijs Merkx, Frank van den Hoogen en Henri Marres voor 
jullie samenwerking bij de mclusie van de patiënten 
Ik dank alle mede-auteurs voor jullie bijdrage 
Verpleegkundigen van de afdeling medische oncologie (E30), oncologie verpleegkundigen van 
de polikliniek interne geneeskunde post rood, en verpleegkundigen van de afdeling KNO en 
kaakchirurgie (C30), wil ik bedanken voor hun hulp bij de behandeling van de IL-12 patiënten 
Collega's oncologen, met name Prof dr Kees Punt, Anja Timmer en Nelleke Ottevanger ik dank 
jullie voor je collegialiteit 
De researchverpleegkundigen, Marlies Peeters, Christel van Riel en Claudia van Opstal, wil ik 
danken voor hun begrip Samen op naar meer fase 1' 
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Lydia Wanders-Borghans en Marie-José van Herpen, ik wil jullie bedanken, dat jullie mijn 
paranimfen willen zijn. Twee orthopedagogen: dat moet lukken. 
Lieve papa en mama, dank voor jullie steun. Mama, het doet pijn, dat je dit niet meer bewust 
mee maakt. Ik denk aan je woorden: "Maak er wat van." . 
Lieve Ans, ik dank je voor jouw inzet en liefde voor onze kinderen. Al meer dan 10 jaar hoor j i j 
bij ons gezin. Bijzonder! 
Lieve Erik, Floor, Cijs en Jaap: aan jullie is dit proefschrift opgedragen, uit de grond van mijn 
hart. Lieve Floor, het werken, zitten en kletsen op onze "meidenzolder" is super gezellig en 
schaffen we dus ook niet af. Wel zal het wat minder vaak gebeuren. Lieve Cijs, "Ik heb je dus nog 
nooit gekend zonder dat je aan je boekje werkte", zei je pas. Dat klopt. Dat wordt wennen! Lieve 
Jaap, enorme dondersteen, ik geniet van je. 
Lieve Erik, twee promoties na elkaar, dat is niet niks. Dank voor je relativering, maar juist ook 
stimulering om dit boekje af te hebben. Bedankt!! 
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Stellingen behorende bij het proefschrift 
I N T R A T U M O R A L A D M I N I S T R A T I O N OF INTERLEUKIN-12 I N H E A D A N D NECK CANCER 
I M M U N E EFFECTS O N T H E PRIMARY T U M O R A N D LYMPH N O D E S 
ι De toxiciteit waargenomen m een fase I studie hoeft met voorspellend te zijn voor de 
toxiciteit in een fase II studie (dit proefschrift) 
2 Het alléén m het bloed monitoren van de effecten op het immuunsysteem na rhlL-12 
toediening is misleidend (dit proefschrift) 
3 Na toediening van rhlL-12 intratumoraal m hoofdhals carcinoom patiënten wordt een 
toename van het aantal NK cellen m de primaire tumor gezien (dit proefschrift) 
4 Intratumorale rhlL-12 toediening in hoofdhals carcinoom patiënten activeert ook de Β cel 
(dit proefschrift) 
5 Door wijdverbreid Τ cel en NK cel "chauvinisme" wordt pharmacodynamisch onderzoek na 
immunothérapie bij kankerpatiënten meestal beperkt to t deze 2 cel soorten Een meer open 
benadering kost meer t i jd , maar levert meer op (dit proefschrift) 
6 Een "additioneel kopje koffie" bij een initieel poliklinisch consult verkleint de kans dat een 
oncologische patient bij de "additionele geneeskunde" terechtkomt 
7 Alle onlogische zaken m een ziekenhuis zijn financieel te verklaren 
8 Op de meeste golfbanen is de dames afslag (rood) m vergelijking met die van de heren 
(geel) veel minder uitdagend Het wordt t i jd voor emancipatie bij het ontwerpen van 
golfbanen 
9 "Spreken is zilver en zwijgen is goud" is vanuit relationeel oogpunt volledig fout 
i o Het wekt bevreemding dat als omslag van het promotiereglement van de Radboud 
Universiteit een afbeelding van een oratie is gebruikt 
i i "Een man, een man een woord, een woord" zet vrouwen onterecht neer als onbetrouwbare 
wezens 
12 Als de hygiene-hypothese zou kloppen, hebben kinderen van tweeverdieners minder allergie 
het huis is viezer, ze gaan minder vaak m bad en bezoeken het kinderdagverblijf 
Nijmegen, 22 december 2004 
Carla van Herpen 



